
<html lang="en"     class="pb-page"  data-request-id="7ae728fd-d537-4f2a-829c-452d4671d354"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b01835;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-9;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands" /></meta><meta name="dc.Creator" content="Liang  Tan" /></meta><meta name="dc.Creator" content="Qingtong  Zhou" /></meta><meta name="dc.Creator" content="Wenzhong  Yan" /></meta><meta name="dc.Creator" content="Jian  Sun" /></meta><meta name="dc.Creator" content="Alan P.  Kozikowski" /></meta><meta name="dc.Creator" content="Suwen  Zhao" /></meta><meta name="dc.Creator" content="Xi-Ping  Huang" /></meta><meta name="dc.Creator" content="Jianjun  Cheng" /></meta><meta name="dc.Description" content="2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivative..." /></meta><meta name="Description" content="2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivative..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 13, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01835" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01835" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01835" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01835" /></link>
        
    
    

<title>Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01835" /></meta><meta property="og:title" content="Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0013.jpeg" /></meta><meta property="og:description" content="2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivatives as dopamine D3R ligands. A number of these new compounds show a high binding affinity for D3R with excellent selectivity. Compound (1R,2R)-22e and its enantiomer (1S,2S)-22e show a comparable binding affinity for the D3R, but the former is a potent D3R agonist, while the latter acts as an antagonist. Molecular docking studies revealed different binding poses of the PCPMA moiety within the orthosteric binding pocket of the D3R, which might explain the different functional profiles of the enantiomers. Compound (1R,2R)-30q shows a high binding affinity for the D3R (Ki = 2.2 nM) along with good selectivity, as well as good bioavailability and brain penetration properties in mice. These results reveal that the PCPMA scaffold may serve as a privileged scaffold for the design of aminergic GPCR ligands." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01835"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01835">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01835&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01835&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01835&amp;href=/doi/10.1021/acs.jmedchem.9b01835" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4579-4602</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01828" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01910" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Liang Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Tan">Liang Tan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingtong Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingtong Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingtong++Zhou">Qingtong Zhou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8124-3079" title="Orcid link">http://orcid.org/0000-0001-8124-3079</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenzhong Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhong Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhong++Yan">Wenzhong Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Sun">Jian Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan P. Kozikowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan P. Kozikowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">StarWise Therapeutics LLC, 2020 North Lincoln Park West, Chicago Illinois 60614, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan+P.++Kozikowski">Alan P. Kozikowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suwen Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suwen Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suwen++Zhao">Suwen Zhao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5609-434X" title="Orcid link">http://orcid.org/0000-0001-5609-434X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xi-Ping Huang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xi-Ping Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c6beb6aeb3a7a8a186b3a8a5e8a3a2b3"><span class="__cf_email__" data-cfemail="fc848c94899d929bbc89929fd2999889">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xi-Ping++Huang">Xi-Ping Huang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1d7e7578737a77775d6e757c737a757c7469787e7533787968337e73"><span class="__cf_email__" data-cfemail="204348454e474a4a605348414e47484149544543480e4544550e434e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Cheng">Jianjun Cheng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6065-2682" title="Orcid link">http://orcid.org/0000-0001-6065-2682</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01835&amp;href=/doi/10.1021%2Facs.jmedchem.9b01835" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4579–4602</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 13, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 November 2019</li><li><span class="item_label"><b>Published</b> online</span>13 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01835</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4579%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLiang%2BTan%252C%2BQingtong%2BZhou%252C%2BWenzhong%2BYan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D9%26contentID%3Dacs.jmedchem.9b01835%26title%3DDesign%2Band%2BSynthesis%2Bof%2BBitopic%2B2-Phenylcyclopropylmethylamine%2B%2528PCPMA%2529%2BDerivatives%2Bas%2BSelective%2BDopamine%2BD3%2BReceptor%2BLigands%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4602%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01835"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1284</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01835" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Qingtong&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wenzhong&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;P. Kozikowski&quot;},{&quot;first_name&quot;:&quot;Suwen&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Xi-Ping&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Cheng&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4579-4602&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01835&quot;},&quot;abstract&quot;:&quot;2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivatives as dopamine D3R ligands. A number of these new compounds show a high binding affinity for D3R with excellent selectivity. Compound (1R,2R)-22e and its enantiomer (1S,2S)-22e show a comparable binding affinity for the D3R, but the former is a potent D3R agonist, while the latter acts as an antagonist. Molecular docking studies revealed different binding poses of the PCPMA moiety within the orthosteric binding pocket of the D3R, which might explain the different functional profiles of the enantiomers. Compound (1R,2R)-30q shows a high binding affinity for the D3R (Ki = 2.2 nM) along with good selectivity, as well as good bioavailability and brain penetration properties in mice. These results reveal that the PCPMA scaffold may serve as a privileged scaffold for the design of aminergic GPCR ligands.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01835&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01835" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01835&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01835" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01835&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01835" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01835&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01835&amp;href=/doi/10.1021/acs.jmedchem.9b01835" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01835" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01835" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01835%26sid%3Dliteratum%253Aachs%26pmid%3D32282200%26genre%3Darticle%26aulast%3DTan%26date%3D2020%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BBitopic%2B2-Phenylcyclopropylmethylamine%2B%2528PCPMA%2529%2BDerivatives%2Bas%2BSelective%2BDopamine%2BD3%2BReceptor%2BLigands%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D9%26spage%3D4579%26epage%3D4602%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (9)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/jmcmar.2020.63.issue-9/20200514/jmcmar.2020.63.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivatives as dopamine D3R ligands. A number of these new compounds show a high binding affinity for D3R with excellent selectivity. Compound (1<i>R</i>,2<i>R</i>)-<b>22e</b> and its enantiomer (1<i>S</i>,2<i>S</i>)-<b>22e</b> show a comparable binding affinity for the D3R, but the former is a potent D3R agonist, while the latter acts as an antagonist. Molecular docking studies revealed different binding poses of the PCPMA moiety within the orthosteric binding pocket of the D3R, which might explain the different functional profiles of the enantiomers. Compound (1<i>R</i>,2<i>R</i>)-<b>30q</b> shows a high binding affinity for the D3R (<i>K</i><sub>i</sub> = 2.2 nM) along with good selectivity, as well as good bioavailability and brain penetration properties in mice. These results reveal that the PCPMA scaffold may serve as a privileged scaffold for the design of aminergic GPCR ligands.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34042" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34042" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">G protein-coupled receptors (GPCRs) constitute the largest family of membrane proteins with more than 800 members.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> GPCRs are the dominant drug targets of over 30% of U.S. FDA-approved small molecule drugs.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The aminergic subfamily of GPCRs is particularly rewarding drug targets that have led to the development of many widely prescribed drugs, and they remain the most actively pursued GPCR drug targets.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Endogenous ligands of aminergic GPCRs are monoamines (i.e., dopamine, serotonin, and histamine), which share a chemotype that features a basic nitrogen atom attached to an aromatic moiety via a linker. Most drugs targeting aminergic GPCRs are small molecules of a similar chemotype or their structural derivatives. As a result, many drugs that target aminergic GPCRs are polypharmacological drugs that show limited selectivity across receptor subtypes.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> On the other hand, the shared chemotype among different aminergic GPCR ligands also offers an opportunity for scaffold repurposing of a drug targeting a specific GPCR to compounds that show selectivity for another receptor.</div><div class="NLM_p">2-Phenylcyclopropylmethylamines (PCPMAs) are a class of compounds that have been reported to act as selective serotonin 2C (5-HT<sub>2C</sub>) agonists,<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> which may have potential value in treating neurological diseases such as schizophrenia and drug addiction.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Compounds <b>1</b> and <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), for example, are highly selective 5-HT<sub>2C</sub> agonists that show in vivo efficacy in schizophrenia-like behavioral models.<a onclick="showRef(event, 'ref4 ref9'); return false;" href="javascript:void(0);" class="ref ref4 ref9">(4,9)</a> In our previous screening data of compounds <b>1</b> and <b>2</b>, we noticed that they showed moderate binding affinities for the dopamine D<sub>3</sub> receptor (D3R) (<i>K</i><sub>i</sub> = 1712 and 811 nM, respectively).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The D3R is another potential drug target that is involved in central nervous system (CNS) diseases such as drug addiction.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Many highly selective D3R ligands have been reported in the literature, and BP-897 (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was the first compound to enter clinical trials.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> are representative D3R antagonists that share a well-known scaffold with a primary pharmacophore that binds to the orthosteric binding pocket (OBP) and a secondary pharmacophore binding to the extended binding pocket (EBP), both of which are connected with a proper linker. GPCR ligands with such a scaffold have been depicted as “bitopic” binders.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Interestingly, the 2-fluoroethoxyl substitution, as in compound <b>1</b>, has been used in the D3R antagonist <b>4</b>,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and a cyclopropane can be found in compounds such as <b>5</b>,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>6</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and <b>7</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which share structural similarities with the PCPMA scaffold of compounds <b>1</b> and <b>2</b>. Also, a cyclopropane was recently introduced into the linker of a reported D3R bitopic agonist <b>8</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PCPMA-based serotonin 2C agonists and their binding activity at D3R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative D3R antagonists and the design of PCPMA derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although several highly selective D3R ligands have been reported in the literature, most compounds suffer from poor bioavailability, low brain penetration, or unwanted side effects in clinical trials.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Therefore, there is still a need for novel D3R selective ligands. On the basis of the cocrystal structures of both the 5-HT<sub>2C</sub> and the D3R receptors,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> we envisioned that the small PCPMA scaffold of compounds <b>1</b> and <b>2</b> binds to the orthosteric pockets of both receptors, with the primary amine group interacting with the conserved Asp<sup>3.32</sup> residue through a conserved salt bridge among aminergic GPCRs.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> By attaching a D3R-preferring spacer and an EBP binding motif to the nitrogen atom of PCPMA, we expect to obtain bitopic PCPMA derivatives as D3R selective ligands (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Therefore, we started a campaign to design and synthesize derivatives of compound <b>1</b> to discover novel D3R ligands, and these results are reported herein. Our research shows that in addition to its action at the 5-HT<sub>2C</sub> receptor, PCPMA may serve as a privileged scaffold that can be repurposed for other aminergic GPCRs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Based on the structural similarity of the PCPMA with D3R ligands <b>5</b> and <b>6</b>, we first set out to synthesize PCPMA derivatives with the triazole-thiol ether as the secondary pharmacophore. 4-Methyl-5-phenyl-4<i>H</i>-1,2,4-triazole-3-thiol (<b>9</b>) was synthesized according to reported procedures and used as the starting material.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A Michael addition reaction of <b>9</b> with methyl acrylate, followed by saponification, afforded the carboxylic acid <b>11</b>. For the PCPMA part, Boc-protected intermediates <b>12a</b> and <b>12b</b> were synthesized according to our published procedures,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and both were alkylated to give <b>13a</b>–<b>d</b> via Mitsunobu reactions with 2-fluoroethanol or direct alkylations with iodomethane or iodoethane, as we previously reported.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> After the deprotection of the Boc, the primary amines <b>14a</b>–<b>d</b> were coupled with <b>11</b> to provide amides <b>15a</b>–<b>d</b>, which were subsequently reduced using the borane-tetrahydrofuran complex to provide target compounds <b>16a</b>–<b>d</b>. These secondary amines could be further alkylated under reductive amination conditions with simple aldehydes to afford compounds <b>17a</b>–<b>l</b> as tertiary amines (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).<named-content content-type="anchor" rid="sch1" type="simple"></named-content></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Triazole-Thiol Ether Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, Cs<sub>2</sub>CO<sub>3</sub>, MeOH, microwave, 100 °C, 30 min, 69%; (b) LiOH–H<sub>2</sub>O, THF, H<sub>2</sub>O, rt, overnight, 60%; (c) [for <b>13a</b>] 2-fluoroethanol, PPh<sub>3</sub>, DEAD, THF, microwave, 60 °C, 30 min, 95%, [for <b>13b</b>] EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 110 °C, 30 min, 83%, [for <b>13c</b> and <b>13d</b>] MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 110 °C, 30 min, 96%; (d) 2 M HCl in diethyl ether, rt, overnight, 99% or 4 M HCl in dioxane, rt, 4–5 h, 82–94%; (e) HATU, NaHCO<sub>3</sub>, DMF, rt, 3 h, 72–90%; (f) BH<sub>3</sub>–THF in THF, reflux, 4 h, 58–92%; (g) aldehydes, NaHB(OAc)<sub>3</sub>, THF, rt, 1 h, 24–89%.</p></p></figure><div class="NLM_p">Compounds with an amide connection between the linker and the secondary pharmacophore, similar to those in reported D3R ligands <b>3</b> and <b>4</b>, were also designed and synthesized. As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, 4-aminobutan-1-ol (<b>18</b>) was acylated with either acid chloride or coupled with aromatic acids to give amides <b>19a</b>–<b>c</b>, and the primary alcohol group was subsequently oxidized to give aldehydes <b>20a</b>–<b>c</b>. PCPMAs <b>14c</b> and <b>14d</b> from <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> were alkylated under reductive amination conditions to attach ethyl or propyl substituents, thereby affording intermediates <b>21a</b>–<b>d</b>, which were then reacted with the former aldehydes under reductive amination conditions to yield compounds <b>22a</b>–<b>i</b> (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Amide Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) [for <b>19a</b>] 2-naphthoyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 87%; [for <b>19b</b>] 1<i>H</i>-indole-2-carboxylic acid, HATU, NaHCO<sub>3</sub>, DMF, rt, 2 h, 80%; [for <b>19c</b>] 4-(2-pyridyl)benzoic acid, HATU, NaHCO<sub>3</sub>, DMF, rt, 2 h, 93%; (b) SO<sub>3</sub>–Py, DMSO, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) [for <b>21a</b> and <b>21b</b>] NaBH<sub>4</sub>, NEt<sub>3</sub>, acetaldehyde, rt, 20 min, 33–34%; [for <b>21c</b> and <b>21d</b>] NaBH<sub>4</sub>, NEt<sub>3</sub>, propionaldehyde, rt, 20 min, 23–31%; (d) NaHB(OAc)<sub>3</sub>, THF, rt, overnight, 37–68% for steps b and d.</p></p></figure><div class="NLM_p">An alternative route for similar amides is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Briefly, starting from phenyl aldehydes <b>23a</b>–<b>f</b>, a sequence of Wittig reaction, ester to Weinreb amide conversion, Corey–Chaykowsky cyclopropanation, and Weinreb amide to aldehyde reduction provided aldehydes <b>28a</b>–<b>f</b>.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Next, the above-mentioned aldehydes <b>20a</b>–<b>c</b> were converted to propyl amines <b>29a</b>–<b>c</b> through reductive amination reactions. Further reductive amination reactions of <b>28a</b>–<b>f</b> with <b>29a</b>–<b>c</b> produced compounds <b>30a</b>–<b>r</b> (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amide Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>3</sub>P═CHC(═O)OMe, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 67–98%; (b) LiOH–H<sub>2</sub>O, THF, H<sub>2</sub>O, rt, 2 h, 75–100%; (c) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, HATU, NaHCO<sub>3</sub>, DMF, rt, overnight, 81–97%; (d) Me<sub>3</sub>S<sup>+</sup>(O)I<sup>–</sup>, NaH, DMSO, rt, overnight, 71–82%; (e) DIBAL-H, THF, −78 °C, 2 h; (f) NaHB(AcO)<sub>3</sub>, propylamine, AcOH, rt, 44–64%; (g) NaHB(OAc)<sub>3</sub>, AcOH, THF, rt, overnight, 11–68% for steps e and g.</p></p></figure><div class="NLM_p">For the PCPMA moiety of all of the new compounds, we obtained only the <i>trans</i> isomers through using <i>E</i> olefins as the cyclopropanation precursors, the same as our previous 5-HT<sub>2C</sub> ligands. Of course, the racemic, <i>trans</i> compound is composed of a pair of (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-enantiomers. In this research, the racemic compounds <b>22e</b>, <b>30p</b>, <b>30q</b>, and <b>30r</b> were separated by chiral HPLC to give optically pure (−)- and (+)-enantiomers for further pharmacological profiling. To determine the absolute configurations of these enantiomers, we resynthesized the enantiomers of <b>22e</b> using a method shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> (for details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Thus, the Boc-protected intermediate <b>13c</b> from <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was separated using chiral HPLC to give both isomers (+)-<b>13c</b> and (−)-<b>13c</b>, which were deprotected subsequently to give HCl salts (−)-<b>14c</b> and (+)-<b>14c</b>, respectively. We had previously determined that the (−)-isomer has the (1<i>R</i>,2<i>R</i>) configuration and that the (+)-isomer has the (1<i>S</i>,2<i>S</i>) configuration for very similar compounds.<a onclick="showRef(event, 'ref4 ref23'); return false;" href="javascript:void(0);" class="ref ref4 ref23">(4,23)</a> Therefore, the configuration of (−)-<b>14c</b> was assigned as (1<i>R</i>,2<i>R</i>) and that of (+)-<b>14c</b> as (1<i>S</i>,2<i>S</i>). Both (−)-<b>14c</b> and (+)-<b>14c</b> were next converted to (−)-<b>21c</b> and (+)-<b>21c</b> and then to (−)-<b>22e</b> and (+)-<b>22e</b>. Thus, the configuration of (−)-<b>22e</b> was assigned as (1<i>R</i>,2<i>R</i>), and (+)-<b>22e</b> as (1<i>S</i>,2<i>S</i>). As will be discussed below, based on structural similarities and the consistency observed in the 5-HT<sub>2C</sub> binding data for compounds <b>30p</b>, <b>30q</b>, and <b>30r</b>, namely, that the (+)-isomer shows better 5-HT<sub>2C</sub> activity, which is in agreement with both the results from the enantiomers of <b>22e</b> and our previous results, the absolute configurations of the (−)-isomers of <b>30p</b>, <b>30q</b>, and <b>30r</b> were assigned as (1<i>R</i>,2<i>R</i>) and the (+)-isomers as (1<i>S</i>,2<i>S</i>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of compounds (1<i>R</i>,2<i>R</i>)- <b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) chiral prep-HPLC separation; (b) 4 M HCl in dioxane, rt, overnight, 98%; (c) propionaldehyde, NaBH<sub>4</sub>, NEt<sub>3</sub>, dioxane, rt, 10 min, 34–63%; (d) <b>20c</b>, NaHB(AcO)<sub>3</sub>, THF, rt, overnight, 32–33%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationships (SARs)</h3><div class="NLM_p">On the basis of the structural similarity between the PCPMA scaffold and the cyclopropane-containing substructures in compounds <b>5</b> and <b>6</b>, we introduced the 1,2,4-triazolylthiol ether moiety as the EBP binding motif, connected to the <i>N</i> atom of PCPMA via a three-carbon spacer. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the binding affinity of compounds <b>16a</b> and <b>17a</b> at D3R increased slightly compared to PCPMA compound <b>1</b> (<i>K</i><sub>i</sub> = 1712 nM),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> but none of them showed significant binding selectivity among five dopamine receptors and the 5-HT<sub>2C</sub> receptor. The <i>N</i>-ethyl compound <b>17b</b> showed more than a 15-fold increase in binding affinity compared to the PCPMA compound <b>1</b> (113.1 nM versus 1712 nM). The 2-fluoroethoxy substituent on the PCPMA part was reduced to an ethoxy group in compounds <b>16b</b>, <b>17c</b>, and <b>17d</b>, which resulted in slight increases in binding affinities, as can be seen by comparing <b>17d</b> versus <b>17b</b>, <b>17c</b> versus <b>17a</b>, and <b>16b</b> versus <b>16a</b>. When the ethoxy substituent on the benzene ring was further truncated to a methoxy group, binding affinities were further increased, as can be seen from compounds <b>16c</b>, <b>17e</b>, and <b>17f</b>, with the last showing a <i>K</i><sub>i</sub> value of 44.0 nM at D3R. The <i>N</i>-ethyl group was changed to a propyl (<b>17g</b>), an isopropyl (<b>17h</b>), or a cyclopropylmethyl group (<b>17i</b>), but none of these compounds showed an increased affinity for D3R compared to the <i>N</i>-ethyl compound <b>17f</b>. The fluorine atom on the left-hand benzene ring was changed to a Cl atom in compounds <b>17j</b>, <b>17k</b>, and <b>17l</b>, with various <i>N</i> substitutions, and these compounds showed comparable binding affinities for D3R and moderate selectivity against D2R, D4R, and 5-HT<sub>2C</sub>, while possessing a lower affinity for the D1R and D5R. Taken together, the introduction of the 1,2,4-triazolylthiol ether significantly enhanced the compound affinity for D3R and reduced their affinity to 5-HT<sub>2C</sub>, but compared to compound BP-897, their affinity and selectivity still required further improvement. In our assays, BP-897 showed a binding affinity of 3.1 nM at D3R, and 365-, 80-, 205-, 395-, and 70-fold selectivity against D1R (1132 nM), D2R (247.0 nM), D4R (634.0 nM), D5R (1223 nM), and 5-HT<sub>2C</sub> (218.0 nM) receptors, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities of Thiol Ethers at D<sub>1-5</sub> and 5-HT<sub>2C</sub> Receptors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0010.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values were calculated from mean p<i>K</i><sub>i</sub> values (mean p<i>K</i><sub>i</sub> ± SEM values from at least three individual experiments are provided in <a class="ref internalNav" href="#notes2" aria-label="Table S1">Table S1</a>).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">All compounds were tested as HCl salts.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div><div class="NLM_p">We then turned to a longer spacer group composed of four carbon atoms, coupled with an amide connection to the EBP-binding aromatic moiety. The results for these analogues are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. For the aromatic moiety, naphthyl, indolyl, and 4-pyridylphenyl were used as they have been reported in numerous D3R selective compounds. Comparing compounds <b>22a</b> and <b>22b</b>, it can be seen that although they show identical binding affinities to D3R, the <i>N</i>-propyl substitution led to a higher selectivity profile for <b>22b</b> versus the <i>N</i>-ethyl substitution present in <b>22a</b>, especially against D2R and D4R. Also, in compound <b>22d</b>, the <i>N</i>-propyl substituent resulted in a 2-fold increase in binding affinity, compared to that of <b>22c</b>, which has an ethyl substituent. The introduction of a 4-pyridyl phenyl group led to a further increase in binding affinity as in compound <b>22e</b>, showing a <i>K</i><sub>i</sub> value of 4.0 nM for D3R. Moreover, compound <b>22e</b> showed excellent selectivity against all of the other dopamine receptors (439-fold against D1R (1758 nM), 786-fold against D2R (3144 nM), 285-fold against D4R (1142 nM), and >5000 nM for D5R). However, it showed only moderate selectivity as the racemic mixture over 5-HT<sub>2C</sub> (53.0 nM versus 4.0 nM, or 13-fold). When the fluorine atom was replaced by a chlorine, compound affinity was maintained within the low nM range, but none of these analogues were more potent, as shown for compounds <b>22f</b>–<b>i</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Affinities of Amide Analogues at D<sub>1-5</sub> and 5-HT<sub>2C</sub> Receptors<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0011.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values were calculated from mean p<i>K</i><sub>i</sub> values (mean p<i>K</i><sub>i</sub> ± SEM values from at least three individual experiments are provided in <a class="ref internalNav" href="#notes2" aria-label="Table S2">Table S2</a>).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">All compounds were tested as HCl salts.</p></div></div><div></div></div><div class="NLM_p last">Next, we removed the 2-methoxy group in the PCPMA moiety. Compounds <b>30a</b>–<b>c</b>, which retain only the <i>meta</i> fluorine substitution, showed good affinities for D3R and excellent selectivity against D2R (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For example, compound <b>30c</b>, with a 4-pyridylphenyl EBP-binding group, showed 45.4 nM binding affinity for D3R, but >5000 nM binding affinity for D2R and only micromolar affinities for all other tested receptors. When a <i>meta</i> chorine was introduced to replace the fluorine atom (compounds <b>30d</b>–<b>f</b>), similar results were observed. Compound <b>30f</b> showed 26.5 nM binding affinity for D3R, with excellent selectivity against D2R, D4R, and D5R and good selectivity over D1R (832 nM) and 5-HT<sub>2C</sub> (898 nM). We then moved the halogen substitution to the <i>para</i> position. As can be seen with compounds <b>30g</b>–<b>i</b> (4-F) and <b>30j</b>–<b>l</b> (4-Cl), these compounds showed good binding profiles, and in particular, compound <b>30l</b> represents the best of them, with a <i>K</i><sub>i</sub> value of 17.6 nM for the D3R and good selectivity against the other four dopamine receptors (1308 nM at D1R, no affinity at D2R, 1413 nM at D4R, and 8844 nM at D5R, respectively), and moderate selectivity over 5-HT<sub>2C</sub> (284 nM). The substitution of a <i>para</i>-CF<sub>3</sub> group, as present in compounds <b>5</b> and <b>6</b>, was also introduced. As can be seen from an examination of the data obtained for compounds <b>30m</b>–<b>o</b>, although their binding affinities were not improved compared to the <i>para</i>-F or <i>para</i>-Cl substitution, all three compounds fail to bind to D2R while showing very good selectivity against the other tested receptors. Notably, the presence of a dichloro substitution pattern, like that present in the drugs aripiprazole and cariprazine, provided compounds <b>30p</b>–<b>r</b>, which show significantly enhanced binding affinities for D3R (1.2–2.6 nM). Compound <b>30r</b>, which has a <i>K</i><sub>i</sub> of 1.2 nM, showed over 1000-fold selectivity against all other dopamine receptors, and an 81-fold selectivity against 5-HT<sub>2C</sub> (<i>K</i><sub>i</sub> = 97.7 nM). The overall profiles of <b>30p</b> and <b>30q</b> were also very encouraging. On the basis of these results, we selected compounds <b>22e</b>, <b>30p</b>, <b>30q</b>, and <b>30r</b> for further studies.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Influence of Chirality on Binding Affinity and Functional Activity</h3><div class="NLM_p">The significance of chirality is a critical consideration in medicinal chemistry and has also been showcased in previous D3R ligand discovery.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> With respect to the chiral centers on the PCPMA skeleton, although all compounds were synthesized as the <i>trans</i> isomers, they were tested as a mixture of (1<i>R</i>,2<i>R</i>) and (1<i>S</i>,2<i>S</i>) isomers in our primary screening. We thus selected the four best compounds, <b>22e</b>, <b>30p</b>, <b>30q</b>, and <b>30r</b>, for chiral separations and further pharmacological profiling. Chiral separations were conducted using chiral HPLC columns, and the absolute configurations of all the isomers were assigned as discussed above. All four pairs of enantiomers were profiled in the same binding assays against the dopamine receptors and the 5-HT<sub>2C</sub> receptor. As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the (1<i>R</i>,2<i>R</i>) enantiomers showed slightly better binding affinities for D3R than the (1<i>S</i>,2<i>S</i>) for compounds <b>30p</b>, <b>30q</b>, and <b>30r</b> (4.4 versus 20.8 nM, 2.2 versus 12.8 nM, and 1.5 versus 5.3 nM, respectively). For compound <b>22e</b>, the enantiomers displayed equal affinities for D3R (4.1 versus 3.8 nM). Interestingly, the enantiomers of all four compounds showed comparable affinities for all dopamine receptors within each pair, but their affinities for 5-HT<sub>2C</sub> were different. The (1<i>R</i>,2<i>R</i>) enantiomers showed 3–22× weaker 5-HT<sub>2C</sub> binding affinity than their (1<i>S</i>,2<i>S</i>) isomers, consistent with the results of our previous PCPMA analogues.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> It would appear that the D3R has little binding preference for the chiral conformations of the PCPMA unit, while the 5-HT<sub>2C</sub> is more sensitive.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enantiomer Activity of Selected Compounds<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0012.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values were calculated from mean p<i>K</i><sub>i</sub> values (mean p<i>K</i><sub>i</sub> ± SEM values from at least three individual experiments are provided in <a class="ref internalNav" href="#notes2" aria-label="Table S3">Table S3</a>).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">All compounds were tested as HCl salts.</p></div></div><div></div></div><div class="NLM_p">These enantiomers were further profiled for their functional activity at the D<sub>3</sub> and 5-HT<sub>2C</sub> receptors. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, for compounds <b>30p</b>–<b>r</b>, both enantiomers showed full or partial agonist activity at D3R with comparable potency between each pair of enantiomers. Interestingly, (1<i>R</i>,2<i>R</i>)-<b>22e</b> showed very potent agonist activity (EC<sub>50</sub> = 3.6 nM, <i>E</i><sub>max</sub> = 77.9%), while (1<i>S</i>,2<i>S</i>)-<b>22e</b> showed no activity in the agonist mode but behaved as a potent antagonist of D3R (<i>K</i><sub>i</sub> = 16.7 nM). At 5-HT<sub>2C</sub> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C–D), both <b>22e</b> enantiomers were weak antagonists with micromolar activity. For compounds <b>30p</b>–<b>r</b>, (1<i>S</i>,2<i>S</i>) isomers were partial agonists with low potency while the (1<i>R</i>,2<i>R</i>) isomers showed very weak antagonist activity at 5-HT<sub>2C</sub> receptors. These results reveal that the selected compounds show better selectivity for D3R versus 5-HT<sub>2C</sub> in the functional assays compared to their selectivity as determined from their binding affinities. Furthermore, these enantiomers were tested at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors for their agonist activity to exclude potential hallucinogenic or valvulopathic side effects related to these receptors, respectively. All enantiomers showed very weak and only partial 5-HT<sub>2A</sub> agonist activity, and no 5-HT<sub>2B</sub> agonism was observed (see <a class="ref internalNav" href="#notes2" aria-label="Table S1">Table S1</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Functional Data of Selected Compounds at D3R and 5-HT<sub>2C</sub></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">D3R G<sub>i</sub></th><th class="colsep0 rowsep0" align="center">D3R Tango</th><th class="colsep0 rowsep0" align="center">5-HT<sub>2C</sub>G<sub>q</sub>(Ca<sup>2+</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>R</i>,2<i>R</i>)-<b>22e</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 3.58 nM (77.9%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 126.4 nM (50.2%)</td><td class="colsep0 rowsep0" align="left">antagonist IC<sub>50</sub> = 14.5 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>S</i>,2<i>S</i>)-<b>22e</b></td><td class="colsep0 rowsep0" align="left">no agonism; antagonist: <i>K</i><sub>i</sub> = 16.7 nM</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">antagonist IC<sub>50</sub> = 0.86 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>R</i>,2<i>R</i>)-<b>30p</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 177.5 nM (71.7%)</td><td class="colsep0 rowsep0" align="left">9.2% at 3 μM</td><td class="colsep0 rowsep0" align="left">antagonist IC<sub>50</sub> = 16.1 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>S</i>,2<i>S</i>)-<b>30p</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 99.2 nM (83.4%)</td><td class="colsep0 rowsep0" align="left">44.4% at 3 μM</td><td class="colsep0 rowsep0" align="left">agonist EC<sub>50</sub> = 3538 nM (30.3%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>R</i>,2<i>R</i>)-<b>30q</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 87.0 nM (40.7%)</td><td class="colsep0 rowsep0" align="left"><5% at 3 μM</td><td class="colsep0 rowsep0" align="left">antagonist: IC<sub>50</sub> > 30 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>S</i>,2<i>S</i>)-<b>30q</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 142.8 nM (63.4%)</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 1000.2 nM (27.1%)</td><td class="colsep0 rowsep0" align="left">agonist EC<sub>50</sub> = 2549 nM (44.2%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>R</i>,2<i>R</i>)-<b>30r</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 12.5 nM (68.1%)</td><td class="colsep0 rowsep0" align="left">3.1% at 3 μM</td><td class="colsep0 rowsep0" align="left">antagonist IC<sub>50</sub> = 10.1 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(1<i>S</i>,2<i>S</i>)-<b>30r</b></td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 29.6 nM (96.2%)</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 11086 nM (119.1%)</td><td class="colsep0 rowsep0" align="left">agonist EC<sub>50</sub> = 738.3 nM (51.9%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quinpirole</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 0.42 nM (95.4%)</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 35.0 nM (95.2%)</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 0.11 nM (100%)</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 0.41 nM (99.0%)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All compounds were tested as HCl salts.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">For agonist activity, <i>E</i><sub>max</sub> values are shown in brackets.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">NT, not tested.</p></div></div></div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Functional characterization of lead compounds at D<sub>3</sub> dopamine receptors (A, B) and 5-HT<sub>2C</sub> receptors (C, D). (A) Inhibition of cAMP production at D<sub>3</sub> (G<sub>i</sub>-agonist activity), (B) β-arrestin2 recruitment (Tango agonist activity), and calcium mobilization at 5-HT<sub>2C</sub> (G<sub>q</sub> agonist activity in panel C and antagonist activity in panel D) represented means ± SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate. The reference agonist (5-HT) was used at a final concentration of 1 nM in antagonist assays (D), in which mesulergine served as a reference antagonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The Tango assay was also performed at D3R to evaluate compound activity for β-arrestin2 recruitment (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Compared to their G<sub>i/o</sub> activity, most compounds showed very weak β-arrestin2 recruitment at D3R. In particular, compounds (1<i>S</i>,2<i>S</i>)-<b>22e</b>, (1<i>R</i>,2<i>R</i>)-<b>30p</b>, (1<i>R</i>,2<i>R</i>)-<b>30q</b>, and (1<i>R</i>,2<i>R</i>)-<b>30r</b> showed no measurable activity in the Tango assay, indicating their preference for the G protein signaling.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Molecular Docking Studies</h3><div class="NLM_p">To understand the molecular basis of the binding profiles of these new compounds, especially compounds (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-<b>22e</b>, we carried out molecular docking studies on them using Schrödinger’s Maestro program. (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-<b>22e</b>, as well as eticlopride, were docked to the antagonist-bound structure of D3R (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The salt bridge between the positive charged tertiary amine and the carboxylate of D110<sup>3.32</sup> was observed for all three ligands (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), which has been reported as highly conserved for most aminergic receptors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Consistent with previous research<a onclick="showRef(event, 'ref21 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref21 ref25 ref26">(21,25,26)</a> and our expectations, the PCPMA moiety of both (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-<b>22e</b> occupies the OBP of D3R, in good alignment with eticlopride, while the attachment to the PCPMA extends into the EBP. Notably, although both (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-<b>22e</b> fit nicely in the OBP with the substituted benzene rings forming π–π stacking and hydrophobic interactions, the orientations of the substituted phenyl ring of (1<i>R</i>,2<i>R</i>)- and (1<i>S</i>,2<i>S</i>)-<b>22e</b> are quite different. For (1<i>R</i>,2<i>R</i>)-<b>22e</b>, the 2-methoxy substituent on the benzene ring is deeply buried within the OBP, forming hydrophobic contacts with C114<sup>3.36</sup>, S196<sup>5.46</sup>, and F346<sup>6.52</sup>, while the 2-methoxy group of the antagonist (1<i>S</i>,2<i>S</i>)-<b>22e</b> flips up toward the extracellular side. As a result, for antagonist (1<i>S</i>,2<i>S</i>)-<b>22e</b>, the cyclopropane linker between the benzene ring and the protonated <i>N</i> overlays perfectly with the amide linker of eticlopride, while for the agonist (1<i>R</i>,2<i>R</i>)-<b>22e</b> the cyclopropane points to another direction due to the flip of the benzene ring. Since a structure of the active state of D3R is currently unavailable, the docking of agonist (1<i>R</i>,2<i>R</i>)-<b>22e</b> to the active state of D3R has not been conducted. This flip of the benzene ring in the inactive conformation of D3R might explain the different functional results observed for these enantiomers.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of binding poses of D3R antagonist eticlopride, (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b>. The receptor structure employed for the molecular docking study was extracted from the crystal structure of the eticlopride–D3R complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>). Carbon atoms of eticlopride, (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b> are colored in green, orange, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A further observation from the functional data is that, while the PCPMA compound <b>2</b> is a potent agonist of 5-HT<sub>2C</sub>, the bitopic derivative (1<i>S</i>,2<i>S</i>)-<b>22e</b> turned out to be a moderate antagonist (IC<sub>50</sub> = 858.5 nM). For the di-Cl substituted compounds <b>30p</b>, <b>30q</b>, and <b>30r</b>, although the (1<i>S</i>,2<i>S</i>) eutomers showed partial agonist activity, their efficacy was very low (<i>E</i><sub>max</sub> = 30.3%, 44.2%, and 51.9%, respectively). To explore the molecular basis for this conversion from PCPMA-based 5-HT<sub>2C</sub> agonists to bitopic antagonists/weak partial agonists, we also performed molecular docking of compounds <b>2</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b> to the crystal structures of 5-HT<sub>2C</sub>. Thus, compound <b>2</b> was docked to the ergotamine-bound active structure of 5-HT<sub>2C</sub> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>), while compound (1<i>S</i>,2<i>S</i>)-<b>22e</b> was docked to the ritanserin-bound inactive structure of 5-HT<sub>2C</sub> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH">6BQH</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, all of these ligands form salt bridges between the protonated nitrogen atoms of the ligands and D134<sup>3.32</sup>, a key interaction for aminergic GPCR ligands. In the cocrystal structures, the deep binding pose of ritanserin, with the phenyl ring inserted more deeply than the ergoline scaffold of ergotamine, was proposed as a possible explanation for its antagonistic activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In our docking poses, in comparison to the PCPMA compound <b>2</b>, the bitopic derivative (1<i>S</i>,2<i>S</i>)-<b>22e</b> inserts approximately one helical turn deeper into the TM bundle, which likely explains its antagonistic action at the 5-HT<sub>2C</sub> receptor. The fluorophenyl groups form halogen-aromatic interactions with F223<sup>5.47</sup>and F320<sup>6.44</sup>, aromatic edge-to-face π–π stacking with F328<sup>6.52</sup> and W324<sup>6.48</sup>, and hydrophobic interactions with T139<sup>3.37</sup>, S138<sup>3.36</sup>, and I142<sup>3.40</sup>. Similar to ritanserin, the deep binding pose of (1<i>S</i>,2<i>S</i>)-<b>22e</b> likely prevents the conformational changes of the toggle switch in TM6 (W324<sup>6.48</sup>) and rotamer switches in the conserved P–I–F motif,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> thus stabilizing the inactive state of 5-HT<sub>2C</sub>. It may thus be postulated that the attachment of the four carbon-linker and the EBP-binding motifs to the PCPMA scaffold results in a deeper binding mode for compound (1<i>S</i>,2<i>S</i>)-<b>22e</b>, thus leading to its antagonism of the receptor.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of binding poses of 5HT<sub>2C</sub> representative agonists (A) and antagonists (B). The receptor structures used in the molecular docking studies were extracted from the crystal structures of the ergotamine–5HT<sub>2C</sub> complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>) and the ritanserin–5HT<sub>2C</sub> complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH">6BQH</a>). Carbon atoms of ergotamine, compound <b>2</b>, ritanserin, and (1<i>S</i>,2<i>S</i>)-<b>22e</b> are colored in orange, pink, green, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetic and Brain Penetration Properties</h3><div class="NLM_p">On the basis of their good binding affinity and selectivity for D3R, we selected compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b>, (1<i>R</i>,2<i>R</i>)-<b>30p</b>, (1<i>R</i>,2<i>R</i>)-<b>30q</b>, and (1<i>R</i>,2<i>R</i>)-<b>30r</b> for further PK profiling in male ICR mice. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, intravenous (iv) administration (5 mg/kg) of these compounds showed moderate exposure in plasma, with high clearance. Oral administration (10 mg/kg) of compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b>, (1<i>R</i>,2<i>R</i>)-<b>30p</b>, and (1<i>R</i>,2<i>R</i>)-<b>30r</b> gave very low bioavailability (3.8%, 6.6%, and 13.0% respectively), but compound (1<i>R</i>,2<i>R</i>)-<b>30q</b> showed a reasonably good oral bioavailability of 34.1%. Furthermore, this compound showed an oral half-life of 4.1 h and an MRT of 6 h.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK and Brain Penetration Properties of Selected Compounds in ICR Mice<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">(1<i>R</i>,2<i>R</i>)-<b>22e</b></th><th class="rowsep1 colsep0" colspan="2" align="center">(1<i>R</i>,2<i>R</i>)-<b>30p</b></th><th class="rowsep1 colsep0" colspan="2" align="center">(1<i>R</i>,2<i>R</i>)-<b>30q</b></th><th class="rowsep1 colsep0" colspan="2" align="center">(1<i>R</i>,2<i>R</i>)-<b>30r</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">43.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">37.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">63.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">118</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.00</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.437</td><td class="colsep0 rowsep0" align="left">2.64</td><td class="colsep0 rowsep0" align="left">1.51</td><td class="colsep0 rowsep0" align="left">2.08</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">4.11</td><td class="colsep0 rowsep0" align="left">0.576</td><td class="colsep0 rowsep0" align="left">2.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (h·ng/mL)</td><td class="colsep0 rowsep0" align="left">660</td><td class="colsep0 rowsep0" align="left">49.5</td><td class="colsep0 rowsep0" align="left">616</td><td class="colsep0 rowsep0" align="left">81.1</td><td class="colsep0 rowsep0" align="left">629</td><td class="colsep0 rowsep0" align="left">428</td><td class="colsep0 rowsep0" align="left">976</td><td class="colsep0 rowsep0" align="left">254</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">126</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">134</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">84.8</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT(h)</td><td class="colsep0 rowsep0" align="left">0.415</td><td class="colsep0 rowsep0" align="left">3.72</td><td class="colsep0 rowsep0" align="left">2.58</td><td class="colsep0 rowsep0" align="left">2.59</td><td class="colsep0 rowsep0" align="left">3.40</td><td class="colsep0 rowsep0" align="left">6.00</td><td class="colsep0 rowsep0" align="left">0.808</td><td class="colsep0 rowsep0" align="left">2.77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dSS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">20.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">23.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.11</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3.8%</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.6%</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">34.1%</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">13.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain concentration at 0.5 h (ng/mL)</td><td class="colsep0 rowsep0" align="left">530 ± 37</td><td class="colsep0 rowsep0" align="left">8.21 ± 2</td><td class="colsep0 rowsep0" align="left">3424 ± 286</td><td class="colsep0 rowsep0" align="left">23.2 ± 4.0</td><td class="colsep0 rowsep0" align="left">833 ± 187</td><td class="colsep0 rowsep0" align="left">51.3 ± 21</td><td class="colsep0 rowsep0" align="left">980 ± 164</td><td class="colsep0 rowsep0" align="left">26.7 ± 9.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma concentration at 0.5 h (ng/mL)</td><td class="colsep0 rowsep0" align="left">446 ± 15</td><td class="colsep0 rowsep0" align="left">16.8 ± 5.0</td><td class="colsep0 rowsep0" align="left">270 ± 22</td><td class="colsep0 rowsep0" align="left">28.4 ± 15</td><td class="colsep0 rowsep0" align="left">215 ± 13</td><td class="colsep0 rowsep0" align="left">35.5 ± 7.0</td><td class="colsep0 rowsep0" align="left">511 ± 67</td><td class="colsep0 rowsep0" align="left">118 ± 7.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain/plasma ratio at 0.5 h</td><td class="colsep0 rowsep0" align="left">1.19</td><td class="colsep0 rowsep0" align="left">0.49</td><td class="colsep0 rowsep0" align="left">12.7</td><td class="colsep0 rowsep0" align="left">0.82</td><td class="colsep0 rowsep0" align="left">3.88</td><td class="colsep0 rowsep0" align="left">1.45</td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain concentration at 2.0 h (ng/mL)</td><td class="colsep0 rowsep0" align="left">19.4 ± 11</td><td class="colsep0 rowsep0" align="left">6.57</td><td class="colsep0 rowsep0" align="left">913 ± 97</td><td class="colsep0 rowsep0" align="left">23.2 ± 4.0</td><td class="colsep0 rowsep0" align="left">543 ± 99</td><td class="colsep0 rowsep0" align="left">160 ± 45</td><td class="colsep0 rowsep0" align="left">227 ± 17.0</td><td class="colsep0 rowsep0" align="left">9.1 ± 5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma concentration at 2.0 h (ng/mL)</td><td class="colsep0 rowsep0" align="left">12.7 ± 3.1</td><td class="colsep0 rowsep0" align="left">8.4 ± 2.4</td><td class="colsep0 rowsep0" align="left">82.6 ± 9.7</td><td class="colsep0 rowsep0" align="left">16.4 ± 3.5</td><td class="colsep0 rowsep0" align="left">94.8 ± 19.3</td><td class="colsep0 rowsep0" align="left">67.7 ± 20</td><td class="colsep0 rowsep0" align="left">118 ± 16.5</td><td class="colsep0 rowsep0" align="left">44.1 ± 7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain/plasma ratio at 2.0 h</td><td class="colsep0 rowsep0" align="left">1.53</td><td class="colsep0 rowsep0" align="left">0.79</td><td class="colsep0 rowsep0" align="left">11.1</td><td class="colsep0 rowsep0" align="left">1.61</td><td class="colsep0 rowsep0" align="left">5.72</td><td class="colsep0 rowsep0" align="left">2.36</td><td class="colsep0 rowsep0" align="left">1.93</td><td class="colsep0 rowsep0" align="left">0.207</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">For all four compounds, the iv dose is 5 mg/kg, and the po dose is 10 mg/kg.</p></div></div></div><div class="NLM_p last">In our previous studies, PCPMA analogues showed very high brain penetration as 5-HT<sub>2C</sub> agonists.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Accordingly, these four selected compounds were further tested for their brain penetration properties in ICR mice. Brain and plasma drug concentrations after both iv and oral dosing were measured at 0.5 and 2.0 h time points, and brain/plasma ratios were calculated. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, all four compounds showed good brain penetration, although significant differences were observed for their brain concentrations following oral dosing, which can be attributed to their different overall PK profiles. Thus, the brain exposures of compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b>, <b>30p</b>, and <b>30r</b> were very low following oral dosing, despite good brain/plasma ratios. As for compound (1<i>R</i>,2<i>R</i>)-<b>30q</b>, high brain/plasma ratios were observed for both iv and oral dosing, at both time points. Calculated concentrations of 108.6 (51.3 ng/mL) and 338.6 nM (160 ng/mL) were observed at 0.5 and 2.0 h, respectively. Moderate but long-lasting brain exposure could be expected for compound (1<i>R</i>,2<i>R</i>)-<b>30q</b>, given the relatively long half-life and MRT observed in PK studies. The overall PK and brain penetration profiles of (1<i>R</i>,2<i>R</i>)-<b>30q</b> support it as a good candidate for further in vivo studies in disease models.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Polypharmacological Profiling at Other Aminergic GPCRs</h3><div class="NLM_p last">As mentioned above, polypharmacology is a common feature of many aminergic GPCR ligands. To further profile the binding selectivity of our bitopic D3R ligands, we selected compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>R</i>,2<i>R</i>)-<b>30q</b> and screened them against 29 other aminergic GPCRs, including serotonin, adrenaline, histamine, and muscarinic receptors. Compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>R</i>,2<i>R</i>)-<b>30q</b> show weak binding affinity for most receptors (p<i>K</i><sub>i</sub> < 6) and modest binding for 5-HT<sub>1A</sub>, 5-HT<sub>2B</sub>, α<sub>2A</sub>, α<sub>2C</sub>, and H1R (see <a class="ref internalNav" href="#notes2" aria-label="Table S4">Table S4</a>). These data show that compounds (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>R</i>,2<i>R</i>)-<b>30q</b> have good selectivity for the D3R against most other aminergic GPCRs.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past decade, cocrystal structures of aminergic GPCRs have greatly facilitated our understanding of ligand–receptor interactions at these receptors as well as the structure-based drug design of novel GPCR ligands. Starting from the PCPMA scaffold, we have designed and synthesized a series of bitopic derivatives that possess excellent binding affinities for the D3R with good selectivity against other dopamine receptors. Among the optimized compounds, (1<i>R</i>,2<i>R</i>)-<b>22e</b> showed a binding affinity of 4.1 nM for D3R, with 1195-, 329-, and 140-fold selectivity over D1R (4898 nM), D2R (1349 nM), and D4R (575 nM), while possessing weak 5-HT<sub>2C</sub> affinity (1122 nM) and no affinity for the D5R. Its enantiomer, (1<i>S</i>,2<i>S</i>)-<b>22e</b>, displayed a comparable affinity for D3R (<i>K</i><sub>i</sub> = 3.8 nM), with 282-, 324-, and 224-fold selectivity against D1R (1071 nM), D2R (1230 nM), and D4R (851 nM), no affinity for D5R, and moderate selectivity over 5-HT<sub>2C</sub> (<i>K</i><sub>i</sub> = 50.1 nM). Notably, although the enantiomers showed almost identical binding affinity for D3R, (1<i>R</i>,2<i>R</i>)-<b>22e</b> behaved as a potent agonist (EC<sub>50</sub> = 3.6 nM), while (1<i>S</i>,2<i>S</i>)-<b>22e</b> showed potent antagonist activity (<i>K</i><sub>i</sub> = 16.7 nM) in the G<sub>i</sub>-cAMP assays. Molecular docking results revealed that these enantiomers adopt different binding poses in the D3R OBP, which emphasizes the importance of compound chirality in medicinal chemistry.</div><div class="NLM_p last">Due to high lipophilicity and large molecular weight, most bitopic ligands suffer from poor PK properties and low brain penetration. In this study, we determined that compound (1<i>R</i>,2<i>R</i>)-<b>30q</b>, which shows a high binding affinity for the D3R (<i>K</i><sub>i</sub> = 2.2 nM) with excellent selectivity against all other dopamine receptors (627-, 244-, and 476-fold against D1R, D2R, and D4R, no binding affinity for D5R) and most other aminergic GPCRs, is a bioavailable (F = 34.1%) and brain penetrant D3R partial agonist (EC<sub>50</sub> = 87.0 nM, <i>E</i><sub>max</sub> = 40.7%). The overall profile of (1<i>R</i>,2<i>R</i>)-<b>30q</b> supports further evaluation in animal studies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General</h3><div class="NLM_p">All commercial chemicals and solvents were used as obtained without further purification. Microwave reactions were run in a Biotage Initiator microwave reactor. Synthetic intermediates were purified on 230–400 mesh silica gel by Teledyne CombiFlash R<sub>f</sub> flash chromatography. <sup>1</sup>H NMR spectra were recorded on a Bruker AVANCE-II or AVANCE-III spectrometer at 500, 600, or 800 MHz. <sup>13</sup>C NMR spectra were recorded on an AVANCE-III spectrometer at 201 MHz. NMR chemical shifts were reported in δ (ppm) using residual solvent peaks as standards (CDCl<sub>3</sub>–7.26 (H), 77.16 (C); CD<sub>3</sub>OD–3.31 (H), 49.00 (C); DMSO-<i>d</i><sub>6</sub>–2.50 (H), 39.52 (C)). Mass spectra were measured using an LCMS-IT-TOF (Shimadzu) mass spectrometer in ESI mode. The purity of all final compounds was determined by analytical HPLC (Shim-pack GIST C<sub>18</sub> column (250 mm × 4.6 mm, particle size 5 μM); 0.05% TFA in H<sub>2</sub>O/0.05% TFA in MeOH gradient eluting system; flow rate = 1.0 mL/min). The purity of all final compounds is over 95%. Optical rotation values were recorded on a Rudolph Autopol VI automatic polarimeter (λ = 589 nm, temperature = 20 °C).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Methyl 3-((4-Methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanoate (<b>10</b>)</h4><div class="NLM_p last">A mixture of <b>9</b> (1.0 g, 5.26 mmol), methyl acrylate (6.0 mL), and Cs<sub>2</sub>CO<sub>3</sub> (3.43 g, 10.52 mmol) was heated at 100 °C for 30 min under microwave radiation. After being cooled to room temperature, the mixture was taken up in ethyl acetate and washed with water. The organic layer was separated, dried, and concentrated. The resulting residue was purified by flash chromatography (0–20% ethyl acetate in petroleum ether) to give the title product as a white solid (4.0 g, 69%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.59–7.51 (m, 5H), 4.58 (t, <i>J</i> = 7.4 Hz, 2H), 3.72 (s, 3H), 3.66 (s, 3H), 2.96 (t, <i>J</i> = 7.4 Hz, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 278.0958; found, 278.0953.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-((4-Methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanoic Acid (<b>11</b>)</h4><div class="NLM_p last">Compound <b>10</b> (4.0 g, 21.0 mmol) was dissolved in a mixture of THF (50 mL)/H<sub>2</sub>O (20 mL), and LiOH–H<sub>2</sub>O (4.2 g, 100 mmol) was then added. The mixture was stirred at room temperature overnight. A solution of 3 M HCl (aq) was added to acidify the mixture, and ethyl acetate was then added. The organic layer was separated, washed with water, dried, and concentrated. The residue was purified by flash chromatography (0–10% methanol in dichloromethane) to give the title compound as a white solid (2.26 g, 60%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.68–7.66 (m, 2H), 7.58–7.52 (m, 3H), 4.47 (t, <i>J</i> = 7.3 Hz, 2H), 3.60 (s, 3H), 2.89 (t, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 174.21, 168.33, 152.21, 132.06, 130.10 (2C), 129.81 (2C), 127.08, 46.09, 33.47, 33.06. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 264.0801; found, 264.0830.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl ((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)carbamate (<b>13a</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((2-(5-fluoro-2-hydroxyphenyl)cyclopropyl) methyl)carbamate (100 mg, 0.36 mmol), 2-fluoroethanol (52 μL, 0.89 mmol), and PPh<sub>3</sub> (233 mg, 0.89 mmol) in dry THF (8 mL) was cooled to 0 °C. Diethyl azodicarboxylate (140 μL, 0.89 mmol) was added dropwise. The reaction mixture was irradiated under microwave at 60 °C for 30 min. The mixture was evaporated to dryness to give a crude product, which was purified by flash chromatography (0–10% ethyl acetate in petroleum ether) to give the title compound as a colorless oil (110 mg, 95%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 6.82 (td, <i>J</i> = 8.4, 3.1 Hz, 1H), 6.77 (dd, <i>J</i> = 8.9, 4.6 Hz, 1H), 6.62 (dd, <i>J</i> = 9.3, 3.1 Hz, 1H), 5.00 (s, 1H), 4.90–4.74 (m, 2H), 4.31–4.18 (m, 2H), 3.51 (d, <i>J</i> = 13.3 Hz, 1H), 2.81 (dd, <i>J</i> = 13.4, 8.5 Hz, 1H), 1.96–1.92 (m, 1H), 1.46 (s, 9H), 1.11–1.04 (m, 1H), 1.02–0.99 (m, 1H), 0.87–0.83 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>, 350.1538; found, 350.1548.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>tert</i>-Butyl ((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)carbamate (<b>13b</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((2-(5-fluoro-2-hydroxyphenyl)cyclopropyl)methyl)carbamate (300 mg, 1.07 mmol), EtI (256 μL, 3.21 mmol), and K<sub>2</sub>CO<sub>3</sub> (442 mg, 3.21 mmol) in DMF (10 mL) was irradiated under a microwave at 110 °C for 30 min. The mixture was diluted with ethyl acetate and washed with water. The organic layers were then combined and washed with brine. The volatiles were removed to give a crude product, which was purified by flash chromatography (0–10% ethyl acetate in petroleum ether) to give the title compound as a colorless oil (275 mg, 83%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 6.81 (td, <i>J</i> = 8.4, 3.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.9, 4.5 Hz, 1H), 6.63 (dd, <i>J</i> = 9.3, 3.1 Hz, 1H), 5.15 (s, 1H), 4.15–4.02 (m, 2H), 3.62–3.55 (m, 1H), 2.75–2.68 (m, 1H), 1.88–1.84 (m, 1H), 1.51 (t, <i>J</i> = 7.0 Hz, 3H), 1.46 (s, 9H), 1.04–0.99 (m, 2H), 0.84–0.80 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>24</sub>FNO<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>, 332.1632; found, 332.1629.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl ((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)carbamate (<b>13c</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((2-(5-fluoro-2-hydroxyphenyl)cyclopropyl)-methyl)carbamate (281 mg, 1.0 mmol), MeI (213 mg, 1.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (828 mg, 6.0 mmol) in DMF (8 mL) was irradiated under microwave at 110 °C for 30 min. The mixture was diluted with ethyl acetate and washed with water. The organic layer was separated, dried, and concentrated. The resulting residue was purified by flash chromatography (0–10% ethyl acetate in petroleum ether) to give the title compound as a colorless oil (284 mg, 96%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 6.84 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 6.75 (dd, <i>J</i> = 9.0, 4.5 Hz, 1H), 6.64 (dd, <i>J</i> = 9.3, 3.1 Hz, 1H), 5.28 (s, 1H), 3.88 (s, 3H), 3.56 (s, 1H), 2.76–2.66 (m, 1H), 1.87–1.81 (m, 1H), 1.47 (s, 9H), 1.05–0.97 (m, 2H), 0.88–0.81 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>FNO<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>, 318.1476; found, 318.1484.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methanamine Hydrochloride (<b>14a</b>)</h4><div class="NLM_p last">A solution of <b>13a</b> (203 mg, 0.62 mmol) in 4 M HCl (g) in dioxane (8 mL) was stirred at room temperature for 5 h. The solvent was evaporated, and the residue was suspended in a mixture of ethyl acetate and petroleum ether (v/v = 1/2, 5.0 mL) and stirred for 15 min. The precipitate was collected by filtration, washed with ethyl acetate (3 mL), and dried under a vacuum to give the title compound as a white solid (134 mg, 82%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 6.96–6.87 (m, 2H), 6.76 (dd, <i>J</i> = 9.4, 3.0 Hz, 1H), 4.87–4.70 (m, 2H), 4.34–4.18 (m, 2H), 3.05–2.97 (m, 2H), 2.19–2.13 (m, 1H), 1.27–1.22 (m, 1H), 1.21–1.15 (m, 1H), 1.05–1.00 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>16</sub>F<sub>2</sub>NO<sup>+</sup> [M + H]<sup>+</sup>, 228.1194; found, 228.1220.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methanamine Hydrochloride (<b>14b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>13b</b> using a similar method as described for <b>14a</b>. White solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 6.91–6.82 (m, 2H), 6.70 (dd, <i>J</i> = 9.5, 2.8 Hz, 1H), 4.11–4.02 (m, 2H), 3.08–2.93 (m, 2H), 2.17–2.12 (m, 1H), 1.43 (t, <i>J</i> = 7.0 Hz, 3H), 1.34–1.27 (m, 1H), 1.12–1.08 (m, 1H), 1.05–1.00 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>17</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 210.1289; found, 210.1285.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methanamine Hydrochloride (<b>14c</b>)</h4><div class="NLM_p last">To a solution of <b>13c</b> (196 mg, 0.66 mmol) in THF (4 mL) was added 2 M HCl (g) in Et<sub>2</sub>O (4 mL) and stirred at room temperature overnight. The volatiles were removed to give a white solid (153 mg, 99%), which was used directly in the next step. <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 6.92–6.87 (m, 2H), 6.72 (dd, <i>J</i> = 9.3, 2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, <i>J</i> = 13.0, 7.1 Hz, 1H), 2.93 (dd, <i>J</i> = 13.1, 8.0 Hz, 1H), 2.14–2.10 (m, 1H), 1.28–1.22 (m, 1H), 1.14–1.09 (m, 1H), 1.04–1.00 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>15</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 196.1132; found, 196.1135.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methanamine Hydrochloride (<b>14d</b>)</h4><div class="NLM_p last">The title compound was prepared using <b>13d</b> at the starting material, in the same manner as described for <b>14c</b>. White solid (yield 99%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.17 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.97 (d, <i>J</i> = 2.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 1H), 3.88 (s, 3H), 3.09 (m, 1H), 2.94 (m, 1H), 2.10 (m, 1H), 1.30–1.24 (m, 1H), 1.12 (m, 1H), 1.03 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>15</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>, 212.0837; found, 212.0834.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanamide (<b>15a</b>)</h4><div class="NLM_p last">To a mixture of <b>14a</b> (120 mg, 0.46 mmol), <b>11</b> (132 mg, 0.50 mmol), and HATU (260 mg, 0.68 mmol) in DMF (10 mL) was added NaHCO<sub>3</sub> (115 mg, 1.37 mmol). The mixture was stirred at room temperature for 3 h. The mixture was then diluted with ethyl acetate and washed with water and brine. The organic layer was dried and concentrated to give a crude product, which was purified by flash chromatography (0–3% methanol in dichloromethane) to give the title compound as a white solid (194 mg, 90%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.67–7.63 (m, 2H), 7.59–7.50 (m, 3H), 6.87 (dd, <i>J</i> = 8.9, 4.7 Hz, 1H), 6.80 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 6.54 (dd, <i>J</i> = 9.7, 3.0 Hz, 1H), 4.79 (t, <i>J</i> = 4.0 Hz, 1H), 4.69 (t, <i>J</i> = 4.0 Hz, 1H), 4.52 (t, <i>J</i> = 6.9 Hz, 2H), 4.26–4.16 (m, 2H), 3.60 (s, 3H), 3.22 (ddd, <i>J</i> = 20.8, 12.8, 6.8 Hz, 2H), 2.79 (t, <i>J</i> = 6.9 Hz, 2H), 2.05–1.99 (m, 1H), 1.19–1.12 (m, 1H), 0.87–0.80 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>27</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 473.1817; found, 473.1815.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanamide (<b>15b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> using a similar method as described for <b>15a</b> as a white solid (yield 72%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.68 (d, <i>J</i> = 7.9 Hz, 2H), 7.59 (t, <i>J</i> = 7.3 Hz, 1H), 7.55 (t, <i>J</i> = 7.6 Hz, 2H), 6.85 (dd, <i>J</i> = 8.9, 4.7 Hz, 1H), 6.80 (td, <i>J</i> = 8.5, 3.0 Hz, 1H), 6.53 (dd, <i>J</i> = 9.6, 3.0 Hz, 1H), 4.55 (t, <i>J</i> = 7.0 Hz, 2H), 4.07–4.00 (m, 2H), 3.62 (s, 3H), 3.35 (dd, <i>J</i> = 13.5, 6.2 Hz, 1H), 3.14 (dd, <i>J</i> = 13.8, 7.2 Hz, 1H), 2.82 (t, <i>J</i> = 7.0 Hz, 2H), 2.06–2.01 (m, 1H), 1.42 (t, <i>J</i> = 7.0 Hz, 3H), 1.22–1.16 (m, 1H), 0.88–0.84 (m, 1H), 0.83–0.79 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>FN<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 455.1912; found, 455.1906.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanamide (<b>15c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14c</b> using a similar method as described for <b>15a</b> as a white solid (yield 72%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.67–7.49 (m, 5H), 6.86–6.78 (m, 2H), 6.53 (dd, <i>J</i> = 9.5, 3.1 Hz, 1H), 4.53 (t, <i>J</i> = 7.0 Hz, 2H), 3.82 (s, 3H), 3.60 (s, 3H), 3.21 (d, <i>J</i> = 6.9 Hz, 2H), 2.86–2.74 (m, 2H), 2.00–1.96 (m, 1H), 1.19–1.11 (m, 1H), 0.86–0.76 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 441.1755; found, 441.1749.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propanamide (<b>15d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14d</b> using a similar method as described for <b>15a</b> as a yellow solid (yield 88%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.58–7.52 (m, 3H), 7.51 (m, 2H), 7.12 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.84 (d, <i>J</i> = 2.6 Hz, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.43 (s, 1H), 4.67–4.58 (m, 2H), 3.89 (s, 3H), 3.68–3.62 (m, 1H), 3.64 (s, 3H), 2.96–2.83 (m, 3H), 1.85 (m, 1H), 1.05–0.95 (m, 2H), 0.85 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup>, 457.1460; found, 457.1457.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>16a</b>)</h4><div class="NLM_p last">To a solution of <b>15a</b> (168 mg, 0.36 mmol) in anhydrous THF (10 mL) was added a solution of BH<sub>3</sub>–THF complex in THF (1 M, 1.4 mL, 1.4 mmol) dropwise at 0 °C under argon. The solution was then heated to reflux and stirred for 4 h. The reaction was quenched by slowly adding MeOH (1 mL) and then 3 M aqueous HCl (1 mL), followed by refluxing for 30 min. The reaction mixture was cooled to room temperature, and then saturated aqueous NaHCO<sub>3</sub> was added slowly to adjust to pH 8–10. The mixture was extracted with ethyl acetate. The extracts were combined, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (0–5% methanol in dichloromethane) to give a colorless oil (112 mg, 69%). The oil was then dissolved in dichloromethane, and 2 M HCl in diethyl ether (2 mL) was added; the mixture was stirred at room temperature for 15 min. Volatiles were removed by evaporation to give the title compound as a white solid. HPLC: 99.3% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.7 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.72 (d, <i>J</i> = 7.0 Hz, 2H), 7.66–7.57 (m, 3H), 6.97–6.87 (m, 2H), 6.75 (dd, <i>J</i> = 9.4, 2.5 Hz, 1H), 4.88–4.69 (m, 2H), 4.45 (t, <i>J</i> = 6.4 Hz, 2H), 4.33–4.19 (m, 2H), 3.66 (s, 3H), 3.24–3.14 (m, 4H), 2.36–2.28 (m, 2H), 2.28–2.21 (m, 1H), 1.37–1.29 (m, 1H), 1.24–1.17 (m, 1H), 1.10–1.04 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.83, 158.86 (d, <i>J</i><sub>CF</sub> = 237.6 Hz), 154.78, 152.82, 132.83 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 132.27, 130.20 (2C), 129.84 (2C), 126.93, 114.18 (d, <i>J</i><sub>CF</sub> = 24.2 Hz), 114.15, 114.06 (d, <i>J</i><sub>CF</sub> = 23.0 Hz), 83.48 (d, <i>J</i><sub>CF</sub> = 168.0 Hz), 69.70 (d, <i>J</i><sub>CF</sub> = 19.0 Hz), 52.96, 46.83, 45.73, 33.65, 26.39, 18.53, 18.34, 13.34. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>29</sub>F<sub>2</sub>N<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 459.2025; found, 459.2022.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>16b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15b</b> in the same manner as described for <b>16a</b>. White solid (yield 92%). HPLC: 99.6% (λ = 254 nm, <i>t</i><sub>R</sub> = 19.6 min). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.70 (d, <i>J</i> = 7.3 Hz, 2H), 7.64–7.55 (m, 3H), 6.91–6.82 (m, 2H), 6.68 (d, <i>J</i> = 9.4 Hz, 1H), 4.44 (t, <i>J</i> = 6.1 Hz, 2H), 4.11–4.00 (m, 2H), 3.65 (s, 3H), 3.22–3.07 (m, 4H), 2.34–2.28 (m, 2H), 2.24–2.18 (m, 1H), 1.42 (t, <i>J</i> = 6.8 Hz, 3H), 1.38–1.31 (m, 1H), 1.15–1.09 (m, 1H), 1.08–1.03 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.86, 158.50 (d, <i>J</i><sub>CF</sub> = 236.7 Hz), 155.05, 152.84, 132.46 (d, <i>J</i><sub>CF</sub> = 7.4 Hz), 132.27, 130.20 (2C), 129.84 (2C), 126.92, 113.86 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 113.72 (d, <i>J</i><sub>CF</sub> = 24.1 Hz), 113.71, 65.61, 52.96, 46.82, 45.63, 33.66, 26.45, 18.32, 18.30, 15.33, 13.86. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 441.2119; found, 441.2112.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>16c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15c</b> in the same manner as described for <b>16a</b>. White solid (yield 62%). HPLC: 98.1% (λ = 254 nm, <i>t</i><sub>R</sub> = 13.9 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.69 (d, <i>J</i> = 7.3 Hz, 2H), 7.64–7.54 (m, 3H), 6.93–6.86 (m, 2H), 6.71 (d, <i>J</i> = 9.4 Hz, 1H), 4.44 (t, <i>J</i> = 6.6 Hz, 2H), 3.85 (s, 3H), 3.64 (s, 3H), 3.24–3.15 (m, 3H), 3.10–3.01 (m, 1H), 2.37–2.26 (m, 2H), 2.22–2.15 (m, 1H), 1.32–1.23 (m, 1H), 1.18–1.13 (m, 1H), 1.08–1.01 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.85, 158.51 (d, <i>J</i><sub>CF</sub> = 237.0 Hz), 155.84, 152.83, 132.26, 132.09 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 130.19 (2C), 129.83 (2C), 126.91, 114.04 (d, <i>J</i><sub>CF</sub> = 24.2 Hz), 113.97 (d, <i>J</i><sub>CF</sub> = 23.0 Hz), 112.38 (d, <i>J</i><sub>CF</sub> = 9.0 Hz), 56.58, 52.94, 46.85, 45.59, 33.66, 26.45, 18.38, 18.25, 13.29. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 427.1962; found, 427.1966.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine (<b>16d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>15d</b> in the same manner as described for <b>16a</b>. Colorless semisolid (yield 58%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.70–7.65 (m, 2H), 7.62–7.53 (m, 3H), 7.10 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 6.86 (d, <i>J</i> = 2.7 Hz, 1H), 4.41–4.35 (m, 2H), 3.85 (s, 3H), 3.62 (s, 3H), 2.85 (dd, <i>J</i> = 12.4, 6.3 Hz, 1H), 2.79 (t, <i>J</i> = 7.1 Hz, 2H), 2.62 (dd, <i>J</i> = 12.4, 7.8 Hz, 1H), 2.20–2.12 (m, 2H), 2.02–1.98 (m, 1H), 1.20–1.15 (m, 1H), 0.99–0.96 (m, 1H), 0.89–0.85 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>ClN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 443.1667; found, 443.1675.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-((2-(5-Fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-<i>N</i>-methyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17a</b>)</h4><div class="NLM_p last">To a mixture of <b>16a</b> (40 mg, 0.087 mmol) and formaldehyde solution (37 wt % in water, 0.195 mL, 2.62 mmol) in acetonitrile (8 mL) was added NaHB(AcO)<sub>3</sub> (46 mg, 0.22 mmol). The mixture was stirred at room temperature for 1 h. The reaction was quenched with water and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was purified by flash chromatography (0–3% methanol in dichloromethane) to give a colorless oil (24 mg, 58%). The oil was taken up in dichloromethane, 2 M HCl (g) in diethyl ether (2 mL) was added, and the mixture was stirred at room temperature for 15 min. Volatiles were removed by evaporation to give the title compound as a white solid. HPLC: 95.7% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.5 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.68 (d, <i>J</i> = 7.1 Hz, 2H), 7.63–7.53 (m, 3H), 6.95–6.84 (m, 2H), 6.71 (dd, <i>J</i> = 9.4, 2.4 Hz, 1H), 4.85–4.67 (m, 2H), 4.40 (s, 2H), 4.33–4.15 (m, 2H), 3.62 (s, 3H), 3.42–3.22 (m, 4H), 2.97 (s, 3H), 2.41–2.34 (m, 2H), 2.32–2.23 (m, 1H), 1.35–1.29 (m, 1H), 1.28–1.22 (m, 1H), 1.10–1.03 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.89, 158.93 (d, <i>J</i><sub>CF</sub> = 237.6 Hz), 154.68, 152.77, 132.54 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 132.27, 130.20 (2C), 129.83 (2C), 126.91, 114.25 (d, <i>J</i><sub>CF</sub> = 7.6 Hz), 114.13 (d, <i>J</i><sub>CF</sub> = 23.0 Hz), 113.80 (d, <i>J</i><sub>CF</sub> = 24.5 Hz), 83.41 (d, <i>J</i><sub>CF</sub> = 168.3 Hz), 69.76 (d, <i>J</i><sub>CF</sub> = 19.3 Hz), 61.18, 54.41, 46.91, 40.56, 33.63, 24.43, 18.50, 18.42, 17.69. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>31</sub>F<sub>2</sub>N<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 473.2181; found, 473.2182.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-Ethyl-<i>N</i>-((2-(5-fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16a</b> and acetaldehyde in the same manner as described for <b>17a</b>. White solid (yield 42%). HPLC: 97.3% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.9 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.66 (d, <i>J</i> = 6.7 Hz, 2H), 7.63–7.53 (m, 3H), 6.95–6.84 (m, 2H), 6.71 (dd, <i>J</i> = 9.3, 2.4 Hz, 1H), 4.84–4.66 (m, 2H), 4.40 (s, 2H), 4.32–4.14 (m, 2H), 3.61 (s, 3H), 3.42–3.32 (m, 6H), 2.40–2.32 (m, 2H), 2.30–2.23 (m, 1H), 1.33 (t, <i>J</i> = 7.2 Hz, 3H), 1.30–1.26 (m, 1H), 1.23–1.20 (m, 1H), 1.10–1.00 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.94, 158.92 (d, <i>J</i><sub>CF</sub> = 237.9 Hz), 154.71, 152.75, 132.56 (d, <i>J</i><sub>CF</sub> = 7.6 Hz), 132.28, 130.21 (2C), 129.79 (2C), 126.90, 114.27 (d, <i>J</i><sub>CF</sub> = 8.0 Hz), 114.17 (d, <i>J</i><sub>CF</sub> = 23.1 Hz), 113.91 (d, <i>J</i><sub>CF</sub> = 24.0 Hz), 83.43 (d, <i>J</i><sub>CF</sub> = 168.3 Hz), 69.77 (d, <i>J</i><sub>CF</sub> = 19.4 Hz), 57.45, 50.39, 47.00, 33.62, 24.01, 18.45, 17.30, 13.44, 9.20. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>F<sub>2</sub>N<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 487.2338; found, 487.2333.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-<i>N</i>-methyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16b</b> and formaldehyde in the same manner as described for <b>17a</b> as a light yellow solid (yield 72%). HPLC: 96.5% (λ = 254 nm, <i>t</i><sub>R</sub> = 16.8 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.68 (d, <i>J</i> = 7.1 Hz, 2H), 7.63–7.54 (m, 3H), 6.91–6.81 (m, 2H), 6.66 (dd, <i>J</i> = 9.5, 2.4 Hz, 1H), 4.41 (t, <i>J</i> = 5.9 Hz, 2H), 4.12–4.00 (m, 2H), 3.62 (s, 3H), 3.37–3.30 (m, 4H), 2.99 (s, 3H), 2.41–2.34 (m, 2H), 2.32–2.25 (m, 1H), 1.40 (t, <i>J</i> = 7.0 Hz, 3H), 1.35–1.30 (m, 1H), 1.21–1.16 (m, 1H), 1.10–1.02 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.60, 158.58 (d, <i>J</i><sub>CF</sub> = 236.4 Hz), 154.94 (d, <i>J</i><sub>CF</sub> = 2.1 Hz), 152.40, 133.42 (d, <i>J</i><sub>CF</sub> = 7.4 Hz), 132.13, 130.15 (2C), 129.77 (2C), 127.00, 113.72 (d, <i>J</i><sub>CF</sub> = 8.6 Hz), 113.39 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 112.95 (d, <i>J</i><sub>CF</sub> = 24.1 Hz), 65.61, 61.89, 54.60, 47.77, 41.52, 33.57, 25.49, 19.29, 18.20, 15.36, 14.01. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 455.2275; found, 455.2275.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-((2-(2-Ethoxy-5-fluorophenyl)cyclopropyl)methyl)-<i>N</i>-ethyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16b</b> and acetaldehyde in the same manner as described for <b>17a</b>. White solid (yield 47%). HPLC: 96.4% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.2 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.70–7.53 (m, 5H), 6.91–6.81 (m, 2H), 6.66 (dd, <i>J</i> = 9.4, 2.4 Hz, 1H), 4.41 (t, <i>J</i> = 6.6 Hz, 2H), 4.14–3.98 (m, 2H), 3.62 (s, 3H), 3.43–3.34 (m, 6H), 2.41–2.33 (m, 2H), 2.32–2.26 (m, 1H), 1.41 (t, <i>J</i> = 6.9 Hz, 3H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H), 1.32–1.27 (m, 1H), 1.20–1.14 (m, 1H), 1.10–1.03 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.88, 158.53 (d, <i>J</i><sub>CF</sub> = 238.4 Hz), 154.99, 152.67, 132.24, 132.19 (d, <i>J</i><sub>CF</sub> = 7.8 Hz), 130.19 and 130.18 (2C), 129.81 and 129.77 (2C), 126.90 and 126.84, 113.96 (d, <i>J</i><sub>CF</sub> = 22.8 Hz), 113.77 (d, <i>J</i><sub>CF</sub> = 7.2 Hz), 113.46 (d, <i>J</i><sub>CF</sub> = 25.0 Hz),65.66 and 65.62, 57.41, 50.50 and 50.13, 49.40, 47.07, 33.63, 24.09 and 23.91, 18.55 and 18.35, 17.23 and 17.07, 15.37, 13.92 and 13.73, 9.41, and 9.14. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 469.2432; found, 469.2439.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-<i>N</i>-methyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and formaldehyde in the same manner as described for <b>17a</b>. White solid (yield 89%). HPLC: 98.9% (λ = 254 nm, <i>t</i><sub>R</sub> = 13.7 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.71–7.65 (m, 2H), 7.60 (m, 3H), 6.90 (m, 2H), 6.74–6.67 (m, 1H), 4.43 (m, 2H), 3.85 (s, 3H), 3.63 (s, 3H), 3.49–3.39 (m, 2H), 3.20 (m, 1H), 3.00 (s, 3H), 2.44–2.36 (m, 2H), 2.30–2.24 (m, 1H), 1.31 (m, 2H), 1.25–1.17 (m, 1H), 1.06 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.94, 158.56 (d, <i>J</i><sub>CF</sub> = 236.6 Hz), 155.77, 152.73, 132.24, 131.79 (d, <i>J</i><sub>CF</sub> = 6.9 Hz), 130.17 (2C), 129.80 (2C), 126.89, 114.07 (d, <i>J</i><sub>CF</sub> = 22.8 Hz), 113.78 (d, <i>J</i><sub>CF</sub> = 24.3 Hz), 112.51 (d, <i>J</i><sub>CF</sub> = 8.3 Hz), 61.17 and 61.03, 56.59, 54.06 and 53.65, 46.93, 40.52 and 40.44, 33.64, 24.37, 18.74 and 18.40, 17.41 and 17.13, 13.45, and 12.85. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 441.2119; found, 441.2117.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-Ethyl-<i>N</i>-((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and acetaldehyde in the same manner as described for <b>17a</b>. White solid (yield 60%). HPLC: 98.0% (λ = 254 nm, <i>t</i><sub>R</sub> = 13.9 min). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.67–7.53 (m, 5H), 6.93–6.85 (m, 2H), 6.68 (dd, <i>J</i> = 9.6, 2.6 Hz, 1H), 4.46–4.35 (m, 2H), 3.84 (s, 3H), 3.61 (s, 3H), 3.46–3.33 (m, 5H), 3.28–3.19 (m, 1H), 2.37 (p, <i>J</i> = 7.1 Hz, 2H), 2.28–2.18 (m, 1H), 1.35 (t, <i>J</i> = 7.3 Hz, 3H), 1.29–1.22 (m, 1H), 1.20–1.14 (m, 1H), 1.07–1.00 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 169.01, 158.57 (d, <i>J</i><sub>CF</sub> = 237.1 Hz), 155.78, 152.72, 132.25, 131.80 (d, <i>J</i><sub>CF</sub> = 6.1 Hz), 130.19 (2C), 129.77 (2C), 126.87, 114.09 (d, <i>J</i><sub>CF</sub> = 22.7 Hz), 113.90 (d, <i>J</i><sub>CF</sub> = 21.2 Hz), 112.55 (d, <i>J</i><sub>CF</sub> = 9.0 Hz), 57.40 and 57.24, 56.63, 50.22 and 50.02, 49.50 and 49.39, 47.01, 33.62, 24.01 and 23.85, 18.63 and 18.51, 17.07, 13.07 and 13.01, 9.31, and 9.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 455.2275; found, 455.2270.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)-<i>N</i>-propylpropan-1-amine Hydrochloride (<b>17g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and propyl aldehyde in the same manner as described for <b>17a</b>. White solid (yield 42%). HPLC: 98.2% (λ = 254 nm, <i>t</i><sub>R</sub> = 16.0 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.66–7.59 (m, 3H), 7.58–7.54 (m, 2H), 6.91–6.85 (m, 2H), 6.67 (dd, <i>J</i> = 9.4, 2.9 Hz, 1H), 4.44–4.38 (m, 2H), 3.84 and 3.83 (s, 3H), 3.61 and 3.60 (s, 3H), 3.49–3.36 (m, 3H), 3.28–3.18 (m, 3H), 2.43–2.35 (m, 2H), 2.30–2.23 (m, 1H), 1.82–1.72 (m, 2H), 1.29–1.25 (m, 1H), 1.20–1.16 (m, 1H), 1.07–0.98 (m, 4H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.98, 158.57 (d, <i>J</i><sub>CF</sub> = 236.8 Hz), 155.73, 152.70, 132.25, 131.83 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 130.19 (2C), 129.77 (2C), 126.84 (d, <i>J</i><sub>CF</sub> = 4.3 Hz), 114.07 (d, <i>J</i><sub>CF</sub> = 23.2 Hz), 113.80 (d, <i>J</i><sub>CF</sub> = 24.3 Hz), 112.55, 57.90 and 57.84, 56.68 and 56.63, 55.79 and 55.45, 50.82 and 50.55, 47.04, 33.63, 23.95 and 23.79, 18.60, 18.46 and 18.36, 17.15 and 17.06, 13.24 and 13.26, 11.21. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 469.2432; found, 469.2434.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)-<i>N</i>-isopropyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and acetone in the same manner as described for <b>17a</b>. White solid (yield 24%). HPLC: 97.9% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.2 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.67–7.64 (m, 2H), 7.60–7.54 (m, 3H), 6.83 (dd, <i>J</i> = 8.9, 4.6 Hz, 1H), 6.77 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 6.54 (dd, <i>J</i> = 9.8, 3.1 Hz, 1H), 4.30–4.23 (m, 2H), 3.81 (s, 3H), 3.61 (s, 3H), 3.18–3.10 (m, 1H), 2.74–2.50 (m, 4H), 2.12–2.01 (m, 3H), 1.13–1.07 (m, 1H), 1.06–1.01 (m, 6H), 0.93–0.88 (m, 1H), 0.85–0.79 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.29, 158.72 (d, <i>J</i> = 237.0 Hz), 155.59, 152.11 (d, <i>J</i><sub>CF</sub> = 3.3 Hz), 134.62 (d, <i>J</i><sub>CF</sub> = 7.3 Hz), 132.04, 130.14 (2C), 129.75 (2C), 127.14, 112.79 (d, <i>J</i><sub>CF</sub> = 23.0 Hz), 112.46 (d, <i>J</i><sub>CF</sub> = 23.9 Hz), 112.38 (d, <i>J</i><sub>CF</sub> = 6.5 Hz), 56.67, 55.40, 51.87, 48.59, 47.70, 33.50, 27.71, 22.74, 18.78, 17.97, 17.87, 14.51. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 469.2432; found, 469.2438.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(Cyclopropylmethyl)-<i>N</i>-((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16c</b> and cyclopropanecarbaldehyde in the same manner as described for <b>17a</b>. White solid (yield 68%). HPLC: 98.8% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.6 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.66–7.63 (m, 2H), 7.62–7.59 (m, 1H), 7.58–7.55 (m, 2H), 6.92–6.85 (m, 2H), 6.68 (dd, <i>J</i> = 9.4, 2.3 Hz, 1H), 4.43 and 4.41 (t, <i>J</i> = 6.4 Hz, 2H), 3.84 (s, 3H), 3.62 and 3.60 (s, 3H), 3.53–3.42 (m, 3H), 3.34–3.24 (m, 2H), 3.19–3.15 (m, 1H), 2.41–2.34 (m, 2H), 2.30–2.24 (m, 1H), 1.31–1.26 (m, 1H), 1.21–1.18 (m, 1H), 1.18–1.11 (m, 1H), 1.09–1.02 (m, 1H), 0.79–0.72 (m, 2H), 0.48–0.39 (m, 2H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.98 and 168.91, 158.55 (d, <i>J</i><sub>CF</sub> = 236.9 Hz), 155.72, 152.64, 132.24, 131.87 (d, <i>J</i><sub>CF</sub> = 7.3 Hz), 130.18 (2C), 129.75 (2C), 126.84 (d, <i>J</i><sub>CF</sub> = 6.1 Hz), 114.04 (d, <i>J</i><sub>CF</sub> = 22.7 Hz), 113.78 and 113.68 (d, <i>J</i><sub>CF</sub> = 24.0 Hz), 112.52 (d, <i>J</i><sub>CF</sub> = 9.4 Hz), 59.21 and 58.86, 57.78 and 57.75, 56.69 and 56.65, 50.80 and 50.43, 47.11, 33.64, 24.12 and 23.94, 18.63 and 18.53, 17.20 and 17.14, 13.24 and 13.22, 6.71 and 6.63, 5.26 and 5.11, 5.08, and 4.91. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>FN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 481.2432; found, 481.2436.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-<i>N</i>-ethyl-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16d</b> and acetaldehyde in the same manner as described for <b>17a</b>. White solid (yield 58%). HPLC: 97.8% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.8 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.64–7.59 (m, 3H), 7.58–7.54 (m, 2H), 7.15 (t, <i>J</i> = 7.0 Hz, 1H), 6.92–6.90 (m, 2H), 4.47–4.37 (m, 2H), 3.85 (s, 3H), 3.60 and 3.59 (s, 3H), 3.46–3.34 (m, 5H), 3.28–3.21 (m, 1H), 2.40–2.34 (m, 2H), 2.25–2.17 (m, 1H), 1.35 (t, <i>J</i> = 7.3 Hz, 3H), 1.27–1.21 (m, 1H), 1.19–1.15 (m, 1H), 1.05–0.99 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 158.31, 152.74, 132.27, 131.83, 130.20 (2C), 129.73 (2C), 128.28, 127.22, 127.08, 126.82, 126.63, 112.88, 57.40 and 57.21, 56.42 and 56.39, 50.11 and 49.97, 46.96 and 46.94, 33.62, 28.10, 23.94 and 23.80, 18.55 and 18.39, 16.93 and 16.81, 12.85 and 12.76, 9.27, and 9.18. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>ClN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 471.1980; found, 471.1977.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)-<i>N</i>-propylpropan-1-amine Hydrochloride (<b>17k</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16d</b> and propyl aldehyde in the same manner as described for <b>17a</b>. White solid (yield 85%). HPLC: 95.6% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.1 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.64–7.58 (m, 3H), 7.57–7.53 (m, 2H), 7.14 (t, <i>J</i> = 7.0 Hz, 1H), 6.92–6.87 (m, 2H), 4.45–4.36 (m, 2H), 3.84 (s, 3H), 3.60 and 3.59 (s, 3H), 3.48–3.35 (m, 3H), 3.27–3.17 (m, 3H), 2.41–2.33 (m, 2H), 2.24–2.17 (m, 1H), 1.81–1.71 (m, 2H), 1.27–1.22 (m, 1H), 1.18–1.14 (m, 1H), 1.05–0.98 (m, 4H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 158.28, 152.71, 132.26, 131.84, 130.20 (2C), 129.72 (2C), 128.24, 127.14, 126.99, 126.82, 126.64, 112.88, 57.87 and 57.76, 56.42 and 56.40, 55.78 and 55.51, 50.68 and 50.49, 46.96, 33.62, 23.89 and 23.74, 18.51 and 18.45, 18.37 and 18.33, 16.95 and 16.80, 12.98 and 12.91, 11.16. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>ClN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 485.2136; found, 485.2131.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)-<i>N</i>-(cyclopropylmethyl)-3-((4-methyl-5-phenyl-4<i>H</i>-1,2,4-triazol-3-yl)thio)propan-1-amine Hydrochloride (<b>17l</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>16d</b> and cyclopropanecarbaldehyde in the same manner as described for <b>17a</b>. White solid (yield 77%). HPLC: 99.3% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.2 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.66–7.56 (m, 5H), 7.19–7.14 (m, 1H), 6.95–6.90 (m, 2H), 4.46–4.40 (m, 2H), 3.86 (s, 3H), 3.62 and 3.60 (s, 3H), 3.55–3.49 (m, 2H), 3.49–3.39 (m, 1H), 3.35–3.30 (m, 1H), 3.30–3.24 (m, 1H), 3.20–3.15 (m, 1H), 2.43–2.35 (m, 2H), 2.28–2.20 (m, 1H), 1.29–1.24 (m, 1H), 1.22–1.17 (m, 1H), 1.17–1.13 (m, 1H), 1.08–1.02 (m, 1H), 0.80–0.73 (m, 2H), 0.48–0.41 (m, 2H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 158.29, 152.72, 132.28, 131.80, 130.22 (2C), 129.72 (2C), 128.24, 127.13, 126.97, 126.80, 126.64, 112.89, 59.25 and 58.95, 57.72, 56.41, 50.69 and 50.38, 47.03, 33.63, 24.05 and 23.88, 18.53 and 18.40, 16.93, 12.94, 6.68 and 6.62, 5.15 and 5.10, 5.01, and 4.84. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>34</sub>ClN<sub>4</sub>OS<sup>+</sup> [M + H]<sup>+</sup>, 497.2136; found, 497.2133.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(4-Hydroxybutyl)-2-naphthamide (<b>19a</b>)</h4><div class="NLM_p last">2-Naphthoyl chloride (218 mg, 1.14 mmol) was dissolved in dichloromethane (10 mL), and then trimethylamine (174 mg, 1.72 mmol) and 4-aminobutanol (112 mg, 1.26 mmol) were added successively. The mixture was stirred at room temperature for 2 h. The solvent was evaporated under a vacuum to give a residue, which was then taken up in ethyl acetate and washed with saturated aqueous NaHCO<sub>3</sub> and then brine. The organic layer was separated and concentrated to give the crude product, which was purified by flash chromatography (0–5% methanol in dichloromethane) to give the title compound as a white solid (243 mg, 87%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 8.30 (s, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 1H), 7.90 (d, <i>J</i> = 8.5 Hz, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.84 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 7.59–7.53 (m, 2H), 3.77 (t, <i>J</i> = 6.1 Hz, 2H), 3.59 (t, <i>J</i> = 6.9 Hz, 2H), 1.82–1.77 (m, 2H), 1.75–1.71 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>18</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 244.1332; found, 244.1329.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-Hydroxybutyl)-1<i>H</i>-indole-2-carboxamide (<b>19b</b>)</h4><div class="NLM_p last">A mixture of 1<i>H</i>-indole-2-carboxylic acid (200 mg, 1.24 mmol), 4-aminobutanol (132 mg, 1.49 mmol), HATU (708 mg, 1.88 mmol), and NaHCO<sub>3</sub> (313 mg, 3.72 mmol) in DMF (10 mL) was stirred at room temperature for 2 h. The mixture was diluted with ethyl acetate, washed with water, and then brine. The organic layer was separated and concentrated to give a crude product, which was purified by flash chromatography (0–5% methanol in dichloromethane) to give the title compound as a white solid (231 mg, 80%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.61 (d, <i>J</i> = 8.0 Hz, 1H), 7.45 (dd, <i>J</i> = 8.3, 0.7 Hz, 1H), 7.24–7.20 (m, 1H), 7.08–7.05 (m, 2H), 3.63 (t, <i>J</i> = 6.5 Hz, 2H), 3.44 (t, <i>J</i> = 7.1 Hz, 2H), 1.75–1.69 (m, 2H), 1.68–1.63 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 233.1285; found, 233.1280.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-Hydroxybutyl)-4-(pyridin-2-yl)benzamide (<b>19c</b>)</h4><div class="NLM_p last">The title compound was prepared from 4-(pyridin-2-yl)benzoic acid using the same method as described for compound <b>19b</b>. White solid (yield 93%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.66 (d, <i>J</i> = 4.8 Hz, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 7.96–7.92 (m, 4H), 7.44–7.40 (m, 1H), 3.63 (t, <i>J</i> = 6.5 Hz, 2H), 3.45 (t, <i>J</i> = 7.1 Hz, 2H), 1.76–1.70 (m, 2H), 1.68–1.61 (m, 2H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 271.1441; found, 271.1434.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> General Procedures for the Preparation of <b>20a</b>–<b>c</b></h3><div class="NLM_p">A mixture of the SO<sub>3</sub>–pyridine complex (5.0 equiv) in dichloromethane (0.25 mol/L) and DMSO (0.25 mol/L) was cooled to 0 °C. Then a mixture of amides <b>19a</b>–<b>c</b> (1.0 equiv) and trimethylamine (5.0 equiv) in DMSO (0.12 mol/L) was added dropwise. The mixture was stirred at room temperature for 1.5 h. Water was added, and the mixture was extracted with ethyl acetate. The combined extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give an oil, which was used in the next step without further purification.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)ethanamine (<b>21a</b>)</h4><div class="NLM_p last">A mixture of <b>14c</b> (162 mg, 0.70 mmol), acetaldehyde (31 mg, 0.70 mmol), and trimethylamine (71 mg, 0.70 mmol) in THF (20 mL) was stirred at room temperature for 1 h. NaBH<sub>4</sub> (79 mg, 2.10 mmol) was then added, and the reaction mixture was stirred at room temperature for 20 min. MeOH (5 mL) was added to quench the reaction. Water was added, and the mixture was extracted with ethyl acetate. The combined extracts were washed with brine and concentrated. The residue was purified by flash chromatography (0–8% methanol in dichloromethane) to give the title compound as a yellow oil (53 mg, 34%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 6.92–6.87 (m, 2H), 6.71 (dd, <i>J</i> = 9.4, 3.0 Hz, 1H), 3.85 (s, 3H), 3.12–2.94 (m, 4H), 2.16–2.13 (m, 1H), 1.31 (t, <i>J</i> = 7.3 Hz, 3H), 1.28–1.22 (m, 1H), 1.14–1.11 (m, 1H), 1.03–0.99 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 224.1445; found, 224.1453.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)ethanamine (<b>21b</b>)</h4><div class="NLM_p last">Using a similar method as described for <b>21a</b>, the title compound was prepared as a brown oil (yield 33%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.17 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.96 (d, <i>J</i> = 2.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 1H), 3.87 (s, 3H), 3.16–3.08 (m, 3H), 3.03 (dd, <i>J</i> = 13.3, 8.3 Hz, 1H), 2.18–2.11 (m, 1H), 1.35 (t, <i>J</i> = 7.3 Hz, 3H), 1.30–1.23 (m, 1H), 1.18–1.12 (m, 1H), 1.07–1.00 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>, 240.1150; found, 240.1156.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)propan-1-amine (<b>21c</b>)</h4><div class="NLM_p last">Using a similar method as described for <b>21a</b>, the title compound was prepared as a colorless oil (yield 23%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 6.89 (dd, <i>J</i> = 8.9, 4.6 Hz, 1H), 6.87–6.84 (m, 1H), 6.67 (dd, <i>J</i> = 9.5, 3.0 Hz, 1H), 3.84 (s, 3H), 2.93 (dd, <i>J</i> = 12.5, 6.5 Hz, 1H), 2.82–2.76 (m, 2H), 2.73 (dd, <i>J</i> = 12.5, 7.8 Hz, 1H), 2.07–2.03 (m, 1H), 1.67–1.60 (m, 2H), 1.22–1.16 (m, 1H), 1.08–1.04 (m, 1H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H), 0.95–0.91 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 238.1602; found, 238.1603.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)propan-1-amine (<b>21d</b>)</h4><div class="NLM_p last">Using a similar method as described for <b>21a</b>, the title compound was prepared as a colorless oil (yield 31%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.16 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.95 (d, <i>J</i> = 2.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 1H), 3.86 (s, 3H), 3.13 (dd, <i>J</i> = 12.9, 7.1 Hz, 1H), 3.05–2.96 (m, 3H), 2.17–2.13 (m, 1H), 1.77–1.71 (m, 2H), 1.31–1.24 (m, 1H), 1.17–1.12 (m, 1H), 1.06–1.01 (m, 4H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>ClNO<sup>+</sup> [M + H]<sup>+</sup>, 254.1306; found, 254.1310.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> General Procedures for the Preparation of <b>22a–i</b></h3><div class="NLM_p">To a solution of amines <b>21a</b>–<b>d</b> (1.0 equiv) in THF was added aldehydes <b>20a</b>–<b>c</b> (1.0 equiv) and NaHB(AcO)<sub>3</sub> (2.0 equiv), and the reaction mixture was stirred at room temperature overnight. Methanol was added to afford a clear solution, which was stirred at room temperature for 15–30 min. The solution was concentrated, and the residue was purified by flash chromatography (0–6% methanol in dichloromethane) to give a colorless oil (<b>22a</b>–<b>i</b> free bases). These free bases were converted into their HCl salts using 2 M HCl (g) in diethyl ether in the same manner as described for <b>17a</b>.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(4-(Ethyl((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)amino)butyl)-2-naphthamide Hydrochloride (<b>22a</b>)</h4><div class="NLM_p last">White solid (yield 37%). HPLC: 99.3% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.4 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.97 (t, <i>J</i> = 8.1 Hz, 1H), 7.95–7.91 (m, 2H), 7.91–7.87 (m, 1H), 7.61–7.56 (m, 2H), 6.91–6.85 (m, 2H), 6.71–6.69 (m, 1H), 3.83 and 3.82 (s, 3H), 3.54–3.48 (m, 2H), 3.42–3.32 (m, 4H), 3.30–3.21 (m, 2H), 2.32–2.28 (m, 1H), 1.90–1.80 (m, 2H), 1.79–1.71 (m, 2H), 1.38–1.35 (m, 3H), 1.34–1.29 (m, 1H), 1.24–1.19 (m, 1H), 1.08–1.04 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.38, 158.66 (d, <i>J</i><sub>CF</sub> = 237.0 Hz), 155.70, 136.29, 134.05, 132.71, 131.95 (d, <i>J</i><sub>CF</sub> = 7.1 Hz), 130.00, 129.39, 128.91, 128.78 (2C), 127.91, 124.80, 113.96 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 113.42 and 113.40 (d, <i>J</i><sub>CF</sub> = 24.1 Hz), 112.55 (d, <i>J</i><sub>CF</sub> = 8.6 Hz), 57.53 and 57.43, 56.56, 55.34 and 55.06, 53.23 and 52.96, 39.94 and 39.91, 27.83, 22.49 and 22.34, 18.44, 17.46 and 17.39, 13.36 and 13.19, 9.31, and 9.10. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 449.2599; found, 449.2604.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>22b</b>)</h4><div class="NLM_p last">White solid (yield 68%). HPLC: 99.4% (λ = 254 nm, <i>t</i><sub>R</sub> = 21.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.39 (d, <i>J</i> = 7.4 Hz, 1H), 7.97 (t, <i>J</i> = 7.6 Hz, 1H), 7.95–7.88 (m, 3H), 7.62–7.53 (m, 2H), 6.92–6.84 (m, 2H), 6.71–6.66 (m, 1H), 3.82 (s, 3H), 3.54–3.48 (m, 2H), 3.40–3.28 (m, 3H), 3.28–3.16 (m, 3H), 2.32–2.27 (m, 1H), 1.90–1.82 (m, 2H), 1.81–1.72 (m, 4H), 1.36–1.32 (m, 1H), 1.23–1.19 (m, 1H), 1.09–1.04 (m, 1H), 1.02–0.97 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.36, 158.68 (d, <i>J</i><sub>CF</sub> = 236.7 Hz), 155.66 (d, <i>J</i><sub>CF</sub> = 2.8 Hz), 136.29, 134.05, 132.71, 131.97 (d, <i>J</i><sub>CF</sub> = 7.4 Hz), 130.00, 129.39, 128.91, 128.79 (2C), 127.91, 124.80, 114.00, and 113.89 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 113.37 and 113.25 (d, <i>J</i><sub>CF</sub> = 24.2 Hz), 112.58 and 112.54 (d, <i>J</i><sub>CF</sub> = 8.5 Hz), 58.07, 56.58, 55.76 and 55.34, 53.90 and 53.52, 39.91 and 39.88, 27.81, 22.42 and 22.27, 18.46 and 18.31, 18.41, 17.52 and 17.45, 13.44, 11.22, and 11.21. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>36</sub>FN<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 463.2755; found, 463.2764.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(4-(Ethyl((2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)amino)butyl)-<i>H</i>-indole-2-carboxamide Hydrochloride (<b>22c</b>)</h4><div class="NLM_p last">White solid (yield 44%). HPLC: 98.9% (λ = 280 nm, <i>t</i><sub>R</sub> = 14.0 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.23–7.19 (m, 1H), 7.07–7.04 (m, 2H), 6.91–6.85 (m, 2H), 6.69 (dd, <i>J</i> = 9.5, 2.9 Hz, 1H), 3.82 (s, 3H), 3.46 (t, <i>J</i> = 6.8 Hz, 2H), 3.37–3.20 (m, 6H), 2.30–2.26 (m, 1H), 1.84–1.76 (m, 2H), 1.75–1.69 (m, 2H), 1.34 (t, <i>J</i> = 7.3 Hz, 3H), 1.30–1.26 (m, 1H), 1.23–1.20 (m, 1H), 1.06–1.01 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.33, 158.63 (d, <i>J</i><sub>CF</sub> = 236.7 Hz), 155.69, 138.29, 132.09, 131.95 (d, <i>J</i><sub>CF</sub> = 7.3 Hz), 128.96, 125.11, 122.75, 121.22, 113.94 (d, <i>J</i><sub>CF</sub> = 22.8 Hz), 113.40 (d, <i>J</i><sub>CF</sub> = 24.3 Hz), 113.07, 112.54 (d, <i>J</i><sub>CF</sub> = 7.2 Hz), 104.51, 57.50 and 57.41, 56.56, 53.19 and 52.91, 48.62, 39.40, 27.88, 22.45 and 22.31, 18.43 and 18.42, 17.46 and 17.40, 13.34 and 13.15, 9.30, and 9.09. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 438.2551; found, 438.2550.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>22d</b>)</h4><div class="NLM_p last">White solid (yield 65%). HPLC: 98.5% (λ = 280 nm, <i>t</i><sub>R</sub> = 14.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.61–7.58 (m, 1H), 7.45–7.43 (m, 1H), 7.23–7.19 (m, 1H), 7.09–7.05 (m, 2H), 6.91–6.85 (m, 2H), 6.70–6.67 (m, 1H), 3.82 (s, 3H), 3.49–3.44 (m, 2H), 3.35–3.25 (m, 3H), 3.25–3.14 (m, 3H), 2.31–2.26 (m, 1H), 1.86–1.69 (m, 6H), 1.34–1.28 (m, 1H), 1.23–1.19 (m, 1H), 1.07–1.03 (m, 1H), 1.03–0.97 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.33, 158.65 (d, <i>J</i><sub>CF</sub> = 236.8 Hz), 155.65, 138.30, 132.08, 131.96 (d, <i>J</i><sub>CF</sub> = 7.6 Hz), 128.96, 125.12, 122.75, 121.23, 113.93, and 113.92 (d, <i>J</i><sub>CF</sub> = 23.3 Hz), 113.31 and 113.28 (d, <i>J</i><sub>CF</sub> = 24.3 Hz), 113.08, 112.56, and 112.54 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 104.51, 58.05, 56.58, 55.71 and 55.30, 53.86 and 53.48, 39.38, 27.85, 22.38 and 22.27, 18.44 and 18.39, 18.29, 17.52 and 17.45, 13.41 and 13.39, 11.20. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 452.2708; found, 452.2714.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(4-(((2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>22e</b>)</h4><div class="NLM_p last">White solid (yield 57%). HPLC: 98.5% (λ = 254 nm, <i>t</i><sub>R</sub> = 13.6 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.90 (d, <i>J</i> = 5.6 Hz, 1H), 8.71 (t, <i>J</i> = 8.1 Hz, 1H), 8.45 (d, <i>J</i> = 8.2 Hz, 1H), 8.17–8.13 (m, 2H), 8.11–8.06 (m, 3H), 6.93–6.91 (m, 1H), 6.89–6.86 (m, 1H), 6.72–6.69 (m, 1H), 3.85 (s, 3H), 3.52–3.47 (m, 2H), 3.40–3.32 (m, 2H), 3.31–3.18 (m, 4H), 2.34–2.30 (m, 1H), 1.91–1.84 (m, 2H), 1.82–1.72 (m, 4H), 1.40–1.34 (m, 1H), 1.25–1.20 (m, 1H), 1.11–1.07 (m, 1H), 1.05–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.77, 158.68 (d, <i>J</i><sub>CF</sub> = 237.2 Hz), 155.69, 153.21 (d, <i>J</i><sub>CF</sub> = 4.2 Hz), 148.23, 143.61, 138.88, 135.19, 132.04 (d, <i>J</i><sub>CF</sub> = 7.3 Hz), 129.73 (2C), 129.60 (2C), 127.56, 127.19, 113.93 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 113.30 (d, <i>J</i><sub>CF</sub> = 24.5 Hz), 112.60 (d, <i>J</i><sub>CF</sub> = 8.2 Hz), 58.06, 56.62, 55.79 and 55.35, 53.88 and 53.49, 40.10 and 40.07, 27.67, 22.50 and 22.37, 18.48 and 18.32, 18.43 and 18.41, 17.54 and 17.45, 13.50, 11.26, and 11.24. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 490.2864; found, 490.2863.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)(ethyl)amino)butyl)-2-naphthamide Hydrochloride (<b>22f</b>)</h4><div class="NLM_p last">White solid (yield 86%). HPLC: 98.8% (λ = 254 nm, <i>t</i><sub>R</sub> = 17.5 min). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD): δ 8.37 (d, <i>J</i> = 3.9 Hz, 1H), 7.99–7.91 (m, 3H), 7.89–7.85 (m, 1H), 7.62–7.54 (m, 2H), 7.15 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.95–6.86 (m, 2H), 3.84 and 3.83 (s, 3H), 3.53–3.49 (m, 2H), 3.42–3.32 (m, 4H), 3.29–3.22 (m, 2H), 2.29–2.24 (m, 1H), 1.88–1.80 (m, 2H), 1.79–1.72 (m, 2H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H), 1.33–1.29 (m, 1H), 1.26–1.20 (m, 1H), 1.08–1.02 (m, 1H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.40, 158.23, 136.28, 134.04, 132.71, 131.95, 129.98, 129.39, 128.91, 128.79, 128.74, 128.11, 127.92, 126.67, 126.65, 124.76, 112.83, 57.52 and 57.44, 56.31(2C), 53.18 and 52.93, 39.93 and 39.89, 27.84, 22.44 and 22.27, 18.29, 17.23 and 17.17, 13.21 and 13.07, 9.25, and 9.06. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 465.2303; found, 465.2309.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>22g</b>)</h4><div class="NLM_p last">Colorless oil (yield 63%). HPLC: 95.4% (λ = 280 nm, <i>t</i><sub>R</sub> = 24.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.38 (d, <i>J</i> = 5.8 Hz, 1H), 7.99–7.93 (m, 3H), 7.91–7.88 (m, 1H), 7.62–7.57 (m, 2H), 7.15 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.94–6.91 (m, 2H), 3.85 and 3.84 (s, 3H), 3.55–3.50 (m, 2H), 3.40–3.33 (m, 2H), 3.30–3.17 (m, 4H), 2.29–2.26 (m, 1H), 1.88–1.81 (m, 2H), 1.81–1.73 (m, 4H), 1.37–1.32 (m, 1H), 1.26–1.21 (m, 1H), 1.09–1.05 (m, 1H), 1.04–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.37, 158.19, 136.27, 134.03, 132.71, 131.98, 129.98, 129.39, 128.90, 128.78, 128.75, 128.07, 127.91, 126.69, 126.58 and 126.55, 124.77, 112.83, 58.03, 56.31, 55.71 and 55.35, 53.81 and 53.46, 39.88, 27.80, 22.36 and 22.20, 18.42 and 18.28, 18.28 and 18.24, 17.26 and 17.20, 13.31 and 13.29, 11.18. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>36</sub>ClN<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 479.2460; found, 479.2458.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>22h</b>)</h4><div class="NLM_p last">White solid (yield 49%). HPLC: 97.2% (λ = 280 nm, <i>t</i><sub>R</sub> = 12.6 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.45 (d, <i>J</i> = 9.0 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 7.13 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.10–7.08 (m, 1H), 7.06 (t, <i>J</i> = 7.5 Hz, 1H), 6.91–6.90 (m, 1H), 6.89 (d, <i>J</i> = 8.7 Hz, 1H), 3.82 (s, 3H), 3.49–3.44 (m, 2H), 3.35–3.13 (m, 6H), 2.28–2.22 (m, 1H), 1.87–1.80 (m, 2H), 1.79–1.68 (m, 4H), 1.35–1.30 (m, 1H), 1.23–1.19 (m, 1H), 1.07–1.03 (m, 1H), 1.01–0.96 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.36, 158.20 and 158.19, 138.31, 132.07, 132.00, 128.97, 128.08, 126.69, 126.57 and 126.55, 125.11, 122.75, 121.23, 113.07, 112.85 and 112.84, 104.45, 58.07, 56.34, 55.73 and 55.35, 53.86 and 53.51, 39.37, 27.88, 22.38 and 22.26, 18.45 and 18.31, 18.27, 17.33 and 17.27, 13.31, 11.21, and 11.20. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>ClN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 468.2412; found, 468.2410.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(4-(((2-(5-Chloro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>22i</b>)</h4><div class="NLM_p last">White solid (yield 64%). HPLC: 98.5% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.3 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.87 (d, <i>J</i> = 5.5 Hz, 1H), 8.69 (t, <i>J</i> = 7.9 Hz, 1H), 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 8.13–8.10 (m, 2H), 8.09–8.04 (m, 3H), 7.15–7.13(m, 1H), 6.93–6.91 (m, 2H), 3.85 (s, 3H), 3.52–3.48 (m, 2H), 3.39–3.14 (m, 5H), 3.08–2.98 (m, 1H), 2.30–2.25 (m, 1H), 1.89–1.72 (m, 6H), 1.37–1.31 (m, 1H), 1.24–1.21 (m, 1H), 1.09–1.06 (m, 1H), 1.05–0.99 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.82, 158.25, 148.24, 143.57, 138.83, 132.06, 129.66 (2C), 129.59 (2C), 128.12, 128.07, 127.58, 127.25, 127.18, 126.66 and 126.61, 126.57, 112.90 and 112.89, 58.11, 56.38, 55.77 and 55.40, 53.86 and 53.51, 40.11 and 40.08, 27.6, 22.44 and 22.29, 18.47 and 18.33, 18.30 and 18.27, 17.40 and 17.31, 13.29, 11.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>ClN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 506.2569; found, 506.2566.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> General Procedures for the Preparation of <b>24a</b>–<b>f</b></h3><div class="NLM_p">To a solution of benzaldehydes <b>23a</b>–<b>f</b> (1.0 equiv) in anhydrous dichloromethane (0.1–0.2 mol/L) was added methyl (triphenylphosphoranylidene)acetate (1.3 equiv), and the solution was stirred at room temperature overnight. The mixture was then concentrated, and the residue was purified by flash chromatography (0–15% ethyl acetate in petroleum ether) to give intermediates <b>24a</b>–<b>f</b>.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Methyl (<i>E</i>)-3-(3-fluorophenyl)acrylate (<b>24a</b>)</h4><div class="NLM_p last">Colorless oil (yield 67%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.67 (d, <i>J</i> = 16.0 Hz, 1H), 7.41–7.35 (m, 1H), 7.31 (d, <i>J</i> = 7.7 Hz, 1H), 7.24 (d, <i>J</i> = 9.7 Hz, 1H), 7.11 (td, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.46 (d, <i>J</i> = 16.0 Hz, 1H), 3.84 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>10</sub>FO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 181.0659; found, 181.0657.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Methyl (<i>E</i>)-3-(3-chlorophenyl)acrylate (<b>24b</b>)</h4><div class="NLM_p last">White solid (yield 96%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.62 (d, <i>J</i> = 16.0 Hz, 1H), 7.50 (t, <i>J</i> = 1.7 Hz, 1H), 7.39 (d, <i>J</i> = 7.5 Hz, 1H), 7.37–7.34 (m, 1H), 7.32 (t, <i>J</i> = 7.7 Hz, 1H), 6.43 (d, <i>J</i> = 16.0 Hz, 1H), 3.81 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>10</sub>ClO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 197.0364; found, 197.0356.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Methyl (<i>E</i>)-3-(4-fluorophenyl)acrylate (<b>24c</b>)</h4><div class="NLM_p last">White solid (yield 93%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 16.0 Hz, 1H), 7.52–7.50 (m, 2H), 7.09–7.05 (m, 2H), 6.36 (d, <i>J</i> = 16.0 Hz, 1H), 3.80 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>10</sub>FO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 181.0659; found, 181.0653.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Methyl (<i>E</i>)-3-(4-chlorophenyl)acrylate (<b>24d</b>)</h4><div class="NLM_p last">White solid (yield 89%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.63 (d, <i>J</i> = 16.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.35 (d, <i>J</i> = 8.3 Hz, 2H), 6.40 (d, <i>J</i> = 16.0 Hz, 1H), 3.80 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>10</sub>ClO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 197.0364; found, 197.0359.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Methyl (<i>E</i>)-3-(4-(trifluoromethyl)phenyl)acrylate (<b>24e</b>)</h4><div class="NLM_p last">White solid (yield 97%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.70 (d, <i>J</i> = 16.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.62 (d, <i>J</i> = 8.4 Hz, 2H), 6.51 (d, <i>J</i> = 16.0 Hz, 1H), 3.83 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>10</sub>F<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 231.0627; found, 231.0625.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Methyl (<i>E</i>)-3-(2,3-dichlorophenyl)acrylate (<b>24f</b>)</h4><div class="NLM_p last">White solid (yield 98%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 8.09 (d, <i>J</i> = 16.0 Hz, 1H), 7.51 (dd, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.49 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.23 (t, <i>J</i> = 7.9 Hz, 1H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 3.83 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>9</sub>Cl<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 230.9974; found, 230.9970.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> General Method for the Preparation of 2<b>5a</b>–f</h3><div class="NLM_p">To a solution of esters <b>24a</b>–<b>f</b> (1.0 equiv) in THF/H<sub>2</sub>O (v/v = 5/2, 0.1 mol/L) was added LiOH–H<sub>2</sub>O (5.0 equiv), and the solution was stirred at room temperature for 2 h. Water was added, and 4 M HCl (aq) was added to adjust the pH to 5. The mixture was extracted with ethyl acetate, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give acid intermediates <b>25a</b>–<b>f</b> as white solids.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (<i>E</i>)-3-(3-Fluorophenyl)acrylic acid (<b>25a</b>)</h4><div class="NLM_p last">White solid (yield 75%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 15.9 Hz, 1H), 7.40–7.37 (m, 1H), 7.33 (d, <i>J</i> = 7.7 Hz, 1H), 7.26–7.24 (m, 1H), 7.12 (td, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.45 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (<i>E</i>)-3-(3-Chlorophenyl)acrylic acid (<b>25b</b>)</h4><div class="NLM_p last">White solid (yield 100%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.72 (d, <i>J</i> = 16.0 Hz, 1H), 7.54 (t, <i>J</i> = 1.6 Hz, 1H), 7.43 (d, <i>J</i> = 7.6 Hz, 1H), 7.40–7.38 (m, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 6.46 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>E</i>)-3-(4-Fluorophenyl)acrylic acid (<b>25c</b>)</h4><div class="NLM_p last">White solid (yield 97%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.67–7.63 (m, 3H), 7.17–7.12 (m, 2H), 6.43 (d, <i>J</i> = 15.9 Hz, 1H).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>E</i>)-3-(4-Chlorophenyl)acrylic acid (<b>25d</b>)</h4><div class="NLM_p last">White solid (yield 98%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.51 (s, 1H), 7.78 (d, <i>J</i> = 8.5 Hz, 2H), 7.64 (d, <i>J</i> = 16.1 Hz, 1H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 6.61 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>E</i>)-3-(4-(Trifluoromethyl)phenyl)acrylic acid (<b>25e</b>)</h4><div class="NLM_p last">White solid (yield 97%). <sup>1</sup>H NMR (800 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.61 (s, 1H), 7.92 (d, <i>J</i> = 8.1 Hz, 2H), 7.76 (d, <i>J</i> = 8.1 Hz, 2H), 7.66 (d, <i>J</i> = 16.0 Hz, 1H), 6.68 (d, <i>J</i> = 16.0 Hz, 1H).</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (<i>E</i>)-3-(2,3-Dichlorophenyl)acrylic acid (<b>25f</b>)</h4><div class="NLM_p last">White solid (yield 94%). <sup>1</sup>H NMR (800 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.72 (br, 1H), 7.89 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.87 (d, <i>J</i> = 15.9 Hz, 1H), 7.70 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.41 (t, <i>J</i> = 7.9 Hz, 1H), 6.63 (d, <i>J</i> = 15.9 Hz, 1H).</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> General Method for the Preparation of Acrylamides <b>26a–f</b></h3><div class="NLM_p">To a solution of acrylacids <b>25a</b>–<b>f</b> in DMF (0.1 mol/L) were added <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (1.2 equiv), HATU (1.5 equiv), and NaHCO<sub>3</sub> (3.0 equiv), and the mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was separated, concentrated, and purified by flash chromatography (0–30% EtOAc in petroleum ether) to give the acrylamides <b>26a</b>–<b>f</b>.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>E</i>)-3-(3-Fluorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylacrylamide (<b>26a</b>)</h4><div class="NLM_p last">Colorless oil (yield 94%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.68 (d, <i>J</i> = 15.8 Hz, 1H), 7.36–7.31 (m, 2H), 7.28–7.25 (m, 1H), 7.07–7.04 (m, 1H), 7.02 (d, <i>J</i> = 15.8 Hz, 1H), 3.77 (s, 3H), 3.31 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>13</sub>FNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 210.0925; found, 210.0921.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>E</i>)-3-(3-Chlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylacrylamide (<b>26b</b>)</h4><div class="NLM_p last">Colorless oil (yield 97%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 15.8 Hz, 1H), 7.55 (t, <i>J</i> = 1.8 Hz, 1H), 7.42 (dt, <i>J</i> = 7.1, 1.7 Hz, 1H), 7.35–7.30 (m, 2H), 7.02 (d, <i>J</i> = 15.8 Hz, 1H), 3.77 (s, 3H), 3.31 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>13</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 226.0629; found, 226.0623.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>E</i>)-3-(4-Fluorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylacrylamide (<b>26c</b>)</h4><div class="NLM_p last">Colorless oil (yield 92%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 15.8 Hz, 1H), 7.57–7.53 (m, 2H), 7.09–7.05 (m, 2H), 6.96 (d, <i>J</i> = 15.8 Hz, 1H), 3.76 (s, 3H), 3.31 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>13</sub>FNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 210.0925; found, 210.0918.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (<i>E</i>)-3-(4-Chlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylacrylamide (<b>26d</b>)</h4><div class="NLM_p last">Colorless oil (yield 96%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.68 (d, <i>J</i> = 15.8 Hz, 1H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.35 (d, <i>J</i> = 8.5 Hz, 2H), 7.01 (d, <i>J</i> = 15.8 Hz, 1H), 3.77 (s, 3H), 3.31 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>13</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 226.0629; found, 226.0625.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (<i>E</i>)-<i>N</i>-Methoxy-<i>N</i>-methyl-3-(4-(trifluoromethyl)phenyl)acrylamide (<b>26e</b>)</h4><div class="NLM_p last">Colorless oil (yield 81%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 15.8 Hz, 1H), 7.66 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (d, <i>J</i> = 8.2 Hz, 2H), 7.10 (d, <i>J</i> = 15.8 Hz, 1H), 3.78 (s, 3H), 3.32 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>F<sub>3</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 260.0893; found, 260.0889.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (<i>E</i>)-3-(2,3-Dichlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylacrylamide (<b>26f</b>)</h4><div class="NLM_p last">Colorless oil (yield 90%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 8.11 (d, <i>J</i> = 15.7 Hz, 1H), 7.55 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.47 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.22 (t, <i>J</i> = 7.9 Hz, 1H), 7.00 (d, <i>J</i> = 15.8 Hz, 1H), 3.76 (s, 3H), 3.32 (s, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>12</sub>Cl<sub>2</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 260.0240; found, 260.0237.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> General Method for the Preparation of <b>27a–f</b></h3><div class="NLM_p">Trimethylsulfoxonium iodide (1.5–2.0 equiv) was suspended in anhydrous DMSO (∼2 mol/L), and sodium hydride (1.5–2.0 equiv) was added in small portions. The mixture was stirred at room temperature from 0.5 to 1 h to afford a clear solution. A solution of acrylamides <b>26a</b>–<b>f</b> (1.0 equiv) in anhydrous DMSO (2 mol/L) was then slowly added, and the solution was stirred at room temperature overnight. The mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was separated, concentrated, and purified by flash chromatography (0–30% ethyl acetate in petroleum ether) to give <b>27a</b>–<b>f</b>.</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-(3-Fluorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylcyclopropane-1-carboxamide (<b>27a</b>)</h4><div class="NLM_p last">Colorless oil (yield 71%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.26–7.22 (m, 1H), 6.94 (d, <i>J</i> = 7.7 Hz, 1H), 6.89 (td, <i>J</i> = 8.4, 2.5 Hz, 1H), 6.82–6.79 (m, 1H), 3.71 (s, 3H), 3.25 (s, 3H), 2.52–2.47 (m, 1H), 2.42 (s, 1H), 1.67–1.62 (m, 1H), 1.32–1.28 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>15</sub>FNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 224.1081; found, 224.1076.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 2-(3-Chlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylcyclopropane-1-carboxamide (<b>27b</b>)</h4><div class="NLM_p last">Colorless oil (yield 77%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.22–7.18 (m, 1H), 7.18–7.15 (m, 1H), 7.08 (t, <i>J</i> = 1.8 Hz, 1H), 7.03–7.01 (m, 1H), 3.70 (s, 3H), 3.23 (s, 3H), 2.48–2.45 (m, 1H), 2.41 (s, 1H), 1.65–1.60 (m, 1H), 1.31–1.26 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>15</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 240.0786; found, 240.0786.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 2-(4-Fluorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylcyclopropane-1-carboxamide (<b>27c</b>)</h4><div class="NLM_p last">Colorless oil (yield 73%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.10–7.07 (m, 2H), 6.99–6.94 (m, 2H), 3.69 (s, 3H), 3.23 (s, 3H), 2.52–2.45 (m, 1H), 2.35 (s, 1H), 1.62–1.58 (m, 1H), 1.28–1.21 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>15</sub>FNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 224.1081; found, 224.1076.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-(4-Chlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylcyclopropane-1-carboxamide (<b>27d</b>)</h4><div class="NLM_p last">Colorless oil (yield 82%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.24 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 (d, <i>J</i> = 8.4 Hz, 2H), 3.69 (s, 3H), 3.23 (s, 3H), 2.48–2.45 (m, 1H), 2.40–2.34 (m, 1H), 1.65–1.61 (m, 1H), 1.29–1.25 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>15</sub>ClNO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 240.0786; found, 240.0780.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>N</i>-Methoxy-<i>N</i>-methyl-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxamide (<b>27e</b>)</h4><div class="NLM_p last">White solid (yield 76%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.53 (d, <i>J</i> = 8.1 Hz, 2H), 7.23 (d, <i>J</i> = 8.1 Hz, 2H), 3.70 (s, 3H), 3.24 (s, 3H), 2.57–2.53 (m, 1H), 2.46 (s, 1H), 1.71–1.67 (m, 1H), 1.36–1.32 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>15</sub>F<sub>3</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 274.1049; found, 274.1045.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 2-(2,3-Dichlorophenyl)-<i>N</i>-methoxy-<i>N</i>-methylcyclopropane-1-carboxamide (<b>27f</b>)</h4><div class="NLM_p last">Colorless oil (yield 77%). <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 7.34 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.14 (t, <i>J</i> = 7.9 Hz, 1H), 7.00 (d, <i>J</i> = 7.5 Hz, 1H), 3.73 (s, 3H), 3.26 (s, 3H), 2.78–2.73 (m, 1H), 2.32 (s, 1H), 1.66–1.63 (m, 1H), 1.35–1.31 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>14</sub>Cl<sub>2</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 274.0396; found, 274.0389.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> General Method for the Preparation of Aldehydes <b>28a–f</b></h3><div class="NLM_p last">A solution of <b>27a</b>–<b>f</b> (1.0 equiv) in anhydrous THF (0.1–0.2 mmol/mL) was cooled to −78 °C under argon. To this solution was added slowly DIBAL-H (1.0 M solution in THF, 2.0 equiv), and the solution was stirred at −78 °C for 2–3 h. A saturated aqueous solution of Rochelle’s salt was added to quench the reaction, and the mixture was warmed to room temperature, stirred for 1 h, and filtered. The solid was washed with ethyl acetate, and the filtrate was extracted with the same solvent. The combined organic phases were washed with brine, dried, and concentrated to give the aldehydes <b>28a</b>–<b>f</b> as a colorless oil, which were used in the next step without further purification.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> General Method for the Preparation of Amines <b>29a–c</b></h3><div class="NLM_p">To a solution of crude aldehydes <b>20a</b>–<b>c</b> (1.0 equiv) in THF (0.25 mol/L) was added propylamine (5.0 equiv), NaHB(AcO)<sub>3</sub> (2.0–2.5 equiv), and AcOH (1.0 equiv) successively. The mixture was stirred at room temperature overnight. Methanol was added to quench the reaction, and the mixture was stirred at room temperature for 15 min. The solvent was evaporated under a vacuum, and the residue formed was purified by flash chromatography (0–10% methanol in dichloromethane) to give propyl amines <b>29a</b>–<b>c</b>.</div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(4-(Propylamino)butyl)-2-naphthamide (<b>29a</b>)</h4><div class="NLM_p last">White solid (yield 44%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.83–8.74 (m, 2H), 8.49 (s, 1H), 8.04–7.94 (m, 4H), 7.65–7.57 (m, 2H), 3.36–3.33 (m, 2H), 2.94–2.89 (m, 2H), 2.84–2.79 (m, 2H), 1.74–1.68 (m, 2H), 1.66–1.59 (m, 4H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>25</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 285.1961; found, 285.1958.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-(4-(Propylamino)butyl)-1<i>H</i>-indole-2-carboxamide (<b>29b</b>)</h4><div class="NLM_p last">White solid (yield 64%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.59 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 7.08–7.05 (m, 2H), 3.45 (t, <i>J</i> = 6.6 Hz, 2H), 3.05–3.01 (m, 2H), 2.94–2.91 (m, 2H), 1.79–1.74 (m, 2H), 1.74–1.65 (m, 4H), 1.00 (t, <i>J</i> = 7.3 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>24</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 274.1914; found, 274.1910.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>N</i>-(4-(Propylamino)butyl)-4-(pyridin-2-yl)benzamide (<b>29c</b>)</h4><div class="NLM_p last">Yellow oil (yield 46%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD): δ 8.65 (dt, <i>J</i> = 4.9, 1.3 Hz, 1H), 8.08–8.05 (m, 2H), 7.97–7.92 (m, 4H), 7.43–7.39 (m, 1H), 3.46 (t, <i>J</i> = 6.5 Hz, 2H), 3.05–2.99 (m, 2H), 2.94–2.90 (m, 2H), 1.78–1.66 (m, 6H), 1.01 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 312.2070; found, 312.2067.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> General Method for the Preparation of <b>30a–r</b></h3><div class="NLM_p">To a solution of crude aldehydes <b>28a</b>–<b>f</b> (1.0 equiv) in CH<sub>3</sub>CN (0.03–0.05 mol/L) were added amine <b>29a</b>–<b>c</b> (1.0 equiv), NaHB(AcO)<sub>3</sub> (2.0 equiv), and AcOH (1.0 equiv), and the reaction mixture was stirred at room temperature overnight. Methanol was added to afford a clear solution, which was stirred at room temperature for 15–30 min. The solution was concentrated and purified by flash chromatography (0–6% methanol in dichloromethane) to give title products as a colorless oil. The free amines <b>30a</b>–<b>r</b> were converted to corresponding HCl salts using a similar method as depicted for <b>17a</b>.</div><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>N</i>-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30a</b>)</h4><div class="NLM_p last">White solid (yield 68%). HPLC: 98.1% (λ = 254 nm, <i>t</i><sub>R</sub> = 20.2 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.39 (s, 1H), 7.99–7.92 (m, 3H), 7.91–7.87 (m, 1H), 7.62–7.56 (m, 2H), 7.27–7.23 (m, 1H), 6.96 (t, <i>J</i> = 7.7 Hz, 1H), 6.91–6.85 (m, 2H), 3.52–3.49 (m, 2H), 3.34–3.25 (m, 4H), 3.24–3.14 (m, 2H), 2.10–2.06 (m, 1H), 1.89–1.82 (m, 2H), 1.81–1.72 (m, 4H), 1.51–1.45 (m, 1H), 1.25–1.21 (m, 1H), 1.17–1.14 (m, 1H), 1.00 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.37, 164.52 (d, <i>J</i><sub>CF</sub> = 244.0 Hz), 145.68 (d, <i>J</i><sub>CF</sub> = 7.0 Hz), 136.29, 134.06, 132.79, 131.19 (d, <i>J</i><sub>CF</sub> = 8.5 Hz), 129.99, 129.38, 128.89, 128.79, 128.77, 127.91, 124.82, 122.80, 113.73 (d, <i>J</i><sub>CF</sub> = 21.8 Hz), 113.37 (d, <i>J</i><sub>CF</sub> = 22.1 Hz), 58.22, 55.93, 53.96, 40.07, 28.00, 23.61, 22.80, 19.42, 18.75, 15.60, 11.44. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 433.2650; found, 433.2645.</div></div><div id="sec4_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> <i>N</i>-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30b</b>)</h4><div class="NLM_p last">White solid (yield 36%). HPLC: 98.8% (λ = 280 nm, <i>t</i><sub>R</sub> = 16.3 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (dd, <i>J</i> = 8.0, 2.5 Hz, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 1H), 7.25–7.20 (m, 2H), 7.11 (d, <i>J</i> = 3.3 Hz, 1H), 7.06 (t, <i>J</i> = 7.5 Hz, 1H), 6.93 (t, <i>J</i> = 8.7 Hz, 1H), 6.89–6.85 (m, 2H), 3.47–3.43 (m, 2H), 3.29–3.21 (m, 4H), 3.20–3.09 (m, 2H), 2.09–2.03 (m, 1H), 1.87–1.79 (m, 2H), 1.78–1.65 (m, 4H), 1.47–1.42 (m, 1H), 1.22–1.19 (m, 1H), 1.16–1.11 (m, 1H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.35, 164.50 (d, <i>J</i><sub>CF</sub> = 243.8 Hz), 145.19 (d, <i>J</i><sub>CF</sub> = 7.7 Hz), 138.31, 132.09, 131.26 (d, <i>J</i><sub>CF</sub> = 8.6 Hz), 128.97, 125.13, 122.87, and 122.83 (d, <i>J</i><sub>CF</sub> = 2.7 Hz), 122.76, 121.24, 113.88 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 113.45 (d, <i>J</i><sub>CF</sub> = 22.2 Hz), 113.08, 104.51 and 104.50, 58.05 and 58.01, 55.69 and 55.60, 53.87 and 53.72, 39.33, 27.86 and 27.84, 23.55 and 23.51, 22.27 and 22.21, 18.67 and 18.62, 18.32 and 18.27, 15.62 and 15.60, 11.21, and 11.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>FN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 422.2602; found, 422.2609.</div></div><div id="sec4_10_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>N</i>-(4-(((2-(3-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30c</b>)</h4><div class="NLM_p last">White solid (yield 55%). HPLC: 99.4% (λ = 254 nm, <i>t</i><sub>R</sub> = 12.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.90 (d, <i>J</i> = 5.3 Hz, 1H), 8.72 (t, <i>J</i> = 7.9 Hz, 1H), 8.45 (d, <i>J</i> = 8.2 Hz, 1H), 8.15 (d, <i>J</i> = 8.1 Hz, 2H), 8.12–8.05 (m, 3H), 7.30–7.23 (m, 1H), 7.02–6.96 (m, 1H), 6.92–6.86 (m, 2H), 3.52–3.46 (m, 2H), 3.36–3.28 (m, 4H), 3.25–3.17 (m, 2H), 2.14–2.11 (m, 1H), 1.90–1.84 (m, 2H), 1.83–1.78 (m, 2H), 1.77–1.69 (m, 2H), 1.53–1.48 (m, 1H), 1.26–1.22 (m, 1H), 1.21–1.16 (m, 1H), 1.01 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.76, 164.52 (d, <i>J</i><sub>CF</sub> = 244.1 Hz), 153.15, 148.32, 145.30, 143.54, 138.92, 135.10, 131.29 and 131.25, 129.75 (2C), 129.61 (2C), 127.60, 127.21, 122.92, 113.88 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 113.48 (d, <i>J</i><sub>CF</sub> = 22.2 Hz), 58.02, 55.72 and 55.61, 53.85and 53.71, 40.06 and 40.04, 27.68 and 27.65, 23.56, 22.39 and 22.29, 18.69, 18.33 and 18.30, 15.66 and 15.65, 11.26, and 11.24. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>35</sub>FN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 460.2759; found, 460.2769.</div></div><div id="sec4_10_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i>-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30d</b>)</h4><div class="NLM_p last">White solid (yield 46%). HPLC: 99.8% (λ = 254 nm, <i>t</i><sub>R</sub> = 25.3 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.41 (s, 1H), 7.97 (t, <i>J</i> = 7.3 Hz, 1H), 7.95–7.89 (m, 3H), 7.60–7.55 (m, 2H), 7.23–7.20 (m, 1H), 7.17–7.14 (m, 2H), 7.06–7.04 (m, 1H), 3.52–3.49 (m, 2H), 3.34–3.12 (m, 6H), 2.09–2.05 (m, 1H), 1.89–1.82 (m, 2H), 1.81–1.72 (m, 4H), 1.51–1.45 (m, 1H), 1.24–1.19 (m, 1H), 1.17–1.13 (m, 1H), 0.99 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.34, 144.67, 136.28, 135.46, 134.04, 132.70, 131.05, 130.01, 129.39, 128.90, 128.81, 128.78, 127.91, 127.31, 126.96, 125.35 and 125.30, 124.83, 58.03, 55.72 and 55.60, 53.88 and 53.74, 39.87 and 39.85, 27.82 and 27.79, 23.43, 22.31 and 22.21, 18.62 and 18.60, 18.33 and 18.29, 15.54, 11.24, and 11.22. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>ClN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 449.2354; found, 449.2361.</div></div><div id="sec4_10_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>N</i>-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30e</b>)</h4><div class="NLM_p last">White solid (yield 8%). HPLC: 97.2% (λ = 280 nm, <i>t</i><sub>R</sub> = 20.5 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (dd, <i>J</i> = 8.0, 2.8 Hz, 1H), 7.47–7.44 (m, 1H), 7.23–7.19 (m, 2H), 7.16–7.13 (m, 2H), 7.12–7.11 (m, 1H), 7.06 (t, <i>J</i> = 7.5 Hz, 1H), 7.05–7.01 (m, 1H), 3.47–3.43 (m, 2H), 3.30–3.19 (m, 4H), 3.19–3.09 (m, 2H), 2.07–2.01 (m, 1H), 1.87–1.79 (m, 2H), 1.78–1.68 (m, 4H), 1.48–1.42 (m, 1H), 1.23–1.18 (m, 1H), 1.15–1.10 (m, 1H), 0.99–0.95 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.34, 144.65, 138.31, 135.45, 132.09, 131.06, 128.97, 127.30, 126.95, 125.33 and 125.27, 125.13, 122.77 and 122.76, 121.24, 113.09, 104.55, 58.06 and 58.02, 55.69 and 55.62, 53.87 and 53.73, 39.33, 27.86 and 27.83, 23.43 and 23.41, 22.27 and 22.22, 18.64 and 18.59, 18.32 and 18.28, 15.53, 11.22, and 11.21. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>ClN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 438.2307; found, 438.2317.</div></div><div id="sec4_10_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>N</i>-(4-(((2-(3-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30f</b>)</h4><div class="NLM_p last">White solid (yield 46%). HPLC: 99.9% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.2 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.91 (d, <i>J</i> = 5.7 Hz, 1H), 8.75–8.71 (m, 1H), 8.46 (d, <i>J</i> = 8.1 Hz, 1H), 8.16 (d, <i>J</i> = 8.1 Hz, 2H), 8.12–8.07 (m, 3H), 7.26–7.23 (m, 1H), 7.19–7.16 (m, 2H), 7.11–7.08 (m, 1H), 3.51–3.47 (m, 2H), 3.36–3.27 (m, 4H), 3.25–3.16 (m, 2H), 2.13–2.09 (m, 1H), 1.91–1.84 (m, 2H), 1.84–1.78 (m, 2H), 1.77–1.72 (m, 2H), 1.54–1.49 (m, 1H), 1.26–1.22 (m, 1H), 1.20–1.16 (m, 1H), 1.01 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.72, 153.08, 148.42, 144.76, 143.46, 138.94, 135.45, 134.99, 131.08, 129.77 (2C), 129.62 (2C), 127.65, 127.30, 127.24, 126.98, 125.39 and 125.36, 58.02, 55.72 and 55.61, 53.83 and 53.71, 40.06 and 40.04, 27.67 and 27.65, 23.45, 22.38 and 22.29, 18.67 and 18.66, 18.33 and 18.30, 15.58, 11.27, and 11.25. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>35</sub>ClN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 476.2463; found, 476.2468.</div></div><div id="sec4_10_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> <i>N</i>-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30g</b>)</h4><div class="NLM_p last">White solid (yield 38%). HPLC: 99.5% (λ = 254 nm, <i>t</i><sub>R</sub> = 20.6 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.40 (s, 1H), 7.97 (t, <i>J</i> = 7.3 Hz, 1H), 7.95–7.89 (m, 3H), 7.61–7.55 (m, 2H), 7.15–7.11 (m, 2H), 6.99–6.95 (m, 2H), 3.53–3.48 (m, 2H), 3.33–3.24 (m, 4H), 3.23–3.14 (m, 2H), 2.08–2.04 (m, 1H), 1.90–1.82 (m, 2H), 1.81–1.72 (m, 4H), 1.44–1.38 (m, 1H), 1.18–1.15 (m, 1H), 1.13–1.09 (m, 1H), 0.99 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.35, 162.88 (d, <i>J</i><sub>CF</sub> = 243.0 Hz), 137.95 and 137.93, 136.29, 134.05, 132.70, 130.00, 129.40, 128.92, 128.80 (d, <i>J</i><sub>CF</sub> = 2.7 Hz), 128.62, 128.61 (d, <i>J</i><sub>CF</sub> = 7.9 Hz), 128.58, 127.92, 124.82, 116.16 (d, <i>J</i><sub>CF</sub> = 21.6 Hz, 2C), 58.15, 55.74 and 55.61, 53.89 and 53.71, 39.87 and 39.85, 27.82 and 27.80, 23.12 and 23.10, 22.33 and 22.20, 18.35 and 18.29, 18.22 and 18.20, 15.21 and 15.19, 11.24, and 11.22. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 433.2650; found, 433.2645.</div></div><div id="sec4_10_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>N</i>-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30h</b>)</h4><div class="NLM_p last">White solid (yield 16%). HPLC: 98.0% (λ = 280 nm, <i>t</i><sub>R</sub> = 16.9 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (dd, <i>J</i> = 8.0, 2.5 Hz, 1H), 7.47–7.44 (m, 1H), 7.23–7.20 (m, 1H), 7.14–7.05 (m, 4H), 6.97–6.92 (m, 2H), 3.47–3.43 (m, 2H), 3.28–3.21 (m, 4H), 3.18–3.11 (m, 2H), 2.05–1.99 (m, 1H), 1.86–1.80 (m, 2H), 1.77–1.67 (m, 4H), 1.40–1.35 (m, 1H), 1.16–1.12 (m, 1H), 1.10–1.06 (m, 1H), 1.00–0.93 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.32, 162.86 (d, <i>J</i><sub>CF</sub> = 242.5 Hz), 138.31, 137.92 (d, <i>J</i><sub>CF</sub> = 2.8 Hz), 132.11 and 132.09, 128.97, 128.59, and 128.57 (d, <i>J</i><sub>CF</sub> = 7.9 Hz, 2C), 125.14, 122.78 and 122.76, 121.25, 116.15 (d, <i>J</i><sub>CF</sub> = 21.7 Hz, 2C), 113.09, 104.55 and 104.51, 58.17 and 58.14, 55.72 and 55.64, 53.86 and 53.68, 39.34, 27.84 and 27.83, 23.11 and 23.08, 22.30 and 22.20, 18.33 and 18.28, 18.22 and 18.21, 15.23 and 15.21, 11.22, and 11.21. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>FN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 422.2602; found, 422.2611.</div></div><div id="sec4_10_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>N</i>-(4-(((2-(4-Fluorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30i</b>)</h4><div class="NLM_p last">White solid (yield 36%). HPLC: 96.2% (λ = 254 nm, <i>t</i><sub>R</sub> = 12.5 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.90–8.86 (m, 1H), 8.67–8.62 (m, 1H), 8.42–8.38 (m, 1H), 8.14–8.11 (m, 2H), 8.08–8.06 (m, 2H), 8.05–8.01 (m, 1H), 7.18–7.14 (m, 2H), 7.02–6.98 (m, 2H), 3.50–3.47 (m, 2H), 3.33–3.26 (m, 4H), 3.24–3.16 (m, 2H), 2.11–2.06 (m, 1H), 1.89–1.82 (m, 2H), 1.81–1.71 (m, 4H), 1.46–1.41 (m, 1H), 1.21–1.18 (m, 1H), 1.15–1.11 (m, 1H), 1.02 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.76, 162.85 (d, <i>J</i><sub>CF</sub> = 242.4 Hz), 153.23, 148.03, 143.75, 138.80, 138.03, 135.31, 129.72 (2C), 129.56 (2C), 128.65 (d, <i>J</i><sub>CF</sub> = 7.6 Hz, 2C), 127.44, 127.13, 116.15 (d, <i>J</i><sub>CF</sub> = 21.6 Hz, 2C), 58.14 and 58.13, 55.70 and 55.60, 53.82 and 53.67, 40.07 and 40.05, 27.66 and 27.64 23.13 and 23.11, 22.40 and 22.27, 18.34 and 18.29, 18.27 and 18.25, 15.26 and 15.24, 11.28, and 11.27. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>35</sub>FN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 460.2759; found, 460.2754.</div></div><div id="sec4_10_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>N</i>-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30j</b>)</h4><div class="NLM_p last">White solid (yield 46%). HPLC: 98.9% (λ = 254 nm, <i>t</i><sub>R</sub> = 25.4 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.40 (d, <i>J</i> = 4.1 Hz, 1H), 7.97 (t, <i>J</i> = 7.7 Hz, 1H), 7.95–7.88 (m, 3H), 7.60–7.55 (m, 2H), 7.24–7.21 (m, 2H), 7.11–7.08 (m, 2H), 3.53–3.47 (m, 2H), 3.34–3.24 (m, 4H), 3.22–3.12 (m, 2H), 2.08–2.03 (m, 1H), 1.89–1.82 (m, 2H), 1.81–1.72 (m, 4H), 1.47–1.42 (m, 1H), 1.20–1.16 (m, 1H), 1.15–1.11 (m, 1H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.36, 140.97, 136.29, 134.05, 132.89, 132.70, 130.01, 129.58, and 129.57 (2C), 129.40, 128.92, 128.80, and 128.79 (2C), 128.48 and 128.46 (2C), 127.92, 124.82, 58.08, 55.76 and 55.65, 53.88 and 53.71, 39.86 and 39.84, 27.82 and 27.79, 23.25 and 23.21, 22.32 and 22.17, 18.49 and 18.45, 18.34 and 18.29, 15.47 and 15.43, 11.24, and 11.22. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>ClN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 449.2354; found, 449.2356.</div></div><div id="sec4_10_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> <i>N</i>-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30k</b>)</h4><div class="NLM_p last">White solid (yield 36%). HPLC: 97.1% (λ = 280 nm, <i>t</i><sub>R</sub> = 20.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (dd, <i>J</i> = 8.1, 2.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.2 Hz, 1H), 7.23–7.20 (m, 3H), 7.11–7.09 (m, 1H), 7.09–7.05 (m, 3H), 3.48–3.43 (m, 2H), 3.30–3.21 (m, 4H), 3.19–3.10 (m, 2H), 2.05–2.00 (m, 1H), 1.87–1.79 (m, 2H), 1.79–1.68 (m, 4H), 1.44–1.38 (m, 1H), 1.19–1.15 (m, 1H), 1.13–1.09 (m, 1H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.36, 140.94, 138.32, 132.88, 132.08, 129.58, and 129.56 (2C), 128.98, 128.45, and 128.43 (2C), 125.14, 122.77, 121.25, 113.09, 104.49, 58.10 and 58.07, 55.76 and 55.69, 53.88 and 53.70, 39.31 and 39.29, 27.86 and 27.84, 23.25 and 23.20, 22.29 and 22.18, 18.47, 18.34 and 18.29, 15.46 and 15.41, 11.21, and 11.20. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>ClN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 438.2307; found, 423.2307.</div></div><div id="sec4_10_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> <i>N</i>-(4-(((2-(4-Chlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30l</b>)</h4><div class="NLM_p last">White solid (yield 47%). HPLC: 99.5% (λ = 254 nm, <i>t</i><sub>R</sub> = 14.0 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.91 (d, <i>J</i> = 5.5 Hz, 1H), 8.72 (t, <i>J</i> = 7.9 Hz, 1H), 8.46 (d, <i>J</i> = 8.1 Hz, 1H), 8.16–8.14 (m, 2H), 8.12–8.06 (m, 3H), 7.26–7.23 (m, 2H), 7.16–7.12 (m, 2H), 3.52–3.45 (m, 2H), 3.35–3.27 (m, 4H), 3.24–3.15 (m, 2H), 2.12–2.07 (m, 1H), 1.90–1.84 (m, 2H), 1.82–1.77 (m, 2H), 1.76–1.72 (m, 2H), 1.50–1.45 (m, 1H), 1.23–1.19 (m, 1H), 1.18–1.14 (m, 1H), 1.01 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.74, 153.10, 148.39, 143.48, 141.07, 138.94, 135.02, 132.85, 129.76 (2C), 129.62 (2C), 129.57 (2C), 128.53 and 128.52 (2C), 127.64, 127.24, 58.07 and 58.04, 55.76 and 55.65, 53.83 and 53.67, 40.0 and, 40.04, 27.67 and 27.65, 23.27 and 23.22, 22.40 and 22.25, 18.56 and 18.48, 18.35 and 18.31, 15.50 and 15.46, 11.27, and 11.25. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>35</sub>ClN<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 476.2463; found, 476.2473.</div></div><div id="sec4_10_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>N</i>-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30m</b>)</h4><div class="NLM_p last">White solid (yield 44%). HPLC: 98.0% (λ = 254 nm, <i>t</i><sub>R</sub> = 25.1 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.42 (d, <i>J</i> = 3.3 Hz, 1H), 7.99 (t, <i>J</i> = 7.9 Hz, 1H), 7.97–7.90 (m, 3H), 7.62–7.56 (m, 2H), 7.54 (d, <i>J</i> = 7.9 Hz, 2H), 7.33–7.29 (m, 2H), 3.56–3.49 (m, 2H), 3.37–3.27 (m, 4H), 3.24–3.15 (m, 2H), 2.19–2.14 (m, 1H), 1.90–1.84 (m, 2H), 1.82–1.74 (m, 4H), 1.59–1.53 (m, 1H), 1.31–1.28 (m, 1H), 1.25–1.19 (m, 1H), 1.01 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.27, 147.01, 136.24, 134.02, 132.69, 130.00, 129.37, 129.22, 128.89, 128.82, 128.77, 127.89, 127.42 (2C), 126.35 (q, <i>J</i><sub>CF</sub> = 3.3 Hz, 2C), 125.75 (q, <i>J</i><sub>CF</sub> = 270.7 Hz), 124.85, 57.92, 55.69 and 55.62, 53.85 and 53.72, 39.88 and 39.86, 27.77 and 27.74, 23.59 and 23.56, 22.30 and 22.17, 19.01 and 18.99, 18.30 and 18.27, 16.04, 11.25, and 11.23. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>F<sub>3</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 483.2618; found, 483.2617.</div></div><div id="sec4_10_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>N</i>-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30n</b>)</h4><div class="NLM_p last">Yellow oil (yield 11%). HPLC: 99.0% (λ = 280 nm, <i>t</i><sub>R</sub> = 16.5 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (dd, <i>J</i> = 8.0, 3.1 Hz, 1H), 7.53–7.50 (m, 2H), 7.45 (dd, <i>J</i> = 8.2, 3.3 Hz, 1H), 7.28–7.25 (m, 2H), 7.23–7.21 (m, 1H), 7.10 (s, 1H), 7.08–7.05 (m, 1H), 3.48–3.44 (m, 2H), 3.30–3.22 (m, 4H), 3.20–3.11 (m, 2H), 2.16–2.11 (m, 1H), 1.88–1.80 (m, 2H), 1.79–1.68 (m, 4H), 1.55–1.49 (m, 1H), 1.28–1.24 (m, 1H), 1.21–1.17 (m, 1H), 0.98 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.36, 146.97, 138.32, 132.07, 129.35 (q, <i>J</i><sub>CF</sub> = 32.8 Hz), 128.97, 127.39 (2C), 126.38 (2C), 125.76 (q, <i>J</i><sub>CF</sub> = 270.9 Hz), 125.15, 122.76, 121.25, 113.09, 104.52, 58.00 and 57.95, 55.77 and 55.73, 53.90 and 53.74, 39.31 and 39.30, 27.84 and 27.82, 23.60 and 23.56, 22.28 and 22.18, 19.00 and 18.98, 18.33 and 18.29, 16.03 and 16.00, 11.21, and 11.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>33</sub>F<sub>3</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 472.2570; found, 472.2572.</div></div><div id="sec4_10_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> <i>N</i>-(4-(Propyl((2-(4-(trifluoromethyl)phenyl)cyclopropyl)methyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30o</b>)</h4><div class="NLM_p last">White solid (yield 43%). HPLC: 97.0% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.7 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.91 (d, <i>J</i> = 5.8 Hz, 1H), 8.74 (t, <i>J</i> = 7.9 Hz, 1H), 8.51–8.42 (m, 1H), 8.17–8.15 (m, 2H), 8.14–8.11 (m, 1H), 8.10–8.07 (m, 2H), 7.56 (d, <i>J</i> = 7.8 Hz, 2H), 7.35 (dd, <i>J</i> = 8.1, 3.6 Hz, 2H), 3.51–3.46 (m, 2H), 3.37–3.32 (m, 3H), 3.30–3.16 (m, 3H), 2.23–2.17 (m, 1H), 1.92–1.85 (m, 2H), 1.83–1.79 (m, 2H), 1.78–1.70 (m, 2H), 1.63–1.57 (m, 1H), 1.34–1.28 (m, 1H), 1.27–1.22 (m, 1H), 1.01 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.72, 153.17, 147.95, 147.14, 143.77, 138.73, 135.29, 129.71 (2C), 129.54 (2C), 129.20 (q, <i>J</i><sub>CF</sub> = 32.3 Hz), 127.47 (2C), 127.36, 127.10, 126.34 (q, <i>J</i><sub>CF</sub> = 3.8 Hz, 2C), 125.75 (q, <i>J</i><sub>CF</sub> = 270.8 Hz), 57.92, 55.64 and 55.59, 53.78 and 53.67, 40.06, 27.61 and 27.59, 23.59, 22.34 and 22.24, 19.13 and 19.08, 18.30 and 18.29, 16.09, 11.30, and 11.28. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>35</sub>F<sub>3</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 510.2727; found, 510.2731.</div></div><div id="sec4_10_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> <i>N</i>-(4-(((2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride (<b>30p</b>)</h4><div class="NLM_p last">White solid (yield 43%). HPLC: 98.0% (λ = 254 nm, <i>t</i><sub>R</sub> = 25.9 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.39 (d, <i>J</i> = 11.4 Hz, 1H), 8.00–7.92 (m, 3H), 7.91–7.87 (m, 1H), 7.63–7.56 (m, 2H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.22–7.19 (m, 1H), 7.07 (d, <i>J</i> = 7.8 Hz, 1H), 3.62–3.58 (m, 1H), 3.56–3.51 (m, 2H), 3.41–3.34 (m, 2H), 3.28–3.17 (m, 3H), 2.37–2.33 (m, 1H), 1.93–1.84 (m, 2H), 1.83–1.72 (m, 4H), 1.50–1.45 (m, 1H), 1.31–1.28 (m, 1H), 1.27–1.23 (m, 1H), 1.05–1.01 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.34, 141.88, 136.27, 134.18 and 134.16, 134.04 and 134.03, 133.92, 132.67 and 132.65, 130.01, 129.67, 129.39, 128.92, 128.90, 128.81, 128.78, 127.90, 126.60 and 126.56, 124.80, 57.87 and 57.82, 55.88 and 55.61, 53.96 and 53.66, 39.88 and 39.81, 27.77, 22.41 and 22.37, 22.28 and 22.14, 18.44 and 18.30, 17.34 and 17.31, 14.81 and 14.73, 11.23. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 483.1964; found, 483.1970.</div></div><div id="sec4_10_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> <i>N</i>-(4-(((2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride (<b>30q</b>)</h4><div class="NLM_p last">White solid (yield 16%). HPLC: 98.2% (λ = 280 nm, <i>t</i><sub>R</sub> = 24.8 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 1H), 7.38–7.35 (m, 1H), 7.22 (t, <i>J</i> = 7.6 Hz, 1H), 7.17 (td, <i>J</i> = 7.9, 3.6 Hz, 1H), 7.08–7.05 (m, 2H), 7.04–7.01 (m, 1H), 3.60–3.56 (m, 1H), 3.51–3.46 (m, 2H), 3.37–3.32 (m, 2H), 3.26–3.15 (m, 3H), 2.35–2.31 (m, 1H), 1.89–1.70 (m, 6H), 1.46–1.40 (m, 1H), 1.27–1.24 (m, 1H), 1.23–1.20 (m, 1H), 1.03–0.99 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.38, 141.88, 138.32, 134.18, 133.94, 132.06, 129.67, 128.97, 128.93, 126.57 and 126.54, 125.12, 122.76, 121.23, 113.08, 104.49, 57.88, 55.88 and 55.66, 53.97 and 53.68, 39.33 and 39.30, 27.84 and 27.82, 22.40 and 22.34, 22.25 and 22.20, 18.45 and 18.30, 17.35 and 17.32, 14.78 and 14.71, 11.20, and 11.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 472.1917; found, 472.1916.</div></div><div id="sec4_10_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> <i>N</i>-(4-(((2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride (<b>30r</b>)</h4><div class="NLM_p last">White solid (yield 43%). HPLC: 97.9% (λ = 254 nm, <i>t</i><sub>R</sub> = 16.3 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.90–8.87 (m, 1H), 8.72–8.67 (m, 1H), 8.45–8.42 (m, 1H), 8.16–8.11 (m, 2H), 8.10–8.05 (m, 3H), 7.40 (d, <i>J</i> = 7.9 Hz, 1H), 7.24 (t, <i>J</i> = 7.9 Hz, 1H), 7.12–7.09 (m, 1H), 3.62–3.57 (m, 1H), 3.52–3.47 (m, 2H), 3.40–3.32 (m, 2H), 3.28–3.18 (m, 3H), 2.39–2.34 (m, 1H), 1.91–1.84 (m, 2H), 1.83–1.73 (m, 4H), 1.51–1.45 (m, 1H), 1.32–1.25 (m, 2H), 1.06–1.01 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.75, 153.10, 148.38, 143.49, 141.98, 138.92, 135.02, 134.18, 133.93, 129.75, and 129.74 (2C), 129.68, 129.61 (2C), 128.98, 127.63, 127.23, 126.66 and 126.61, 57.83 and 57.80, 55.87 and 55.58, 53.92 and 53.63, 40.06 and 40.01, 27.65, 22.46 and 22.22, 22.37 and 22.33, 18.45 and 18.32, 17.38 and 17.34, 14.83 and 14.79, 11.25, and 11.24. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 510.2073; found, 510.2082.</div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Chiral Separation of Racemic <b>22e</b></h3><div class="NLM_p">Analytical conditions: Chiralpak AY-3 column (15 cm × 4.6 mm), 30% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the fluent phase, flow rate = 1.0 mL/min, λ = 254 nm. Preparative conditions: Chiralcel AY-5 column (25 cm × 50 mm, 10 μM), 30% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the eluting system, flow rate = 60 mL/min, λ = 254 nm. (1<i>R</i>,2<i>R</i>)-<b>22e</b> was isolated as the first-eluting peaks (ee = 100%) and (1<i>S</i>,2<i>S</i>)-<b>22e</b> as the second-eluting peaks (ee = 100%), both of which appeared as a colorless oil after evaporation. The oil was dissolved in dichloromethane and stirred with 2 M HCl in diethyl ether (20 mL/mmol substrate) at room temperature for 15 min, which was then condensed to dryness to give HCl salts, respectively.</div><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> <i>N</i>-(4-((((1<i>R</i>,2<i>R</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((1<i>R</i>,2<i>R</i>)-<b>22e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.1% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.5 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.87 (d, <i>J</i> = 5.7 Hz, 1H), 8.65 (t, <i>J</i> = 7.9 Hz, 1H), 8.40 (d, <i>J</i> = 8.1 Hz, 1H), 8.12 (t, <i>J</i> = 8.1 Hz, 2H), 8.09–8.00 (m, 3H), 6.94–6.91 (m, 1H), 6.90–6.86 (m, 1H), 6.72–6.68 (m, 1H), 3.85 (s, 3H), 3.52–3.47 (m, 2H), 3.39–3.32 (m, 2H), 3.29–3.25 (m, 1H), 3.24–3.17 (m, 2H), 2.34–2.29 (m, 1H), 1.90–1.83 (m, 2H), 1.82–1.71 (m, 4H), 1.38–1.34 (m, 1H), 1.25–1.20 (m, 1H), 1.11–1.06 (m, 1H), 1.04–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.80, 158.65 (d, <i>J</i><sub>CF</sub> = 236.7 Hz), 155.67, 153.39, 147.71, 143.99, 138.69, 135.60, 132.04 (d, <i>J</i><sub>CF</sub> = 7.4 Hz), 129.68 (2C), 129.51 (2C), 127.27, 127.03, 113.91 (d, <i>J</i><sub>CF</sub> = 23.1 Hz),113.31 and 113.28 (d, <i>J</i><sub>CF</sub> = 24.5 Hz), 112.60 (d, <i>J</i><sub>CF</sub> = 8.7 Hz), 58.05, 56.63, 55.77 and 55.33, 53.87 and 53.48, 40.09 and 40.06, 27.65, 22.50 and 22.36, 18.47 and 18.31, 18.43 and 18.41, 17.55 and 17.46, 13.51, 11.27, and 11.26. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 490.2864; found, 490.2863. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −13.00 (<i>c</i> 0.4, MeOH).</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> <i>N</i>-(4-((((1<i>S</i>,2<i>S</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((1<i>S</i>,2<i>S</i>)-<b>22e</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.7% (λ = 254 nm, <i>t</i><sub>R</sub> = 15.4 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.88 (d, <i>J</i> = 5.7 Hz, 1H), 8.67 (t, <i>J</i> = 8.0 Hz, 1H), 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 8.15–8.11 (m, 2H), 8.09–8.04 (m, 3H), 6.94–6.91 (m, 1H), 6.90–6.87 (m, 1H), 6.72–6.69 (m, 1H), 3.85 (s, 3H), 3.52–3.47 (m, 2H), 3.39–3.32 (m, 2H), 3.29–3.24 (m, 2H), 3.24–3.18 (m, 2H), 2.35–2.29 (m, 1H), 1.90–1.83 (m, 2H), 1.82–1.71 (m, 4H), 1.38–1.34 (m, 1H), 1.24–1.21 (m, 1H), 1.10–1.07 (m, 1H), 1.05–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.75, 158.66 (d, <i>J</i><sub>CF</sub> = 236.7 Hz), 155.67, 153.19, 148.12, 143.68, 138.82, 135.23, 132.05 (d, <i>J</i><sub>CF</sub> = 7.6 Hz), 129.73 (2C), 129.57 (2C), 127.48, 127.15, 113.91 (d, <i>J</i><sub>CF</sub> = 23.1 Hz), 113.31 and 113.28 (d, <i>J</i><sub>CF</sub> = 23.9 Hz), 112.59 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 58.04, 56.63, 55.77 and 55.32, 53.87 and 53.48, 40.10 and 40.07, 27.64, 22.50 and 22.37, 18.47 and 18.31, 18.43 and 18.41, 17.55 and 17.46, 13.51, 11.27, and 11.26. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 490.2864; found, 490.2867. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +11.67 (<i>c</i> 0.6, MeOH).</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Chiral Separation of Racemic <b>30p</b></h3><div class="NLM_p">Analytical conditions: Chiralpak AY-3 column (15 cm × 4.6 mm), 10% EtOH and 0.1% diethylamine in <i>n</i>-hexane as the fluent phase, flow rate = 1.0 mL/min, λ = 254 nm. Preparative conditions: Chiralcel AY-5 column (25 cm × 50 mm, 10 μM), 15% EtOH in <i>n</i>-hexane as the eluting system, flow rate = 60 mL/min, λ = 254 nm. (1<i>R</i>,2<i>R</i>)-<b>30p</b> was isolated as the first-eluting peaks (ee = 95.1%) and (1<i>S</i>,2<i>S</i>)-<b>30p</b> as the second-eluting peaks (ee = 97.3%), both of which appeared as a colorless oil after evaporation. The oil was dissolved in dichloromethane and stirred with 2 M HCl in diethyl ether (20 mL/mmol substrate) at room temperature for 15 min, which was then condensed to dryness to give HCl salts, respectively.</div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> <i>N</i>-(4-((((1<i>R</i>,2<i>R</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride ((1<i>R</i>,2<i>R</i>)-<b>30p</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.1% (λ = 254 nm, <i>t</i><sub>R</sub> = 27.1 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.38 (d, <i>J</i> = 11.3 Hz, 1H), 7.98–7.91 (m, 3H), 7.90–7.86 (m, 1H), 7.62–7.56 (m, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 7.21–7.18 (m, 1H), 7.05 (d, <i>J</i> = 7.8 Hz, 1H), 3.62–3.57 (m, 1H), 3.55–3.50 (m, 2H), 3.41–3.33 (m, 2H), 3.27–3.16 (m, 3H), 2.35–2.31 (m, 1H), 1.92–1.83 (m, 2H), 1.82–1.73 (m, 4H), 1.47–1.43 (m, 1H), 1.29–1.25 (m, 1H), 1.25–1.21 (m, 1H), 1.04–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.36, 141.89, 136.28, 134.19 and 134.17, 134.04, 133.93, 132.67 and 136.66, 130.01, 129.68, 129.39, 128.92, 128.91, 128.80, 128.78, 127.90, 126.60 and 126.56, 124.79, 57.88 and 57.84, 55.90 and 55.64, 53.98 and 53.67, 39.87 and 39.80, 27.78, 22.41 and 22.37, 22.27 and 22.14, 18.46 and 18.31, 17.35 and 17.32, 14.80 and 14.72, 11.22, and 11.21. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 483.1964; found, 483.1957. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −2.50 (<i>c</i> 0.4, MeOH).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> <i>N</i>-(4-((((1<i>S</i>,2<i>S</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-2-naphthamide Hydrochloride ((1<i>S</i>,2<i>S</i>)-<b>30p</b>)</h4><div class="NLM_p last">White solid. HPLC: 96.0% (λ = 254 nm, <i>t</i><sub>R</sub> = 27.0 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.38 (d, <i>J</i> = 11.4 Hz, 1H), 7.99–7.91 (m, 3H), 7.90–7.86 (m, 1H), 7.61–7.56 (m, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 7.21–7.17 (m, 1H), 7.05 (d, <i>J</i> = 7.9 Hz, 1H), 3.62–3.56 (m, 1H), 3.55–3.48 (m, 2H), 3.39–3.31 (m, 2H), 3.26–3.16 (m, 3H), 2.37–2.31 (m, 1H), 1.92–1.84 (m, 2H), 1.82–1.74 (m, 4H), 1.49–1.44 (m, 1H), 1.28–1.25 (m, 1H), 1.24–1.22 (m, 1H), 1.05–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 170.33, 141.87, 136.27, 134.18 and 134.16, 134.03, 133.92, 132.67 and 132.66, 130.01, 129.66, 129.38, 128.91, 128.89, 128.79, 128.78, 127.89, 126.60 and 126.55, 124.80, 57.87 and 57.83, 55.88 and 55.62, 53.97 and 53.66, 39.88 and 39.81, 27.76, 22.41 and 22.36, 22.27 and 22.15, 18.44 and 18.30, 17.34 and 17.31, 14.81 and 14.73, 11.22. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 483.1964; found, 483.1961. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +1.94 (<i>c</i> 0.6, MeOH).</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> Chiral separation of racemic <b>30q</b></h3><div class="NLM_p">Analytical conditions: Chiralcel OJ-H column (25 cm × 4.6 mm), 10% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the fluent phase, flow rate = 1.0 mL/min, λ = 214 nm. Preparative conditions: Chiralcel OJ-5A column (25 cm × 50 mm, 10 μM), 1% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the eluting system, flow rate = 60 mL/min, λ = 220 nm. (1<i>R</i>,2<i>R</i>)-<b>30q</b> was isolated as the first-eluting peaks (ee = 98.6%) and (1<i>S</i>,2<i>S</i>)-<b>30q</b> as the second-eluting peaks (ee = 97.4%), both of which appeared as a colorless oil after evaporation. The oil was dissolved in dichloromethane and stirred with 2 M HCl in diethyl ether (20 mL/mmol substrate) at room temperature for 15 min, which was then condensed to dryness to give HCl salts, respectively.</div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> <i>N</i>-(4-((((1<i>R</i>,2<i>R</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride ((1<i>R</i>,2<i>R</i>)-<b>30q</b>)</h4><div class="NLM_p last">White solid. HPLC: 97.5% (λ = 280 nm, <i>t</i><sub>R</sub> = 22.5 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.36 (dt, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.23–7.21 (m, 1H), 7.17 (td, <i>J</i> = 7.9, 3.5 Hz, 1H), 7.09–7.05 (m, 2H), 7.02 (dt, <i>J</i> = 7.8, 1.8 Hz, 1H), 3.59–3.54 (m, 1H), 3.50–3.45 (m, 2H), 3.37–3.28 (m, 2H), 3.23–3.15 (m, 3H), 2.34–2.30 (m, 1H), 1.89–1.82 (m, 2H), 1.81–1.71 (m, 4H), 1.47–1.41 (m, 1H), 1.26–1.23 (m, 1H), 1.23–1.20 (m, 1H), 1.02–0.99 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.33, 141.86, 138.29, 134.15, 133.91, 132.06, 129.65 and 129.64, 128.96, 128.91, 126.56 and 126.53, 125.12, 122.77, 121.23, 113.09, 104.54, 57.85, 55.84 and 55.62, 53.94 and 53.66, 39.34 and 39.31, 27.81 and 27.79, 22.39 and 22.32, 22.24 and 22.19, 18.43 and 18.28, 17.34 and 17.30, 14.79 and 14.73, 11.21, and 11.20. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 472.1917; found, 472.1921. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −0.25 (<i>c</i> 0.4, MeOH).</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>N</i>-(4-((((1<i>S</i>,2<i>S</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-1<i>H</i>-indole-2-carboxamide Hydrochloride ((1<i>S</i>,2<i>S</i>)-<b>30q</b>)</h4><div class="NLM_p last">White solid. HPLC: 97.8% (λ = 280 nm, <i>t</i><sub>R</sub> = 22.8 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.38–7.35 (m, 1H), 7.23–7.20 (m, 1H), 7.17 (td, <i>J</i> = 7.9, 3.6 Hz, 1H), 7.08–7.05 (m, 2H), 7.04–7.02 (m, 1H), 3.59–3.55 (m, 1H), 3.50–3.46 (m, 2H), 3.37–3.29 (m, 2H), 3.25–3.15 (m, 3H), 2.34–2.30 (m, 1H), 1.90–1.82 (m, 2H), 1.81–1.70 (m, 4H), 1.47–1.41 (m, 1H), 1.26–1.23 (m, 1H), 1.23–1.20 (m, 1H), 1.02–0.98 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 164.35, 141.87, 138.30, 134.16, 133.92, 132.06, 129.65, 128.97, 128.92, 126.56 and 126.54, 125.12, 122.76, 121.22, 113.09, 104.52, 57.86, 55.85 and 55.64, 53.95 and 55.66, 39.34 and 39.31, 27.82 and 27.81, 22.39 and 22.33, 22.25 and 22.20, 18.44 and 18.29, 17.35 and 17.31, 14.79 and 14.72, 11.20, and 11.19. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 472.1917; found, 472.1926. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +0.17 (<i>c</i> 0.6, MeOH).</div></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> Chiral Separation of Racemic <b>30r</b></h3><div class="NLM_p">Analytical conditions: Chiralcel OD-H column (15 cm × 4.6 mm), 15% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the fluent phase, flow rate = 1.0 mL/min, λ = 254 nm. Preparative conditions: Chiralcel OD-5 column (25 cm × 50 mm, 10 μM), 20% isopropanol and 0.1% diethylamine in <i>n</i>-hexane as the eluting system, flow rate = 60 mL/min, λ = 254 nm. (1<i>R</i>,2<i>R</i>)-<b>30r</b> was isolated as the first-eluting peaks (ee = 99.4%) and (1<i>S</i>,2<i>S</i>)-<b>30r</b> as the second-eluting peaks (ee = 99.4%), both of which appeared as a colorless oil after evaporation. Both enantiomers were dissolved in dichloromethane and stirred with 2 M HCl in diethyl ether (20 mL/mmol substrate) at room temperature for 15 min and then condensed to dryness to give the corresponding HCl salts.</div><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> <i>N</i>-(4-((((1<i>R</i>,2<i>R</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((1<i>R</i>,2<i>R</i>)-<b>30r</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.4% (λ = 254 nm, <i>t</i><sub>R</sub> = 18.28 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.88 (d, <i>J</i> = 5.8 Hz, 1H), 8.68 (t, <i>J</i> = 7.9 Hz, 1H), 8.43 (d, <i>J</i> = 8.1 Hz, 1H), 8.15–8.11 (m, 2H), 8.09–8.05 (m, 3H), 7.42–7.38 (m, 1H), 7.24 (t, <i>J</i> = 7.9 Hz, 1H), 7.11–7.09 (m, 1H), 3.61–3.56 (m, 1H), 3.53–3.47 (m, 2H), 3.40–3.32 (m, 2H), 3.29–3.18 (m, 3H), 2.39–2.33 (m, 1H), 1.93–1.84 (m, 2H), 1.83–1.72 (m, 4H), 1.53–1.46 (m, 1H), 1.30–1.25 (m, 2H), 1.06–1.02 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.72, 153.07, 148.32, 143.53, 141.98, 138.87, 135.04, 134.15, 133.87, 129.75, and 129.74 (2C), 129.66 and 129.64, 129.60, and 129.59 (2C), 128.97 and 128.87, 127.57, 127.21 and 126.94, 126.66 and 126.61, 57.83 and 57.79, 55.85 and 55.56, 53.92 and 53.62, 40.06 and 40.01, 27.62, 22.45 and 22.22, 22.36 and 22.33, 18.44 and 18.31, 17.39 and 17.35, 14.87 and 14.83, 11.27. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 510.2073; found, 510.2070. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −1.58 (<i>c</i> 0.4, MeOH).</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> <i>N</i>-(4-((((1<i>S</i>,2<i>S</i>)-2-(2,3-Dichlorophenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((1<i>S</i>,2<i>S</i>)-<b>30r</b>)</h4><div class="NLM_p last">White solid. HPLC: 97.3% (λ = 254 nm, <i>t</i><sub>R</sub> = 18.4 min). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.88 (d, <i>J</i> = 5.8 Hz, 1H), 8.68 (t, <i>J</i> = 7.9 Hz, 1H), 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 8.15–8.11 (m, 2H), 8.09–8.04 (m, 3H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (t, <i>J</i> = 7.9 Hz, 1H), 7.11–7.08 (m, 1H), 3.62–3.57 (m, 1H), 3.54–3.48 (m, 2H), 3.40–3.32 (m, 2H), 3.29–3.18 (m, 3H), 2.38–2.34 (m, 1H), 1.91–1.84 (m, 2H), 1.83–1.74 (m, 4H), 1.52–1.47 (m, 1H), 1.32–1.24 (m, 2H), 1.07–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.77, 153.20, 148.13, 143.68, 141.98, 138.82, 135.23, 134.16, 133.91, 129.73, and 129.72 (2C), 129.67, 129.58, and 129.57 (2C), 128.98, 127.49, 127.16, 126.66 and 126.61, 57.85 and 57.80, 55.87 and 55.58, 53.94 and 53.64, 40.05 and 40.00, 27.64, 22.46 and 22.22, 22.37 and 22.33, 18.45 and 18.32, 17.40 and 17.34, 14.85 and 14.81, 11.26, and 11.25. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 510.2073; found, 510.2081. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +2.87 (<i>c</i> 0.5, MeOH).</div></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> Chiral Separation of Racemic <b>13c</b></h3><div class="NLM_p">Analytical conditions: Chiralcel OJ-H column (25 cm × 4.6 mm), 1% EtOH in <i>n</i>-hexane as the fluent phase, flow rate = 1.0 mL/min, λ = 280 nm. Preparative conditions: Chiralcel OJ-5A column (25 cm × 50 mm, 10 μM), 1% EtOH in <i>n</i>-hexane as the eluting system, flow rate = 60 mL/min, λ = 214 nm). (+)-<b>13c</b> was isolated as the first-eluting peaks and (−)-<b>13c</b> as the second-eluting peaks, both after evaporation appeared as colorless oil, and ee > 95%.</div><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (+)-<i>tert</i>-Butyl (((1<i>R</i>,2<i>R</i>)-2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-carbamate ((+)-<b>13c</b>)</h4><div class="NLM_p last">Ee: 98.5%. <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 6.84 (td, <i>J</i> = 8.4, 3.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.9, 4.5 Hz, 1H), 6.64 (dd, <i>J</i> = 9.2, 3.1 Hz, 1H), 3.88 (s, 3H), 3.55 (d, <i>J</i> = 13.0 Hz, 1H), 2.72 (dd, <i>J</i> = 13.1, 8.7 Hz, 1H), 1.85–1.81 (m, 1H), 1.47 (s, 9H), 1.05–0.98 (m, 2H), 0.88–0.83 (m, 1H). [α]<sub class="stack">D</sub><sup class="stack">20</sup> +10.93 (<i>c</i> 0.5, CHCl<sub>3</sub>).</div></div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (−)-<i>tert</i>-Butyl(((1<i>S</i>,2<i>S</i>)-2-(5-fluoro-2-methoxyphenyl)cyclopropyl)methyl)-carbamate ((−)-<b>13c</b>)</h4><div class="NLM_p last">Ee: 96.4%. <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>): δ 6.84 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.9, 4.5 Hz, 1H), 6.64 (dd, <i>J</i> = 9.2, 3.1 Hz, 1H), 3.89 (s, 3H), 3.55 (d, <i>J</i> = 12.8 Hz, 1H), 2.72 (dd, <i>J</i> = 13.1, 8.6 Hz, 1H), 1.85–1.81 (m, 1H), 1.47 (s, 9H), 1.05–0.98 (m, 2H), 0.88–0.83 (m, 1H). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −11.13 (<i>c</i> 0.5, CHCl<sub>3</sub>).</div></div><div id="sec4_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> (−)-((1<i>R</i>,2<i>R</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methanamine Hydrochloride ((−)-<b>14c</b>)</h4><div class="NLM_p last">Compound (+)-<b>13c</b> (378 mg, 1.28 mmol) was dissolved in 4 M HCl (g) in dioxane (20 mL) and stirred at room temperature overnight. The solvent was evaporated, and the residue was suspended in a mixture of ethyl acetate and petroleum ether (v/v = 1/2, 10 mL) for 10 min. The precipitate was collected by filtration, washed with ethyl acetate (3 mL), and dried under a vacuum to give the title compound as a yellow solid (290 mg, 98%). <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 6.93–6.86 (m, 2H), 6.72 (dd, <i>J</i> = 9.4, 2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, <i>J</i> = 13.1, 7.1 Hz, 1H), 2.93 (dd, <i>J</i> = 13.1, 8.0 Hz, 1H), 2.14–2.10 (m, 1H), 1.28–1.23 (m, 1H), 1.14–1.10 (m, 1H), 1.04–0.99 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>15</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 196.1132; found, 196.1128. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.80 (<i>c</i> 0.5, MeOH).</div></div><div id="sec4_15_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (+)-((1<i>S</i>,2<i>S</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methanamine Hydrochloride ((+)-<b>14c</b>)</h4><div class="NLM_p last">The title compound was prepared from (−)-<b>13c</b> as described for (−)-<b>14c</b> as a yellow solid. <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 6.92–6.87 (m, 2H), 6.72 (dd, <i>J</i> = 9.4, 2.9 Hz, 1H), 3.86 (s, 3H), 3.07 (dd, <i>J</i> = 13.0, 7.1 Hz, 1H), 2.93 (dd, <i>J</i> = 13.0, 8.0 Hz, 1H), 2.14–2.08 (m, 1H), 1.28–1.23 (m, 1H), 1.14–1.08 (m, 1H), 1.05–0.99 (m, 1H). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>15</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 196.1132; found, 196.1129. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +14.20 (<i>c</i> 0.5, MeOH).</div></div><div id="sec4_15_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> (−)-<i>N</i>-(((1<i>R</i>,2<i>R</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)propan-1-amine ((−)-<b>21c</b>)</h4><div class="NLM_p last">The title compound was prepared from (−)-<b>14c</b> as described for <b>21a</b> as a colorless oil. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 238.1602; found, 238.1603. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.60 (<i>c</i> 0.5, MeOH).</div></div><div id="sec4_15_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (+)-<i>N</i>-(((1<i>S</i>,2<i>S</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)propan-1-amine ((+)-<b>21c</b>)</h4><div class="NLM_p last">The title compound was prepared from (+)-<b>14c</b> as described for <b>21a</b> as a colorless oil. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>FNO<sup>+</sup> [M + H]<sup>+</sup>, 238.1602; found, 238.1605. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +16.13 (<i>c</i> 0.5, MeOH).</div></div><div id="sec4_15_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (−)-<i>N</i>-(4-((((1<i>R</i>,2<i>R</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((−)-<b>22e</b>)</h4><div class="NLM_p last">A mixture of (−)-<b>21c</b> (41 mg, 0.17 mmol) and <b>20c</b> (46 mg, 0.17 mmol) in THF (15 mL) was stirred at room temperature for 15 min. NaHB(AcO)<sub>3</sub> (73 mg, 0.35 mmol) was added, and the reaction mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with ethyl acetate. The combined extracts were washed with brine and concentrated, and the residue was purified by flash chromatography (0–5% methanol in dichloromethane) to give a colorless oil (28 mg, 33%), which was converted into the HCl salt using a similar method as depicted for <b>17a</b>. <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.86 (d, <i>J</i> = 5.8 Hz, 1H), 8.62 (t, <i>J</i> = 7.9 Hz, 1H), 8.38 (d, <i>J</i> = 8.1 Hz, 1H), 8.14–8.10 (m, 2H), 8.09–8.06 (m, 2H), 8.03–8.00 (m, 1H), 6.93–6.91 (m, 1H), 6.90–6.86 (m, 1H), 6.72–6.68 (m, 1H), 3.85 (s, 3H), 3.52–3.47 (m, 2H), 3.41–3.32 (m, 2H), 3.30–3.16 (m, 4H), 2.35–2.29 (m, 1H), 1.90–1.83 (m, 2H), 1.83–1.72 (m, 4H), 1.39–1.33 (m, 1H), 1.25–1.21 (m, 1H), 1.10–1.07 (m, 1H), 1.05–1.00 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.80, 158.65 (d, <i>J</i><sub>CF</sub> = 236.9 Hz), 155.67, 153.45, 147.55, 144.11, 138.63, 135.72, 132.05 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 129.67 and 129.66 (2C), 129.48 (2C), 127.18, 126.97, 113.90 (d, <i>J</i><sub>CF</sub> = 22.8 Hz), 113.31 and 113.28 (d, <i>J</i><sub>CF</sub> = 24.3 Hz), 112.58 (d, <i>J</i><sub>CF</sub> = 8.6 Hz), 58.04, 56.64, 55.76 and 55.32, 53.87 and 53.47, 40.09 and 40.05, 27.65, 22.49 and 22.36, 18.46 and 18.31, 18.43 and 18.41, 17.55 and 17.46, 13.52, 11.27, and 11.26. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 490.2864; found, 490.2863. [α]<sub class="stack">D</sub><sup class="stack">20</sup> −13.00 (<i>c</i> 0.5, MeOH).</div></div><div id="sec4_15_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> (+)-<i>N</i>-(4-((((1<i>S</i>,2<i>S</i>)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl)methyl)(propyl)amino)butyl)-4-(pyridin-2-yl)benzamide Hydrochloride ((+)-<b>22e</b>)</h4><div class="NLM_p last">The title compound was prepared from (+)-<b>21c</b> using the same method as described for (−)-<b>22e</b>. <sup>1</sup>H NMR (800 MHz, CD<sub>3</sub>OD): δ 8.88 (d, <i>J</i> = 5.8 Hz, 1H), 8.66 (t, <i>J</i> = 7.9 Hz, 1H), 8.41 (d, <i>J</i> = 8.1 Hz, 1H), 8.14–8.11 (m, 2H), 8.09–8.03 (m, 3H), 6.94–6.91 (m, 1H), 6.90–6.86 (m, 1H), 6.72–6.69 (m, 1H), 3.85 (s, 3H), 3.53–3.47 (m, 2H), 3.41–3.32 (m, 2H), 3.30–3.18 (m, 4H), 2.34–2.30 (m, 1H), 1.89–1.83 (m, 2H), 1.83–1.72 (m, 4H), 1.39–1.32 (m, 1H), 1.25–1.21 (m, 1H), 1.10–1.06 (m, 1H), 1.05–0.99 (m, 3H). <sup>13</sup>C NMR (201 MHz, CD<sub>3</sub>OD): δ 168.75, 158.65 (d, <i>J</i><sub>CF</sub> = 237.0 Hz), 155.67, 153.18, 148.14, 143.66, 138.83, 135.21, 132.05 (d, <i>J</i><sub>CF</sub> = 7.3 Hz), 129.73 and 129.72 (2C), 129.58 (2C), 127.50, 127.16, 113.91 (d, <i>J</i><sub>CF</sub> = 22.7 Hz), 113.31 and 113.28 (d, <i>J</i><sub>CF</sub> = 24.2 Hz), 112.60 (d, <i>J</i><sub>CF</sub> = 8.4 Hz), 58.05, 56.64, 55.77 and 55.33, 53.87 and 53.48, 40.10 and 40.07, 27.65, 22.50 and 22.37, 18.47 and 18.31, 18.43 and 18.41, 17.55 and 17.46, 13.52, 11.27, and 11.26. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 490.2864; found, 490.2859. [α]<sub class="stack">D</sub><sup class="stack">20</sup> +11.80 (<i>c</i> 0.5, MeOH).</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> Radioligand Binding Assays</h3><div class="NLM_p last">Radioligand binding affinities were determined by the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), directed by Bryan L Roth, M.D., Ph.D., the University of North Carolina at Chapel Hill, North Carolina, and Program Officer Jamie Driscoll at NIMH, Bethesda, MD. Detail binding protocols and assay conditions are also available at <a href="https://pdspdb.unc.edu/pdspWeb/?site=assays" class="extLink">https://pdspdb.unc.edu/pdspWeb/?site=assays</a>.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> D<sub>3</sub> GloSensor cAMP Assays</h3><div class="NLM_p last">Human D<sub>3</sub> and GloSensor cAMP plasmids (Promega) were cotransfected (4 μg receptor DNA and 4 μg GloSensor cAMP reporter DNA for a 10 cm dish, increased proportionally if using a larger size of dishes) in HEK293 T cells overnight in full growth medium (DMEM + 10% FBS) and plated in poly-<span class="smallcaps smallerCapital">l</span>-Lys-coated 384-well white assay plates using DMEM containing 1% dialyzed FBS at a density of 15 000–20 000 cells per 40 μL/well. After a minimum of 6 h recovery (up to 24 h), cells were removed from the medium, stimulated with 25 μL/well drug solutions prepared in assay buffer (1× HBSS, 20 mM HEPES, pH 7.4, 0.1% BSA) for 15 min, followed by the addition of 10 μL/well of the mixture of 2 mM luciferin and 100 nM isoproterenol (final), all at room temperature. For antagonist assays, 10 nM dopamine (final) was added at 10 min after test compounds. Luminescence was counted after 20 min of incubation. Agonist EC<sub>50</sub> or antagonist <i>K</i><sub>i</sub> values were shown as the mean from at least three individual experiments.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> GPCR Tango (β-Arrestin2 Recruitment) Assays</h3><div class="NLM_p last">GPCR Tango assays are conducted as described previously.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In brief, HTLA cells, stably expressing a β-arrestin2-TEV fusion protein and a tTA-dependent luciferase reporter, were transiently transfected (8 μg receptor DNA per 10 cm dish) in full growth medium (DMEM with 10% FBS) and plated in poly-<span class="smallcaps smallerCapital">l</span>-Lys-coated 384-well white assay plates in DMEM with 1% dialyzed FBS at a density of 10 000–15 000 cells/well in a total of 40 μL. After a minimum of 3 h of recovery, drug dilutions were made in DMEM with 1% dFBS at 5× of the final concentrations for agonist assays and added to cells at 10 μL/well for incubation (around 16 h). Medium and drugs were removed, and Bright-Glo reagents (Promega) were added. Luminescence was counted on a luminescence counter after 20 min of incubation at room temperature. Results (relative luminescence counts) were analyzed in Prism 7.0. EC<sub>50</sub> or % activation values were shown as the mean from at least three individual experiments.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> 5-HT<sub>2C</sub> Calcium Mobilization Assays</h3><div class="NLM_p last">HEK293 cells stably expressing 5-HT<sub>2C</sub> receptors were plated in poly-<span class="smallcaps smallerCapital">l</span>-Lys-coated 384-well black assay plates in DMEM containing 1% dialyzed FBS overnight at a density of 15 000 cells/well/40 μL and incubated overnight. Cells were removed from the medium and loaded with Calcium dye (Fluo-4 Direct, Invitrogen), 20 μL/well, prepared in assay buffer (1× HBSS, 20 mM HEPES, pH 7.4, 2.5 mM probenecid), for 50 min in the cell culture incubator (37 °C), followed by 10 min of incubation at room temperature in the dark (to equilibrate to room temperature). Drug solutions (at 3× of the final concentrations) were prepared in assay buffer and aliquoted in a matching 384-well plate. A cell plate and a drug plate were both then loaded into the FLIPR<sup>TETRA</sup> (Molecular Devices). A FLIPR protocol was designed to transfer 10 μL/well drug solutions into the cell plate, and fluorescence was read for a total of 2 min at a rate of 1 read per second, including 10 s before drug addition. The initial 10 readings served as the background for each well, and the average background was subtracted from the maximum reading within 60 s after drug addition. Fluorescence intensity (fold of basal) upon drug stimulation was exported and analyzed in Prism 7.0. For antagonist assays, an additional 10 μL of 5-HT (final of 1 nM) was added 15 min after the first drug addition, and fluorescence intensity (fold of basal) was exported and analyzed as above. EC<sub>50</sub> or IC<sub>50</sub> values were shown as the mean from at least three individual experiments.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> Computational Methods</h3><div class="NLM_p last">Molecular dockings were performed using modules (Maestro, Ligprep, Protein Preparation Wizard, and Glide) in the Schrödinger software package (Release 2017–4). The crystal structures of antagonist-bound D3R (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and agonist- and antagonist-bound 5HT<sub>2C</sub> (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH">6BQH</a>)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> were retrieved from the Protein Data Bank. The missing side chains and hydrogen bonds were fixed and optimized using the Protein Preparation Wizard.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> All ligands were prepared using LigPrep with default settings. The docking grid was prepared with Glide defining the binding site by crystal ligands and setting the ligand diameter midpoint box to 10 Å on all three axes, while the hydroxyl groups in Ser, Thr, and Tyr and the thiol group in Cys around the pocket were allowed to rotate through the “Rotatable Groups” option. Finally, all of these ligands were docked into the calculated receptor grid using the XP scoring function and enhanced sampling. The docked results were visualized and analyzed in Maestro, and the best scoring poses were selected. All residues within 5 Å of the docked ligands were subjected to relax with the sampling method “Minimize” in the Prime MM-GBSA module,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which were then rescored by Glide XP. Finally, by visual inspection of the optimized docking pose and considering the XP docking scores, the predicted binding poses of these ligands were obtained.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> PK and Brain Penetration Studies</h3><div class="NLM_p last">Studies were performed by Suzhou Kangrun Pharmaceutical Testing Service, Inc. (Suzhou, China). Male ICR mice (age 6–8 weeks, ∼25 g body weight) were purchased from JOINN Laboratories, Inc. (Suzhou). For PK studies, compounds were dissolved in saline and administered at doses of 5 mg/kg (iv) and 10 mg/kg (po), respectively, with nine animals in each group. Blood samples (0.1 mL) were collected from mouse orbit at 0, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h, which were then centrifuged at 5000 rpm at 4 °C for 10 min to collect plasma samples. Brain tissues were collected at 0.5 and 2.0 h, which were washed with saline, weighed, and homogenated in 50% cold methanol (brain weight (g)/50% methanol (mL) = 1/3) to obtain drug solutions. All samples were stored at −80 °C before analysis. Drug concentrations in the samples were determined using liquid chromatography–mass spectrometry (LC–MS/MS). All studies were performed with approved animal use protocols from the institutional animal care and use committees.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i148"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01835" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14843" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14843" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01835?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01835</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding p<i>K</i><sub>i</sub> ± SEM values; 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> activity of selected compounds; binding affinities of (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>R</i>,2<i>R</i>)-<b>30q</b> at aminergic GPCRs (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">D3R+eticlopride (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">D3R+(1<i>R</i>,2<i>R</i>)-<b>22e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">D3R+(1<i>S</i>,2<i>S</i>)-<b>22e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (active) + ergotamine (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (active) + compound <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (inactive) + ritanserin (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (inactive) + (1<i>S</i>,2<i>S</i>)-<b>22e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_009.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_001.pdf">jm9b01835_si_001.pdf (1.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_002.csv">jm9b01835_si_002.csv (8.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_003.pdb">jm9b01835_si_003.pdb (790.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_004.pdb">jm9b01835_si_004.pdb (793.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_005.pdb">jm9b01835_si_005.pdb (793.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_006.pdb">jm9b01835_si_006.pdb (498.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_007.pdb">jm9b01835_si_007.pdb (493.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_008.pdb">jm9b01835_si_008.pdb (538.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_009.pdb">jm9b01835_si_009.pdb (541.55 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01835" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xi-Ping Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, National Institute of Mental Health Psychoactive
Drug Screening Program (NIMH PDSP), University
of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4f373f273a2e21280f3a212c612a2b3a"><span class="__cf_email__" data-cfemail="384048504d59565f784d565b165d5c4d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Cheng</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6065-2682" title="Orcid link">http://orcid.org/0000-0001-6065-2682</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#13707b767d74797953607b727d747b727a6776707b3d7677663d707d"><span class="__cf_email__" data-cfemail="8ae9e2efe4ede0e0caf9e2ebe4ede2ebe3feefe9e2a4efeeffa4e9e4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Tan</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingtong Zhou</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8124-3079" title="Orcid link">http://orcid.org/0000-0001-8124-3079</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhong Yan</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Sun</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan P. Kozikowski</span> - <span class="hlFld-Affiliation affiliation">StarWise
Therapeutics LLC, 2020
North Lincoln Park West, Chicago Illinois 60614, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suwen Zhao</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China</span>; 
    <span class="hlFld-Affiliation affiliation">School of
Life Science and Technology, ShanghaiTech
University, 393 Middle
Huaxia Road, Pudong New District, Shanghai 201210, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5609-434X" title="Orcid link">http://orcid.org/0000-0001-5609-434X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.T. and Q.Z. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i150">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">J.C. and S.Z. are thankful to the Shanghai Municipal Government, ShanghaiTech University, for startup financial support. This work is supported by the National Natural Science Foundation of China (81703361 to J.C., 31971178 to S.Z., and 21704064 to Q.Z.) and the National Key R&D Program of China (2018YFA0507000 to S.Z.). We thank the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) directed by B. L. Roth for conducting radioligand binding assays, J. Zhang and L. Yang for NMR data collection, and F. Zhao for LC–MS data collection. We thank R.C. Stevens, Z.-J. Liu, G. Zhong, H. Tao, C. Zhang, and Y. Xu for their helpful discussions and support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">EBP</td><td class="NLM_def"><p class="first last">extended binding pocket</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G protein-coupled receptors</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">OBP</td><td class="NLM_def"><p class="first last">orthosteric binding pocket</p></td></tr><tr><td class="NLM_term">PCPMA</td><td class="NLM_def"><p class="first last">2-phenylcyclopropylmethylamine</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+Diversity+of+G+Protein-Coupled+Receptors+and+Significance+for+Drug+Discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eYHCUmGQOusqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520Diversity%2520of%2520G%2520Protein-Coupled%2520Receptors%2520and%2520Significance%2520for%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR Drug Discovery: New Agents, Targets and Indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schiothauthor=D.+E.+Gloriam&title=Trends+in+GPCR+Drug+Discovery%3A+New+Agents%2C+Targets+and+Indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0li-0pdYyapO-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520Drug%2520Discovery%253A%2520New%2520Agents%252C%2520Targets%2520and%2520Indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podlewska, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span> <span> </span><span class="NLM_article-title">Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3784</span>– <span class="NLM_lpage">3839</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00836</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00836" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFerurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3784-3839&author=M.+Vassauthor=S.+Podlewskaauthor=I.+J.+P.+de+Eschauthor=A.+J.+Bojarskiauthor=R.+Leursauthor=A.+J.+Kooistraauthor=C.+de+Graaf&title=Aminergic+GPCR-Ligand+Interactions%3A+A+Chemical+and+Structural+Map+of+Receptor+Mutation+Data&doi=10.1021%2Facs.jmedchem.8b00836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data</span></div><div class="casAuthors">Vass, Marton; Podlewska, Sabina; de Esch, Iwan J. P.; Bojarski, Andrzej J.; Leurs, Rob; Kooistra, Albert J.; de Graaf, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3784-3839</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aminergic family of G protein-coupled receptors (GPCRs) plays an important role in various diseases and represents a major drug discovery target class.  Structure detn. of all major aminergic subfamilies has enabled structure-based ligand design for these receptors.  Site-directed mutagenesis data provides an invaluable complementary source of information for elucidating the structural determinants of binding of different ligand chemotypes.  The current study provides a comparative anal. of 6692 mutation data points on 34 aminergic GPCR subtypes, covering the chem. space of 540 unique ligands from mutagenesis expts., and information from exptl. detd. structures of 52 distinct aminergic receptor-ligand complexes.  The integrated anal. enables detailed investigation of structural receptor-ligand interactions and assessment of the transferability of combined binding mode and mutation data across ligand chemotypes and receptor subtypes.  An overview is provided of the possibilities and limitations of using mutation data to guide the design of novel aminergic receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9WHKk1wW24bVg90H21EOLACvtfcHk0licRx64zQH7sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFerurjK&md5=b6301276cd3a5a3b062d8c4632681fc8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00836%26sid%3Dliteratum%253Aachs%26aulast%3DVass%26aufirst%3DM.%26aulast%3DPodlewska%26aufirst%3DS.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26atitle%3DAminergic%2520GPCR-Ligand%2520Interactions%253A%2520A%2520Chemical%2520and%2520Structural%2520Map%2520of%2520Receptor%2520Mutation%2520Data%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3784%26epage%3D3839%26doi%3D10.1021%2Facs.jmedchem.8b00836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaisin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1992</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1021/jm5019274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1992-2002&author=J.+Chengauthor=P.+M.+Giguereauthor=O.+K.+Onajoleauthor=W.+Lvauthor=A.+Gaisinauthor=H.+Gunosewoyoauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=G.+Vistoliauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Optimization+of+2-Phenylcyclopropylmethylamines+as+Selective+Serotonin+2C+Receptor+Agonists+and+Their+Evaluation+as+Potential+Antipsychotic+Agents&doi=10.1021%2Fjm5019274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Onajole, Oluseye K.; Lv, Wei; Gaisin, Arsen; Gunosewoyo, Hendra; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Vistoli, Giulio; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1992-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a new series of compds. that are potent, selective 5-HT2C receptor agonists is described herein as the authors continue the efforts to optimize the 2-phenylcyclopropylmethylamine scaffold.  Modifications focused on the alkoxyl substituent present on the arom. ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors.  ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compds. possessing drug-like profiles and having antipsychotic properties.  Compd. I, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date.  The likely binding mode of this series of compds. to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Ar63unExNbVg90H21EOLACvtfcHk0licRx64zQH7sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D&md5=f2884cbae8062702164da57a0de7381f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5019274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019274%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DGaisin%26aufirst%3DA.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DOptimization%2520of%25202-Phenylcyclopropylmethylamines%2520as%2520Selective%2520Serotonin%25202C%2520Receptor%2520Agonists%2520and%2520Their%2520Evaluation%2520as%2520Potential%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1992%26epage%3D2002%26doi%3D10.1021%2Fjm5019274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=578-591&author=J.+Chengauthor=P.+M.+Giguereauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=H.+Zhuauthor=J.+D.+McCorvyauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Further+Advances+in+Optimizing+%282-Phenylcyclopropyl%29methylamines+as+Novel+Serotonin+2C+Agonists%3A+Effects+on+Hyperlocomotion%2C+Prepulse+Inhibition%2C+and+Cognition+Models&doi=10.1021%2Facs.jmedchem.5b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Huang, Xi-Ping; Zhu, Hu; McCorvy, John D.; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">578-591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel compds. with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists.  Compd. (+)-22a was identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors.  ADMET assays showed that compd. (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile.  Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol.  These data support the further development of (+)-22a as a drug candidate for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQRNc_Uk6IsbVg90H21EOLACvtfcHk0ljztQylGItZOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrur%252FE&md5=7331d1c14a844d2dfcc3e637597b9e15</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01153%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFurther%2520Advances%2520in%2520Optimizing%2520%25282-Phenylcyclopropyl%2529methylamines%2520as%2520Novel%2520Serotonin%25202C%2520Agonists%253A%2520Effects%2520on%2520Hyperlocomotion%252C%2520Prepulse%2520Inhibition%252C%2520and%2520Cognition%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D578%26epage%3D591%26doi%3D10.1021%2Facs.jmedchem.5b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2c) Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9866</span>– <span class="NLM_lpage">9880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9866-9880&author=J.+Chengauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=H.+Zhuauthor=T.+Kenakinauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Design+and+Discovery+of+Functionally+Selective+Serotonin+2C+%285-HT2c%29+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.6b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists</span></div><div class="casAuthors">Cheng, Jianjun; McCorvy, John D.; Giguere, Patrick M.; Zhu, Hu; Kenakin, Terry; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9866-9880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the structural similarity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative biol. cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compds. were designed and synthesized.  The compds. were evaluated for their selectivity toward 5-HT2A, 5-HT2B, and 5-HT2C receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT2C agonists.  Selected compds. were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway vs. β-arrestin recruitment.  The most functionally selective compd. (+)-7e produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays.  We report for the first time that selective 5-HT2C agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaXMjfBCeBR7Vg90H21EOLACvtfcHk0ljztQylGItZOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF&md5=bb0e1b524230649fac9f5b736ddc283d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01194%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520Discovery%2520of%2520Functionally%2520Selective%2520Serotonin%25202C%2520%25285-HT2c%2529%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9866%26epage%3D9880%26doi%3D10.1021%2Facs.jmedchem.6b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-Substituted 2-Phenylcyclopropylmethylamines as Functionally Selective Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for Potential Use as Antipsychotic Medications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6288</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6273-6288&author=G.+Zhangauthor=J.+Chengauthor=J.+D.+McCorvyauthor=P.+J.+Lorelloauthor=B.+J.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Discovery+of+N-Substituted+2-Phenylcyclopropylmethylamines+as+Functionally+Selective+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+Potential+Use+as+Antipsychotic+Medications&doi=10.1021%2Facs.jmedchem.7b00584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span></div><div class="casAuthors">Zhang, Guiping; Cheng, Jianjun; McCorvy, John D.; Lorello, Paul J.; Caldarone, Barbara J.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6273-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preference for Gq signaling.  A no. of these compds. exhibit 5-HT2C selectivity with a preference for Gq-mediated signaling compared with β-arrestin recruitment.  Furthermore, the N-Me compd. I•HCl, which displayed an EC50 of 23 nM in the calcium flux assay while showing no β-arrestin recruitment activity, is the most functionally selective 5-HT2C agonist reported to date.  The N-benzyl compd. II•HCl, which showed an EC50 of 24 nM at the 5-HT2C receptor, is fully selective over the 5-HT2B receptor.  In an amphetamine-induced hyperactivity model, compd. II showed significant antipsychotic-drug-like activity.  These compds. shed light on the role of functional selectivity at the 5-HT2C receptor with respect to antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGjR92vyblbVg90H21EOLACvtfcHk0lifDzSW3cR7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK&md5=9da7c5db2f4e54db114a544d5f2e56b7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00584%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DLorello%26aufirst%3DP.%2BJ.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520N-Substituted%25202-Phenylcyclopropylmethylamines%2520as%2520Functionally%2520Selective%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520Potential%2520Use%2520as%2520Antipsychotic%2520Medications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6273%26epage%3D6288%26doi%3D10.1021%2Facs.jmedchem.7b00584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for the Treatment of CNS Disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+Chengauthor=A.+P.+Kozikowski&title=We+Need+2C+but+Not+2B%3A+Developing+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+the+Treatment+of+CNS+Disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0lifDzSW3cR7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520Need%25202C%2520but%2520Not%25202B%253A%2520Developing%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Agonists Modulate Schizophrenia-Like Behaviors in Mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnpp.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=28294132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2163-2177&author=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=J.+Chengauthor=M.+Huangauthor=C.+M.+Schmerbergauthor=H.+Y.+Meltzerauthor=B.+L.+Rothauthor=A.+P.+Kozikowskiauthor=W.+C.+Wetsel&title=5-HT2C+Agonists+Modulate+Schizophrenia-Like+Behaviors+in+Mice&doi=10.1038%2Fnpp.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice</span></div><div class="casAuthors">Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Cheng, Jianjun; Huang, Mei; Schmerberg, Claire M.; Meltzer, Herbert Y.; Roth, Bryan L.; Kozikowski, Alan P.; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2163-2177</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of neg. and cognitive symptoms.  The heterogeneity of pharmacol. responses in schizophrenic patients suggests that addnl. drug targets may be effective in improving aspects of this syndrome.  Recent evidence suggests that 5-HT2C receptors may be a promising target for schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusively in CNS, and have wt.-loss-promoting capabilities.  A difficulty in developing 5-HT2C agonists is that most ligands also possess 5-HT2B and/or 5-HT2A activities.  We have developed selective 5-HT2C ligands and herein describe their preclin. effectiveness for treating schizophrenia-like behaviors.  JJ-3-45, JJ-3-42, and JJ-5-34 reduced amphetamine-stimulated hyperlocomotion, restored amphetamine-disrupted prepulse inhibition, improved social behavior, and novel object recognition memory in NMDA receptor hypofunctioning NR1-knockdown mice, and were essentially devoid of catalepsy.  However, they decreased motivation in a breakpoint assay and did not promote reversal learning in MK-801-treated mice.  Somewhat similar effects were obsd. with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.  Microdialysis studies revealed that both JJ-3-42 and lorcaserin reduced dopamine efflux in the infralimbic cortex, while only JJ-3-42 decreased it in striatum.  Collectively, these results provide addnl. evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related disorders than current APDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwGQU6HLhHrVg90H21EOLACvtfcHk0lifDzSW3cR7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D&md5=f4b074cad46559dd52e7d622c8af24f9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3D5-HT2C%2520Agonists%2520Modulate%2520Schizophrenia-Like%2520Behaviors%2520in%2520Mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2163%26epage%3D2177%26doi%3D10.1038%2Fnpp.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platania, C. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">Current Drug Treatments Targeting Dopamine D3 Receptor</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+M.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+Drug+Treatments+Targeting+Dopamine+D3+Receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0lifDzSW3cR7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520Drug%2520Treatments%2520Targeting%2520Dopamine%2520D3%2520Receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perachon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sautel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Cocaine-Seeking Behaviour by a Partial Dopamine D<sub>3</sub> Receptor Agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1038/22560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2F22560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10432116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=1999&pages=371-375&author=M.+Pillaauthor=S.+Perachonauthor=F.+Sautelauthor=F.+Garridoauthor=A.+Mannauthor=C.+G.+Wermuthauthor=J.+C.+Schwartzauthor=B.+J.+Everittauthor=P.+Sokoloff&title=Selective+Inhibition+of+Cocaine-Seeking+Behaviour+by+a+Partial+Dopamine+D3+Receptor+Agonist&doi=10.1038%2F22560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of cocaine-seeking behavior by a partial dopamine D3 receptor agonist</span></div><div class="casAuthors">Pilla, Maria; Perachon, Sylvie; Sautel, Francois; Garrido, Fabrice; Mann, Andre; Wermuth, Camille G.; Schwartz, Jean-Charles; Everitt, Barry J.; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">6742</span>),
    <span class="NLM_cas:pages">371-375</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Environmental stimuli that are reliably assocd. with the effects of many abused drugs, esp. stimulants such as cocaine, can produce craving and relapse in abstinent human substance abusers.  In animals, such cues can induce and maintain drug-seeking behavior and also reinstate drug-seeking after extinction.  Reducing the motivational effects of drug-related cues might therefore be useful in the treatment of addiction.  Converging pharmacol., human post-mortem and genetic studies implicate the dopamine D3 receptor in drug addiction.  Here we have designed BP 897, the first D3-receptor-selective agonist, as assessed in vitro with recombinant receptors and in vivo with mice bearing disrupted D3-receptor genes.  BP 897 is a partial agonist in vitro and acts in vivo as either an agonist or an antagonist.  We show that BP 897 inhibits cocaine-seeking behavior that depends upon the presentation of drug-assocd. cues, without having any intrinsic, primary rewarding effects.  Our data indicate that compds. like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug-assocd. environmental stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6SwJsmcTSCLVg90H21EOLACvtfcHk0lhovO9RzPYaJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFOntr0%253D&md5=3f4055a4cd1b6cee7e890ff1b96b21b6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F22560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F22560%26sid%3Dliteratum%253Aachs%26aulast%3DPilla%26aufirst%3DM.%26aulast%3DPerachon%26aufirst%3DS.%26aulast%3DSautel%26aufirst%3DF.%26aulast%3DGarrido%26aufirst%3DF.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DEveritt%26aufirst%3DB.%2BJ.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DSelective%2520Inhibition%2520of%2520Cocaine-Seeking%2520Behaviour%2520by%2520a%2520Partial%2520Dopamine%2520D3%2520Receptor%2520Agonist%26jtitle%3DNature%26date%3D1999%26volume%3D400%26spage%3D371%26epage%3D375%26doi%3D10.1038%2F22560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+Medicinal+Chemistry+Lectureship%3A+Designing+Bivalent+or+Bitopic+Molecules+for+G-Protein+Coupled+Receptors.+The+Whole+Is+Greater+Than+the+Sum+of+Its+Parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0lhovO9RzPYaJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520Medicinal%2520Chemistry%2520Lectureship%253A%2520Designing%2520Bivalent%2520or%2520Bitopic%2520Molecules%2520for%2520G-Protein%2520Coupled%2520Receptors.%2520The%2520Whole%2520Is%2520Greater%2520Than%2520the%2520Sum%2520of%2520Its%2520Parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Fluorine-Containing D<sub>3</sub> Dopamine Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1021/jm101323b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101323b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFWntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1555-1564&author=Z.+D.+Tuauthor=S.+H.+Liauthor=J.+Q.+Cuiauthor=J.+B.+Xuauthor=M.+Taylorauthor=D.+Hoauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Synthesis+and+Pharmacological+Evaluation+of+Fluorine-Containing+D3+Dopamine+Receptor+Ligands&doi=10.1021%2Fjm101323b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Fluorine-Containing D3 Dopamine Receptor Ligands</span></div><div class="casAuthors">Tu, Zhu-De; Li, Shi-Hong; Cui, Jin-Quan; Xu, Jin-Bin; Taylor, Michelle; Ho, David; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of fluorine-contg. N-(2-methoxyphenyl)piperazine and N-(2-fluoroethoxy)piperazine analogs, e. g. I, were synthesized, and their affinities for human dopamine D2, D3, and D4 receptors were detd.  Radioligand binding studies identified five compds., 18a, 20a, 20c, 20e, and 21e, which bind with high affinity at D3 (Ki = 0.17-5 nM) and moderate to high selectivity for D3 vs D2 receptors (ranging from ∼25- to 163-fold).  These compds. were also evaluated for intrinsic activity at D2 and D3 receptors using a forskolin-dependent adenylyl cyclase assay.  This panel of compds. exhibits varying receptor subtype binding selectivity and intrinsic activity at D2 vs D3 receptors.  These compds. may be useful for behavioral pharmacol. studies on the role of D2-like dopamine receptors in neuropsychiatric and neurol. disorders.  Furthermore, compd. 20e, which has the highest binding affinity and selectivity for the D3 receptor (Ki = 0.17 nM for D3, 163-fold selectivity for D3 vs D2 receptors), represents a candidate fluorine-18 radiotracer for in vivo PET imaging studies on the regulation of D3 receptor expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_lRIZaeiUnbVg90H21EOLACvtfcHk0lhovO9RzPYaJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFWntrY%253D&md5=138e7cf0e434cd726af353d75f99b0f6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm101323b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101323b%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DZ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DCui%26aufirst%3DJ.%2BQ.%26aulast%3DXu%26aufirst%3DJ.%2BB.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DD.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Fluorine-Containing%2520D3%2520Dopamine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1555%26epage%3D1564%26doi%3D10.1021%2Fjm101323b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arista, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di-Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamprecht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D<sub>3</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1021/jm901319p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901319p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKrtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=374-391&author=F.+Micheliauthor=L.+Aristaauthor=G.+Bonanomiauthor=F.+E.+Blaneyauthor=S.+Braggioauthor=A.+M.+Capelliauthor=A.+Checchiaauthor=F.+Damianiauthor=R.+Di-Fabioauthor=S.+Fontanaauthor=G.+Gentileauthor=C.+Griffanteauthor=D.+Hamprechtauthor=C.+Marchioroauthor=M.+Mugnainiauthor=J.+Pinerauthor=E.+Rattiauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=A.+Worbyauthor=C.+R.+Ashbyauthor=C.+Heidbreder&title=1%2C2%2C4-Triazolyl+Azabicyclo%5B3.1.0%5Dhexanes%3A+A+New+Series+of+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Fjm901319p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Micheli, Fabrizio; Arista, Luca; Bonanomi, Giorgio; Blaney, Frank E.; Braggio, Simone; Capelli, Anna Maria; Checchia, Anna; Damiani, Federica; Di-Fabio, Romano; Fontana, Stefano; Gentile, Gabriella; Griffante, Cristiana; Hamprecht, Dieter; Marchioro, Carla; Mugnaini, Manolo; Piner, Jacqui; Ratti, Emiliangelo; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Worby, Angela; Ashby, Charles R.; Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">374-391</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new highly potent and selective dopamine (DA) D3 receptor antagonists has recently allowed the characterization of the DA D3 receptor in a range of preclin. animal models of drug addiction.  A novel series of 1,2,4-triazol-3-yl-azabicyclo[3.1.0]hexanes, members of which showed a high affinity and selectivity for the DA D3 receptor and excellent pharmacokinetic profiles, is reported here.  Members of a group of derivs. from this series showed good oral bioavailability and brain penetration and very high in vitro affinity and selectivity for the DA D3 receptor, as well as high in vitro potency for antagonism at this receptor.  Several members of this series also significantly attenuate the expression of conditioned place preference (CPP) to nicotine and cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgBjd6ObO27bVg90H21EOLACvtfcHk0lh71NDsAkq9jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKrtr%252FK&md5=c21c283590b4345f9f6a73284fae6170</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm901319p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901319p%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DArista%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCapelli%26aufirst%3DA.%2BM.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DDamiani%26aufirst%3DF.%26aulast%3DDi-Fabio%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DGentile%26aufirst%3DG.%26aulast%3DGriffante%26aufirst%3DC.%26aulast%3DHamprecht%26aufirst%3DD.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMugnaini%26aufirst%3DM.%26aulast%3DPiner%26aufirst%3DJ.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3D1%252C2%252C4-Triazolyl%2520Azabicyclo%255B3.1.0%255Dhexanes%253A%2520A%2520New%2520Series%2520of%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D374%26epage%3D391%26doi%3D10.1021%2Fjm901319p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelletti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremonesi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Cin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feriani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehanne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajbaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellacani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomelleri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8549</span>– <span class="NLM_lpage">8576</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8549-8576&author=F.+Micheliauthor=A.+Bacchiauthor=S.+Braggioauthor=L.+Castellettiauthor=P.+Cavalliniauthor=P.+Cavanniauthor=S.+Cremonesiauthor=M.+Dal+Cinauthor=A.+Ferianiauthor=S.+Gehanneauthor=M.+Kajbafauthor=L.+Marchioauthor=S.+Nolaauthor=B.+Oliosiauthor=A.+Pellacaniauthor=E.+Perdonaauthor=A.+Savaauthor=T.+Semeraroauthor=L.+Tarsiauthor=S.+Tomelleriauthor=A.+Wongauthor=F.+Visentiniauthor=L.+Zonziniauthor=C.+Heidbreder&title=1%2C2%2C4-Triazolyl+5-Azaspiro%5B2.4%5Dheptanes%3A+Lead+Identification+and+Early+Lead+Optimization+of+a+New+Series+of+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Facs.jmedchem.6b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Micheli, Fabrizio; Bacchi, Alessia; Braggio, Simone; Castelletti, Laura; Cavallini, Palmina; Cavanni, Paolo; Cremonesi, Susanna; Dal Cin, Michele; Feriani, Aldo; Gehanne, Sylvie; Kajbaf, Mahmud; Marchio, Luciano; Nola, Selena; Oliosi, Beatrice; Pellacani, Annalisa; Perdona, Elisabetta; Sava, Anna; Semeraro, Teresa; Tarsi, Luca; Tomelleri, Silvia; Wong, Andrea; Visentini, Filippo; Zonzini, Laura; Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8549-8576</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 1,2,4-triazolyl 5-azaspiro[2.4]heptanes with high affinity and selectivity at the dopamine (DA) D3 receptor (D3R) is described.  Some of these compds. also have high selectivity over the hERG channel and were characterized with respect to their pharmacokinetic properties both in vitro and in vivo during lead identification and early lead optimization phases.  A few derivs. with overall favorable developability characteristics were selected for further late lead optimization studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCKMOaVTpugrVg90H21EOLACvtfcHk0lh71NDsAkq9jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltrjN&md5=9588db3bf4e320c6d082b4318a8143a4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00972%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCastelletti%26aufirst%3DL.%26aulast%3DCavallini%26aufirst%3DP.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DCremonesi%26aufirst%3DS.%26aulast%3DDal%2BCin%26aufirst%3DM.%26aulast%3DFeriani%26aufirst%3DA.%26aulast%3DGehanne%26aufirst%3DS.%26aulast%3DKajbaf%26aufirst%3DM.%26aulast%3DMarchio%26aufirst%3DL.%26aulast%3DNola%26aufirst%3DS.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DPellacani%26aufirst%3DA.%26aulast%3DPerdona%26aufirst%3DE.%26aulast%3DSava%26aufirst%3DA.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTomelleri%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3D1%252C2%252C4-Triazolyl%25205-Azaspiro%255B2.4%255Dheptanes%253A%2520Lead%2520Identification%2520and%2520Early%2520Lead%2520Optimization%2520of%2520a%2520New%2520Series%2520of%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8549%26epage%3D8576%26doi%3D10.1021%2Facs.jmedchem.6b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. M.</span></span> <span> </span><span class="NLM_article-title">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D<sub>3</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4968</span>, <span class="refDoi"> DOI: 10.1021/jm401798r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401798r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4962-4968&author=J.+Y.+Chenauthor=B.+Levantauthor=C.+Jiangauthor=T.+M.+Keckauthor=A.+H.+Newmanauthor=S.+M.+Wang&title=Tranylcypromine+Substituted+cis-Hydroxycyclobutylnaphthamides+as+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Fjm401798r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Jiang, Cheng; Keck, Thomas M.; Newman, Amy Hauck; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4962-4968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine.  Although tranylcypromine has a low affinity for the rat D3 receptor (Ki = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has Ki values of 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, resp., and displays resp. selectivities of >10000-fold and 223-fold over the rat and human D2 receptors.  Evaluation in a β-arrestin functional assay showed that (1R,2S)-11 is a potent and competitive antagonist at the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWudWdAfWgLVg90H21EOLACvtfcHk0lgI1gFLbdBiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D&md5=e2ddf0711d00103be281cb043b19ec3a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm401798r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401798r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DS.%2BM.%26atitle%3DTranylcypromine%2520Substituted%2520cis-Hydroxycyclobutylnaphthamides%2520as%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4962%26epage%3D4968%26doi%3D10.1021%2Fjm401798r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D<sub>3</sub> Receptor (D3R) Selective Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+Significance+of+Chirality+in+Drug+Design+and+Synthesis+of+Bitopic+Ligands+as+D3+Receptor+%28D3R%29+Selective+Agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0lgI1gFLbdBiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520Significance%2520of%2520Chirality%2520in%2520Drug%2520Design%2520and%2520Synthesis%2520of%2520Bitopic%2520Ligands%2520as%2520D3%2520Receptor%2520%2528D3R%2529%2520Selective%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+Medication+Targets+for+Psychostimulant+Addiction%3A+Unraveling+the+Dopamine+D3+Receptor+Hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0lgI1gFLbdBiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520Medication%2520Targets%2520for%2520Psychostimulant%2520Addiction%253A%2520Unraveling%2520the%2520Dopamine%2520D3%2520Receptor%2520Hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D<sub>3</sub> Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+Receptor+Antagonist+%28GSK598809%29+Potentiates+the+Hypertensive+Effects+of+Cocaine+in+Conscious%2C+Freely-Moving+Dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0ljHOt0LNMQHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520Receptor%2520Antagonist%2520%2528GSK598809%2529%2520Potentiates%2520the%2520Hypertensive%2520Effects%2520of%2520Cocaine%2520in%2520Conscious%252C%2520Freely-Moving%2520Dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpsoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harpsoeauthor=K.+Lansuauthor=S.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.-P.+Huangauthor=Y.+Wuauthor=L.+Shenauthor=W.+E.+Bjorn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=5-HT2C+Receptor+Structures+Reveal+the+Structural+Basis+of+GPCR+Polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Å and 2.7 Å, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0ljHOt0LNMQHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarpsoe%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3D5-HT2C%2520Receptor%2520Structures%2520Reveal%2520the%2520Structural%2520Basis%2520of%2520GPCR%2520Polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+Human+Dopamine+D3+Receptor+in+Complex+with+a+D2%2FD3+Selective+Antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0ljHOt0LNMQHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Dopamine%2520D3%2520Receptor%2520in%2520Complex%2520with%2520a%2520D2%252FD3%2520Selective%2520Antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1002%2Fcmdc.201300114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=23619931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1eksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=994-1001&author=S.+Samantaauthor=T.+L.+Limauthor=Y.+Lam&title=Synthesis+and+in+vitro+Evaluation+of+West+Nile+Virus+Protease+Inhibitors+Based+on+the+2-%7B6-%5B2-%285-Phenyl-4H-%7B1%2C2%2C4%5Dtriazol-3-ylsulfanyl%29acetylamino%5Dbenzothiazol-2-ylsulfanyl%7Dacetamide+Scaffold&doi=10.1002%2Fcmdc.201300114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold</span></div><div class="casAuthors">Samanta, Sanjay; Lim, Ting Liang; Lam, Yulin</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">994-1001</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Triazolylthioacetamido benzothiazolylthioacetamides and benzimidazolylthioacetamides I (R = Ph, 4-H2NC6H4, 4-O2NC6H4, 4-HOC6H4, cyclohexyl, n-Pr, 2-MeC6H4, 4-pyridinyl; R1 = H, Me, Et; R2 = H, Me; R3 = 4-FC6H4, 4-MeOC6H4, Ph, 4-MeC6H4, 4-ClC6H4, 4-MeC6H4, 4-EtC6H4, 4-n-PrC6H4, 3-FC6H4, 3-ClC6H4, 3-MeOC6H4, 3-EtC6H4; X = NH, S; Y = bond, CH2) such as I (R = R1 = R2 = H; R3 = 4-EtC6H4; X = S; Y = bond) (II) were prepd. as inhibitors of the West Nile virus (WNV) NS2B-NS3 protease for potential use as treatments for West Nile virus infection.  II was an uncompetitive inhibitor (IC50 = 3.4 ± 0.2 μM) of the WNV NS2B-NS3 protease.  Mol. docking of II into the WNV protease showed that it interfered with productive interactions of the NS2B cofactor with the NS3 protease and was an allosteric inhibitor of the WNV NS3 protease.  The stabilities and their toxicities to baby hamster kidney fibroblast cells of selected I were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcs3Xu65ygprVg90H21EOLACvtfcHk0lgC8G05hVizjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1eksrs%253D&md5=133605413f60e638ad024314f6ea9f8c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300114%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DT.%2BL.%26aulast%3DLam%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520Evaluation%2520of%2520West%2520Nile%2520Virus%2520Protease%2520Inhibitors%2520Based%2520on%2520the%25202-%257B6-%255B2-%25285-Phenyl-4H-%257B1%252C2%252C4%255Dtriazol-3-ylsulfanyl%2529acetylamino%255Dbenzothiazol-2-ylsulfanyl%257Dacetamide%2520Scaffold%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D994%26epage%3D1001%26doi%3D10.1002%2Fcmdc.201300114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malberg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1902</span>, <span class="refDoi"> DOI: 10.1021/jm801354e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801354e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1885-1902&author=S.+J.+Choauthor=N.+H.+Jensenauthor=T.+Kuromeauthor=S.+Kadariauthor=M.+L.+Manzanoauthor=J.+E.+Malbergauthor=B.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Selective+5-Hydroxytryptamine+2C+Receptor+Agonists+Derived+from+the+Lead+Compound+Tranylcypromine%3A+Identification+of+Drugs+with+Antidepressant-Like+Action&doi=10.1021%2Fjm801354e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span></div><div class="casAuthors">Cho, Sung Jin; Jensen, Niels H.; Kurome, Toru; Kadari, Sudhakar; Manzano, Michael L.; Malberg, Jessica E.; Caldarone, Barbara; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1885-1902</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here the design, synthesis, and pharmacol. properties of a series of compds. related to tranylcypromine (9), which itself was discovered as a lead compd. in a high-throughput screening campaign.  Starting from 9, which shows modest activity as a 5-HT2C agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT2C agonists through iterative structural modifications.  Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring.  Among the tested compds., several were potent and efficacious 5-HT2C receptor agonists with selectivity over both 5-HT2A and 5-HT2B receptors in functional assays.  The most promising compd. is 37, with 120- and 14-fold selectivity over 5-HT2A and 5-HT2B, resp. (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, resp.).  In animal studies, compd. 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh5xre4fJybVg90H21EOLACvtfcHk0lgC8G05hVizjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D&md5=d7711d01a8d462824a8fcf535e0a1be4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm801354e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801354e%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKurome%26aufirst%3DT.%26aulast%3DKadari%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DM.%2BL.%26aulast%3DMalberg%26aufirst%3DJ.%2BE.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%25205-Hydroxytryptamine%25202C%2520Receptor%2520Agonists%2520Derived%2520from%2520the%2520Lead%2520Compound%2520Tranylcypromine%253A%2520Identification%2520of%2520Drugs%2520with%2520Antidepressant-Like%2520Action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1885%26epage%3D1902%26doi%3D10.1021%2Fjm801354e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9841</span>– <span class="NLM_lpage">9878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00435</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00435" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9841-9878&author=L.+Tanauthor=W.+Yanauthor=J.+D.+McCorvyauthor=J.+Cheng&title=Biased+Ligands+of+G+Protein-Coupled+Receptors+%28GPCRs%29%3A+Structure-Functional+Selectivity+Relationships+%28SFSRs%29+and+Therapeutic+Potential&doi=10.1021%2Facs.jmedchem.8b00435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span></div><div class="casAuthors">Tan, Liang; Yan, Wenzhong; McCorvy, John D.; Cheng, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9841-9878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter.  Biased ligands selective for either pathway are expected to regulate biol. functions of GPCRs in a more precise way, therefore providing new drug mols. with superior efficacy and/or reduced side effects.  During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others.  In this Perspective, recent advances in this field are reviewed by discussing the structure-functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these mols.  Further understanding of the biol. functions assocd. with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFjkAvar29LVg90H21EOLACvtfcHk0lgC8G05hVizjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N&md5=a7bd605b82666357f5a0a209002225e5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DBiased%2520Ligands%2520of%2520G%2520Protein-Coupled%2520Receptors%2520%2528GPCRs%2529%253A%2520Structure-Functional%2520Selectivity%2520Relationships%2520%2528SFSRs%2529%2520and%2520Therapeutic%2520Potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9841%26epage%3D9878%26doi%3D10.1021%2Facs.jmedchem.8b00435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10676</span>– <span class="NLM_lpage">10691</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.-H.+Biauthor=Z.-X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+High+Affinity+2-%5B%28Diphenylmethyl%29sulfinyl%5Dacetamide+%28Modafinil%29+Analogues+as+Atypical+Dopamine+Transporter+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0libMBzLDQrIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520High%2520Affinity%25202-%255B%2528Diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528Modafinil%2529%2520Analogues%2520as%2520Atypical%2520Dopamine%2520Transporter%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+Determinants+of+Selectivity+and+Efficacy+at+the+Dopamine+D3+Receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0libMBzLDQrIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520Determinants%2520of%2520Selectivity%2520and%2520Efficacy%2520at%2520the%2520Dopamine%2520D3%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">PRESTO-Tango as an Open-Source Resource for Interrogation of the Druggable Human GPCRome</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnsmb.3014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=25895059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=362-369&author=W.+K.+Kroezeauthor=M.+F.+Sassanoauthor=X.-P.+Huangauthor=K.+Lansuauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=N.+Sciakyauthor=B.+L.+Roth&title=PRESTO-Tango+as+an+Open-Source+Resource+for+Interrogation+of+the+Druggable+Human+GPCRome&doi=10.1038%2Fnsmb.3014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span></div><div class="casAuthors">Kroeze, Wesley K.; Sassano, Maria F.; Huang, Xi-Ping; Lansu, Katherine; McCorvy, John D.; Giguere, Patrick M.; Sciaky, Noah; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are essential mediators of cellular signaling and are important targets of drug action.  Of the approx. 350 nonolfactory human GPCRs, more than 100 are still considered to be 'orphans' because their endogenous ligands remain unknown.  Here, we describe a unique open-source resource that allows interrogation of the druggable human GPCRome via a G protein-independent β-arrestin-recruitment assay.  We validate this unique platform at more than 120 nonorphan human GPCR targets, demonstrate its utility for discovering new ligands for orphan human GPCRs and describe a method (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation (PRESTO-Tango)) for the simultaneous and parallel interrogation of the entire human nonolfactory GPCRome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbl7caV9gUrVg90H21EOLACvtfcHk0libMBzLDQrIVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D&md5=2a78b74a5f1425fa9e8b79b730c16be6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3014%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPRESTO-Tango%2520as%2520an%2520Open-Source%2520Resource%2520for%2520Interrogation%2520of%2520the%2520Druggable%2520Human%2520GPCRome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzhigirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9644-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1007%2Fs10822-013-9644-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=23579614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=221-234&author=G.+M.+Sastryauthor=M.+Adzhigireyauthor=T.+Dayauthor=R.+Annabhimojuauthor=W.+Sherman&title=Protein+and+Ligand+Preparation%3A+Parameters%2C+Protocols%2C+and+Influence+on+Virtual+Screening+Enrichments&doi=10.1007%2Fs10822-013-9644-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span></div><div class="casAuthors">Sastry G Madhavi; Adzhigirey Matvey; Day Tyler; Annabhimoju Ramakrishna; Sherman Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of computer-aided molecular design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure-based virtual screening plays an important role in drug discovery and complements other screening approaches.  In general, protein crystal structures are prepared prior to docking in order to add hydrogen atoms, optimize hydrogen bonds, remove atomic clashes, and perform other operations that are not part of the x-ray crystal structure refinement process.  In addition, ligands must be prepared to create 3-dimensional geometries, assign proper bond orders, and generate accessible tautomer and ionization states prior to virtual screening.  While the prerequisite for proper system preparation is generally accepted in the field, an extensive study of the preparation steps and their effect on virtual screening enrichments has not been performed.  In this work, we systematically explore each of the steps involved in preparing a system for virtual screening.  We first explore a large number of parameters using the Glide validation set of 36 crystal structures and 1,000 decoys.  We then apply a subset of protocols to the DUD database.  We show that database enrichment is improved with proper preparation and that neglecting certain steps of the preparation process produces a systematic degradation in enrichments, which can be large for some targets.  We provide examples illustrating the structural changes introduced by the preparation that impact database enrichment.  While the work presented here was performed with the Protein Preparation Wizard and Glide, the insights and guidance are expected to be generalizable to structure-based virtual screening with other docking methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd2Qiai-OqeXqj_yg7twvpfW6udTcc2eYiR4fGvsMc67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D&md5=9eb1a820e121aca2742ed53f24481ace</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9644-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9644-8%26sid%3Dliteratum%253Aachs%26aulast%3DSastry%26aufirst%3DG.%2BM.%26aulast%3DAdzhigirey%26aufirst%3DM.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DProtein%2520and%2520Ligand%2520Preparation%253A%2520Parameters%252C%2520Protocols%252C%2520and%2520Influence%2520on%2520Virtual%2520Screening%2520Enrichments%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D221%26epage%3D234%26doi%3D10.1007%2Fs10822-013-9644-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genheden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryde, U.</span></span> <span> </span><span class="NLM_article-title">The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1517/17460441.2015.1032936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1517%2F17460441.2015.1032936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=25835573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=449-461&author=S.+Genhedenauthor=U.+Ryde&title=The+MM%2FPBSA+and+MM%2FGBSA+Methods+to+Estimate+Ligand-Binding+Affinities&doi=10.1517%2F17460441.2015.1032936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities</span></div><div class="casAuthors">Genheden, Samuel; Ryde, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-461</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The mol. mechanics energies combined with the Poisson-Boltzmann or generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) methods are popular approaches to est. the free energy of the binding of small ligands to biol. macromols.  They are typically based on mol. dynamics simulations of the receptor-ligand complex and are therefore intermediate in both accuracy and computational effort between empirical scoring and strict alchem. perturbation methods.  They have been applied to a large no. of systems with varying success.  Areas covered: The authors review the use of MM/PBSA and MM/GBSA methods to calc. ligand-binding affinities, with an emphasis on calibration, testing and validation, as well as attempts to improve the methods, rather than on specific applications.  Expert opinion: MM/PBSA and MM/GBSA are attractive approaches owing to their modular nature and that they do not require calcns. on a training set.  They have been used successfully to reproduce and rationalize exptl. findings and to improve the results of virtual screening and docking.  However, they contain several crude and questionable approxns., for example, the lack of conformational entropy and information about the no. and free energy of water mols. in the binding site.  Moreover, there are many variants of the method and their performance varies strongly with the tested system.  Likewise, most attempts to ameliorate the methods with more accurate approaches, for example, quantum-mech. calcns., polarizable force fields or improved solvation have deteriorated the results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTBKte1pAZR7Vg90H21EOLACvtfcHk0ljVgHt2tgDfUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D&md5=b123b88809f275564f95a2271ebd159f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1032936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1032936%26sid%3Dliteratum%253Aachs%26aulast%3DGenheden%26aufirst%3DS.%26aulast%3DRyde%26aufirst%3DU.%26atitle%3DThe%2520MM%252FPBSA%2520and%2520MM%252FGBSA%2520Methods%2520to%2520Estimate%2520Ligand-Binding%2520Affinities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D449%26epage%3D461%26doi%3D10.1517%2F17460441.2015.1032936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Gemma  Navarro</span>, <span class="hlFld-ContribAuthor ">Marc  Gómez‐Autet</span>, <span class="hlFld-ContribAuthor ">Laura  Redondo</span>, <span class="hlFld-ContribAuthor ">Javier  Fernández‐Ruiz</span>, <span class="hlFld-ContribAuthor ">Laura  Pérez‐Benito</span>, <span class="hlFld-ContribAuthor ">Arnau  Cordomí</span>, <span class="hlFld-ContribAuthor ">Leonardo  Pardo</span>, <span class="hlFld-ContribAuthor ">Rafael  Franco</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB
              2
              Receptor**. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (68)
                                     , 15839-15842. <a href="https://doi.org/10.1002/chem.202003389" title="DOI URL">https://doi.org/10.1002/chem.202003389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202003389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202003389%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DDiscovery%252Bof%252BHomobivalent%252BBitopic%252BLigands%252Bof%252Bthe%252BCannabinoid%252BCB%252B2%252BReceptor%252A%252A%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D68%26spage%3D15839%26epage%3D15842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Claude  Martel</span>, <span class="hlFld-ContribAuthor ">Silvia  Gatti McArthur</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.01003" title="DOI URL">https://doi.org/10.3389/fphar.2020.01003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.01003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.01003%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DDopamine%252BReceptor%252BSubtypes%25252C%252BPhysiology%252Band%252BPharmacology%25253A%252BNew%252BLigands%252Band%252BConcepts%252Bin%252BSchizophrenia%26aulast%3DMartel%26aufirst%3DJean%2BClaude%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PCPMA-based serotonin 2C agonists and their binding activity at D3R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative D3R antagonists and the design of PCPMA derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Triazole-Thiol Ether Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, Cs<sub>2</sub>CO<sub>3</sub>, MeOH, microwave, 100 °C, 30 min, 69%; (b) LiOH–H<sub>2</sub>O, THF, H<sub>2</sub>O, rt, overnight, 60%; (c) [for <b>13a</b>] 2-fluoroethanol, PPh<sub>3</sub>, DEAD, THF, microwave, 60 °C, 30 min, 95%, [for <b>13b</b>] EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 110 °C, 30 min, 83%, [for <b>13c</b> and <b>13d</b>] MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 110 °C, 30 min, 96%; (d) 2 M HCl in diethyl ether, rt, overnight, 99% or 4 M HCl in dioxane, rt, 4–5 h, 82–94%; (e) HATU, NaHCO<sub>3</sub>, DMF, rt, 3 h, 72–90%; (f) BH<sub>3</sub>–THF in THF, reflux, 4 h, 58–92%; (g) aldehydes, NaHB(OAc)<sub>3</sub>, THF, rt, 1 h, 24–89%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Amide Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) [for <b>19a</b>] 2-naphthoyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 87%; [for <b>19b</b>] 1<i>H</i>-indole-2-carboxylic acid, HATU, NaHCO<sub>3</sub>, DMF, rt, 2 h, 80%; [for <b>19c</b>] 4-(2-pyridyl)benzoic acid, HATU, NaHCO<sub>3</sub>, DMF, rt, 2 h, 93%; (b) SO<sub>3</sub>–Py, DMSO, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (c) [for <b>21a</b> and <b>21b</b>] NaBH<sub>4</sub>, NEt<sub>3</sub>, acetaldehyde, rt, 20 min, 33–34%; [for <b>21c</b> and <b>21d</b>] NaBH<sub>4</sub>, NEt<sub>3</sub>, propionaldehyde, rt, 20 min, 23–31%; (d) NaHB(OAc)<sub>3</sub>, THF, rt, overnight, 37–68% for steps b and d.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amide Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>3</sub>P═CHC(═O)OMe, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 67–98%; (b) LiOH–H<sub>2</sub>O, THF, H<sub>2</sub>O, rt, 2 h, 75–100%; (c) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, HATU, NaHCO<sub>3</sub>, DMF, rt, overnight, 81–97%; (d) Me<sub>3</sub>S<sup>+</sup>(O)I<sup>–</sup>, NaH, DMSO, rt, overnight, 71–82%; (e) DIBAL-H, THF, −78 °C, 2 h; (f) NaHB(AcO)<sub>3</sub>, propylamine, AcOH, rt, 44–64%; (g) NaHB(OAc)<sub>3</sub>, AcOH, THF, rt, overnight, 11–68% for steps e and g.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of compounds (1<i>R</i>,2<i>R</i>)- <b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) chiral prep-HPLC separation; (b) 4 M HCl in dioxane, rt, overnight, 98%; (c) propionaldehyde, NaBH<sub>4</sub>, NEt<sub>3</sub>, dioxane, rt, 10 min, 34–63%; (d) <b>20c</b>, NaHB(AcO)<sub>3</sub>, THF, rt, overnight, 32–33%.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Functional characterization of lead compounds at D<sub>3</sub> dopamine receptors (A, B) and 5-HT<sub>2C</sub> receptors (C, D). (A) Inhibition of cAMP production at D<sub>3</sub> (G<sub>i</sub>-agonist activity), (B) β-arrestin2 recruitment (Tango agonist activity), and calcium mobilization at 5-HT<sub>2C</sub> (G<sub>q</sub> agonist activity in panel C and antagonist activity in panel D) represented means ± SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate. The reference agonist (5-HT) was used at a final concentration of 1 nM in antagonist assays (D), in which mesulergine served as a reference antagonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of binding poses of D3R antagonist eticlopride, (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b>. The receptor structure employed for the molecular docking study was extracted from the crystal structure of the eticlopride–D3R complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>). Carbon atoms of eticlopride, (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>S</i>,2<i>S</i>)-<b>22e</b> are colored in green, orange, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/medium/jm9b01835_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of binding poses of 5HT<sub>2C</sub> representative agonists (A) and antagonists (B). The receptor structures used in the molecular docking studies were extracted from the crystal structures of the ergotamine–5HT<sub>2C</sub> complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>) and the ritanserin–5HT<sub>2C</sub> complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH">6BQH</a>). Carbon atoms of ergotamine, compound <b>2</b>, ritanserin, and (1<i>S</i>,2<i>S</i>)-<b>22e</b> are colored in orange, pink, green, and cyan, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01835/20200507/images/large/jm9b01835_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01835&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+Diversity+of+G+Protein-Coupled+Receptors+and+Significance+for+Drug+Discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eZOwgxgUxcaqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520Diversity%2520of%2520G%2520Protein-Coupled%2520Receptors%2520and%2520Significance%2520for%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR Drug Discovery: New Agents, Targets and Indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schiothauthor=D.+E.+Gloriam&title=Trends+in+GPCR+Drug+Discovery%3A+New+Agents%2C+Targets+and+Indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0ljieAzOuLjGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520Drug%2520Discovery%253A%2520New%2520Agents%252C%2520Targets%2520and%2520Indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podlewska, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span> <span> </span><span class="NLM_article-title">Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3784</span>– <span class="NLM_lpage">3839</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00836</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00836" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFerurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3784-3839&author=M.+Vassauthor=S.+Podlewskaauthor=I.+J.+P.+de+Eschauthor=A.+J.+Bojarskiauthor=R.+Leursauthor=A.+J.+Kooistraauthor=C.+de+Graaf&title=Aminergic+GPCR-Ligand+Interactions%3A+A+Chemical+and+Structural+Map+of+Receptor+Mutation+Data&doi=10.1021%2Facs.jmedchem.8b00836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data</span></div><div class="casAuthors">Vass, Marton; Podlewska, Sabina; de Esch, Iwan J. P.; Bojarski, Andrzej J.; Leurs, Rob; Kooistra, Albert J.; de Graaf, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3784-3839</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The aminergic family of G protein-coupled receptors (GPCRs) plays an important role in various diseases and represents a major drug discovery target class.  Structure detn. of all major aminergic subfamilies has enabled structure-based ligand design for these receptors.  Site-directed mutagenesis data provides an invaluable complementary source of information for elucidating the structural determinants of binding of different ligand chemotypes.  The current study provides a comparative anal. of 6692 mutation data points on 34 aminergic GPCR subtypes, covering the chem. space of 540 unique ligands from mutagenesis expts., and information from exptl. detd. structures of 52 distinct aminergic receptor-ligand complexes.  The integrated anal. enables detailed investigation of structural receptor-ligand interactions and assessment of the transferability of combined binding mode and mutation data across ligand chemotypes and receptor subtypes.  An overview is provided of the possibilities and limitations of using mutation data to guide the design of novel aminergic receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9WHKk1wW24bVg90H21EOLACvtfcHk0ljieAzOuLjGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFerurjK&md5=b6301276cd3a5a3b062d8c4632681fc8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00836%26sid%3Dliteratum%253Aachs%26aulast%3DVass%26aufirst%3DM.%26aulast%3DPodlewska%26aufirst%3DS.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26atitle%3DAminergic%2520GPCR-Ligand%2520Interactions%253A%2520A%2520Chemical%2520and%2520Structural%2520Map%2520of%2520Receptor%2520Mutation%2520Data%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3784%26epage%3D3839%26doi%3D10.1021%2Facs.jmedchem.8b00836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaisin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1992</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1021/jm5019274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1992-2002&author=J.+Chengauthor=P.+M.+Giguereauthor=O.+K.+Onajoleauthor=W.+Lvauthor=A.+Gaisinauthor=H.+Gunosewoyoauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=G.+Vistoliauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Optimization+of+2-Phenylcyclopropylmethylamines+as+Selective+Serotonin+2C+Receptor+Agonists+and+Their+Evaluation+as+Potential+Antipsychotic+Agents&doi=10.1021%2Fjm5019274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Onajole, Oluseye K.; Lv, Wei; Gaisin, Arsen; Gunosewoyo, Hendra; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Vistoli, Giulio; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1992-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a new series of compds. that are potent, selective 5-HT2C receptor agonists is described herein as the authors continue the efforts to optimize the 2-phenylcyclopropylmethylamine scaffold.  Modifications focused on the alkoxyl substituent present on the arom. ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors.  ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compds. possessing drug-like profiles and having antipsychotic properties.  Compd. I, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date.  The likely binding mode of this series of compds. to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Ar63unExNbVg90H21EOLACvtfcHk0liiKDxqOHHZIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D&md5=f2884cbae8062702164da57a0de7381f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5019274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019274%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DGaisin%26aufirst%3DA.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DOptimization%2520of%25202-Phenylcyclopropylmethylamines%2520as%2520Selective%2520Serotonin%25202C%2520Receptor%2520Agonists%2520and%2520Their%2520Evaluation%2520as%2520Potential%2520Antipsychotic%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1992%26epage%3D2002%26doi%3D10.1021%2Fjm5019274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=578-591&author=J.+Chengauthor=P.+M.+Giguereauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=H.+Zhuauthor=J.+D.+McCorvyauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Further+Advances+in+Optimizing+%282-Phenylcyclopropyl%29methylamines+as+Novel+Serotonin+2C+Agonists%3A+Effects+on+Hyperlocomotion%2C+Prepulse+Inhibition%2C+and+Cognition+Models&doi=10.1021%2Facs.jmedchem.5b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Huang, Xi-Ping; Zhu, Hu; McCorvy, John D.; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">578-591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel compds. with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists.  Compd. (+)-22a was identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors.  ADMET assays showed that compd. (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile.  Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol.  These data support the further development of (+)-22a as a drug candidate for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQRNc_Uk6IsbVg90H21EOLACvtfcHk0liiKDxqOHHZIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrur%252FE&md5=7331d1c14a844d2dfcc3e637597b9e15</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01153%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFurther%2520Advances%2520in%2520Optimizing%2520%25282-Phenylcyclopropyl%2529methylamines%2520as%2520Novel%2520Serotonin%25202C%2520Agonists%253A%2520Effects%2520on%2520Hyperlocomotion%252C%2520Prepulse%2520Inhibition%252C%2520and%2520Cognition%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D578%26epage%3D591%26doi%3D10.1021%2Facs.jmedchem.5b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2c) Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9866</span>– <span class="NLM_lpage">9880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9866-9880&author=J.+Chengauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=H.+Zhuauthor=T.+Kenakinauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Design+and+Discovery+of+Functionally+Selective+Serotonin+2C+%285-HT2c%29+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.6b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists</span></div><div class="casAuthors">Cheng, Jianjun; McCorvy, John D.; Giguere, Patrick M.; Zhu, Hu; Kenakin, Terry; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9866-9880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the structural similarity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative biol. cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compds. were designed and synthesized.  The compds. were evaluated for their selectivity toward 5-HT2A, 5-HT2B, and 5-HT2C receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT2C agonists.  Selected compds. were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway vs. β-arrestin recruitment.  The most functionally selective compd. (+)-7e produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays.  We report for the first time that selective 5-HT2C agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaXMjfBCeBR7Vg90H21EOLACvtfcHk0liiKDxqOHHZIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF&md5=bb0e1b524230649fac9f5b736ddc283d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01194%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520Discovery%2520of%2520Functionally%2520Selective%2520Serotonin%25202C%2520%25285-HT2c%2529%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9866%26epage%3D9880%26doi%3D10.1021%2Facs.jmedchem.6b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-Substituted 2-Phenylcyclopropylmethylamines as Functionally Selective Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for Potential Use as Antipsychotic Medications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6288</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6273-6288&author=G.+Zhangauthor=J.+Chengauthor=J.+D.+McCorvyauthor=P.+J.+Lorelloauthor=B.+J.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Discovery+of+N-Substituted+2-Phenylcyclopropylmethylamines+as+Functionally+Selective+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+Potential+Use+as+Antipsychotic+Medications&doi=10.1021%2Facs.jmedchem.7b00584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span></div><div class="casAuthors">Zhang, Guiping; Cheng, Jianjun; McCorvy, John D.; Lorello, Paul J.; Caldarone, Barbara J.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6273-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preference for Gq signaling.  A no. of these compds. exhibit 5-HT2C selectivity with a preference for Gq-mediated signaling compared with β-arrestin recruitment.  Furthermore, the N-Me compd. I•HCl, which displayed an EC50 of 23 nM in the calcium flux assay while showing no β-arrestin recruitment activity, is the most functionally selective 5-HT2C agonist reported to date.  The N-benzyl compd. II•HCl, which showed an EC50 of 24 nM at the 5-HT2C receptor, is fully selective over the 5-HT2B receptor.  In an amphetamine-induced hyperactivity model, compd. II showed significant antipsychotic-drug-like activity.  These compds. shed light on the role of functional selectivity at the 5-HT2C receptor with respect to antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGjR92vyblbVg90H21EOLACvtfcHk0ljbgrsXbdFIKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK&md5=9da7c5db2f4e54db114a544d5f2e56b7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00584%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DLorello%26aufirst%3DP.%2BJ.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520N-Substituted%25202-Phenylcyclopropylmethylamines%2520as%2520Functionally%2520Selective%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520Potential%2520Use%2520as%2520Antipsychotic%2520Medications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6273%26epage%3D6288%26doi%3D10.1021%2Facs.jmedchem.7b00584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for the Treatment of CNS Disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+Chengauthor=A.+P.+Kozikowski&title=We+Need+2C+but+Not+2B%3A+Developing+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+the+Treatment+of+CNS+Disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0ljbgrsXbdFIKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520Need%25202C%2520but%2520Not%25202B%253A%2520Developing%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Agonists Modulate Schizophrenia-Like Behaviors in Mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnpp.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=28294132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2163-2177&author=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=J.+Chengauthor=M.+Huangauthor=C.+M.+Schmerbergauthor=H.+Y.+Meltzerauthor=B.+L.+Rothauthor=A.+P.+Kozikowskiauthor=W.+C.+Wetsel&title=5-HT2C+Agonists+Modulate+Schizophrenia-Like+Behaviors+in+Mice&doi=10.1038%2Fnpp.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice</span></div><div class="casAuthors">Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Cheng, Jianjun; Huang, Mei; Schmerberg, Claire M.; Meltzer, Herbert Y.; Roth, Bryan L.; Kozikowski, Alan P.; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2163-2177</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of neg. and cognitive symptoms.  The heterogeneity of pharmacol. responses in schizophrenic patients suggests that addnl. drug targets may be effective in improving aspects of this syndrome.  Recent evidence suggests that 5-HT2C receptors may be a promising target for schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusively in CNS, and have wt.-loss-promoting capabilities.  A difficulty in developing 5-HT2C agonists is that most ligands also possess 5-HT2B and/or 5-HT2A activities.  We have developed selective 5-HT2C ligands and herein describe their preclin. effectiveness for treating schizophrenia-like behaviors.  JJ-3-45, JJ-3-42, and JJ-5-34 reduced amphetamine-stimulated hyperlocomotion, restored amphetamine-disrupted prepulse inhibition, improved social behavior, and novel object recognition memory in NMDA receptor hypofunctioning NR1-knockdown mice, and were essentially devoid of catalepsy.  However, they decreased motivation in a breakpoint assay and did not promote reversal learning in MK-801-treated mice.  Somewhat similar effects were obsd. with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.  Microdialysis studies revealed that both JJ-3-42 and lorcaserin reduced dopamine efflux in the infralimbic cortex, while only JJ-3-42 decreased it in striatum.  Collectively, these results provide addnl. evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related disorders than current APDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwGQU6HLhHrVg90H21EOLACvtfcHk0ljbgrsXbdFIKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D&md5=f4b074cad46559dd52e7d622c8af24f9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3D5-HT2C%2520Agonists%2520Modulate%2520Schizophrenia-Like%2520Behaviors%2520in%2520Mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2163%26epage%3D2177%26doi%3D10.1038%2Fnpp.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platania, C. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">Current Drug Treatments Targeting Dopamine D3 Receptor</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+M.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+Drug+Treatments+Targeting+Dopamine+D3+Receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0ljHURdhH7mSbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520Drug%2520Treatments%2520Targeting%2520Dopamine%2520D3%2520Receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perachon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sautel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Cocaine-Seeking Behaviour by a Partial Dopamine D<sub>3</sub> Receptor Agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1038/22560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2F22560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10432116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=1999&pages=371-375&author=M.+Pillaauthor=S.+Perachonauthor=F.+Sautelauthor=F.+Garridoauthor=A.+Mannauthor=C.+G.+Wermuthauthor=J.+C.+Schwartzauthor=B.+J.+Everittauthor=P.+Sokoloff&title=Selective+Inhibition+of+Cocaine-Seeking+Behaviour+by+a+Partial+Dopamine+D3+Receptor+Agonist&doi=10.1038%2F22560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of cocaine-seeking behavior by a partial dopamine D3 receptor agonist</span></div><div class="casAuthors">Pilla, Maria; Perachon, Sylvie; Sautel, Francois; Garrido, Fabrice; Mann, Andre; Wermuth, Camille G.; Schwartz, Jean-Charles; Everitt, Barry J.; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">6742</span>),
    <span class="NLM_cas:pages">371-375</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Environmental stimuli that are reliably assocd. with the effects of many abused drugs, esp. stimulants such as cocaine, can produce craving and relapse in abstinent human substance abusers.  In animals, such cues can induce and maintain drug-seeking behavior and also reinstate drug-seeking after extinction.  Reducing the motivational effects of drug-related cues might therefore be useful in the treatment of addiction.  Converging pharmacol., human post-mortem and genetic studies implicate the dopamine D3 receptor in drug addiction.  Here we have designed BP 897, the first D3-receptor-selective agonist, as assessed in vitro with recombinant receptors and in vivo with mice bearing disrupted D3-receptor genes.  BP 897 is a partial agonist in vitro and acts in vivo as either an agonist or an antagonist.  We show that BP 897 inhibits cocaine-seeking behavior that depends upon the presentation of drug-assocd. cues, without having any intrinsic, primary rewarding effects.  Our data indicate that compds. like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug-assocd. environmental stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6SwJsmcTSCLVg90H21EOLACvtfcHk0ljHURdhH7mSbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFOntr0%253D&md5=3f4055a4cd1b6cee7e890ff1b96b21b6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F22560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F22560%26sid%3Dliteratum%253Aachs%26aulast%3DPilla%26aufirst%3DM.%26aulast%3DPerachon%26aufirst%3DS.%26aulast%3DSautel%26aufirst%3DF.%26aulast%3DGarrido%26aufirst%3DF.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DEveritt%26aufirst%3DB.%2BJ.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DSelective%2520Inhibition%2520of%2520Cocaine-Seeking%2520Behaviour%2520by%2520a%2520Partial%2520Dopamine%2520D3%2520Receptor%2520Agonist%26jtitle%3DNature%26date%3D1999%26volume%3D400%26spage%3D371%26epage%3D375%26doi%3D10.1038%2F22560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+Medicinal+Chemistry+Lectureship%3A+Designing+Bivalent+or+Bitopic+Molecules+for+G-Protein+Coupled+Receptors.+The+Whole+Is+Greater+Than+the+Sum+of+Its+Parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0ljHURdhH7mSbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520Medicinal%2520Chemistry%2520Lectureship%253A%2520Designing%2520Bivalent%2520or%2520Bitopic%2520Molecules%2520for%2520G-Protein%2520Coupled%2520Receptors.%2520The%2520Whole%2520Is%2520Greater%2520Than%2520the%2520Sum%2520of%2520Its%2520Parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Fluorine-Containing D<sub>3</sub> Dopamine Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1021/jm101323b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101323b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFWntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1555-1564&author=Z.+D.+Tuauthor=S.+H.+Liauthor=J.+Q.+Cuiauthor=J.+B.+Xuauthor=M.+Taylorauthor=D.+Hoauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Synthesis+and+Pharmacological+Evaluation+of+Fluorine-Containing+D3+Dopamine+Receptor+Ligands&doi=10.1021%2Fjm101323b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Fluorine-Containing D3 Dopamine Receptor Ligands</span></div><div class="casAuthors">Tu, Zhu-De; Li, Shi-Hong; Cui, Jin-Quan; Xu, Jin-Bin; Taylor, Michelle; Ho, David; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1555-1564</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of fluorine-contg. N-(2-methoxyphenyl)piperazine and N-(2-fluoroethoxy)piperazine analogs, e. g. I, were synthesized, and their affinities for human dopamine D2, D3, and D4 receptors were detd.  Radioligand binding studies identified five compds., 18a, 20a, 20c, 20e, and 21e, which bind with high affinity at D3 (Ki = 0.17-5 nM) and moderate to high selectivity for D3 vs D2 receptors (ranging from ∼25- to 163-fold).  These compds. were also evaluated for intrinsic activity at D2 and D3 receptors using a forskolin-dependent adenylyl cyclase assay.  This panel of compds. exhibits varying receptor subtype binding selectivity and intrinsic activity at D2 vs D3 receptors.  These compds. may be useful for behavioral pharmacol. studies on the role of D2-like dopamine receptors in neuropsychiatric and neurol. disorders.  Furthermore, compd. 20e, which has the highest binding affinity and selectivity for the D3 receptor (Ki = 0.17 nM for D3, 163-fold selectivity for D3 vs D2 receptors), represents a candidate fluorine-18 radiotracer for in vivo PET imaging studies on the regulation of D3 receptor expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_lRIZaeiUnbVg90H21EOLACvtfcHk0liRa9OshcPNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFWntrY%253D&md5=138e7cf0e434cd726af353d75f99b0f6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm101323b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101323b%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DZ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DCui%26aufirst%3DJ.%2BQ.%26aulast%3DXu%26aufirst%3DJ.%2BB.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DD.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Fluorine-Containing%2520D3%2520Dopamine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1555%26epage%3D1564%26doi%3D10.1021%2Fjm101323b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arista, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelli, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Checchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di-Fabio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamprecht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terreni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D<sub>3</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1021/jm901319p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901319p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKrtr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=374-391&author=F.+Micheliauthor=L.+Aristaauthor=G.+Bonanomiauthor=F.+E.+Blaneyauthor=S.+Braggioauthor=A.+M.+Capelliauthor=A.+Checchiaauthor=F.+Damianiauthor=R.+Di-Fabioauthor=S.+Fontanaauthor=G.+Gentileauthor=C.+Griffanteauthor=D.+Hamprechtauthor=C.+Marchioroauthor=M.+Mugnainiauthor=J.+Pinerauthor=E.+Rattiauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=A.+Worbyauthor=C.+R.+Ashbyauthor=C.+Heidbreder&title=1%2C2%2C4-Triazolyl+Azabicyclo%5B3.1.0%5Dhexanes%3A+A+New+Series+of+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Fjm901319p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Micheli, Fabrizio; Arista, Luca; Bonanomi, Giorgio; Blaney, Frank E.; Braggio, Simone; Capelli, Anna Maria; Checchia, Anna; Damiani, Federica; Di-Fabio, Romano; Fontana, Stefano; Gentile, Gabriella; Griffante, Cristiana; Hamprecht, Dieter; Marchioro, Carla; Mugnaini, Manolo; Piner, Jacqui; Ratti, Emiliangelo; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Worby, Angela; Ashby, Charles R.; Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">374-391</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new highly potent and selective dopamine (DA) D3 receptor antagonists has recently allowed the characterization of the DA D3 receptor in a range of preclin. animal models of drug addiction.  A novel series of 1,2,4-triazol-3-yl-azabicyclo[3.1.0]hexanes, members of which showed a high affinity and selectivity for the DA D3 receptor and excellent pharmacokinetic profiles, is reported here.  Members of a group of derivs. from this series showed good oral bioavailability and brain penetration and very high in vitro affinity and selectivity for the DA D3 receptor, as well as high in vitro potency for antagonism at this receptor.  Several members of this series also significantly attenuate the expression of conditioned place preference (CPP) to nicotine and cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgBjd6ObO27bVg90H21EOLACvtfcHk0liRa9OshcPNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKrtr%252FK&md5=c21c283590b4345f9f6a73284fae6170</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm901319p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901319p%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DArista%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCapelli%26aufirst%3DA.%2BM.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DDamiani%26aufirst%3DF.%26aulast%3DDi-Fabio%26aufirst%3DR.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DGentile%26aufirst%3DG.%26aulast%3DGriffante%26aufirst%3DC.%26aulast%3DHamprecht%26aufirst%3DD.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMugnaini%26aufirst%3DM.%26aulast%3DPiner%26aufirst%3DJ.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DWorby%26aufirst%3DA.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3D1%252C2%252C4-Triazolyl%2520Azabicyclo%255B3.1.0%255Dhexanes%253A%2520A%2520New%2520Series%2520of%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D374%26epage%3D391%26doi%3D10.1021%2Fjm901319p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelletti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremonesi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Cin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feriani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehanne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajbaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliosi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellacani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomelleri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidbreder, C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8549</span>– <span class="NLM_lpage">8576</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8549-8576&author=F.+Micheliauthor=A.+Bacchiauthor=S.+Braggioauthor=L.+Castellettiauthor=P.+Cavalliniauthor=P.+Cavanniauthor=S.+Cremonesiauthor=M.+Dal+Cinauthor=A.+Ferianiauthor=S.+Gehanneauthor=M.+Kajbafauthor=L.+Marchioauthor=S.+Nolaauthor=B.+Oliosiauthor=A.+Pellacaniauthor=E.+Perdonaauthor=A.+Savaauthor=T.+Semeraroauthor=L.+Tarsiauthor=S.+Tomelleriauthor=A.+Wongauthor=F.+Visentiniauthor=L.+Zonziniauthor=C.+Heidbreder&title=1%2C2%2C4-Triazolyl+5-Azaspiro%5B2.4%5Dheptanes%3A+Lead+Identification+and+Early+Lead+Optimization+of+a+New+Series+of+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Facs.jmedchem.6b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Micheli, Fabrizio; Bacchi, Alessia; Braggio, Simone; Castelletti, Laura; Cavallini, Palmina; Cavanni, Paolo; Cremonesi, Susanna; Dal Cin, Michele; Feriani, Aldo; Gehanne, Sylvie; Kajbaf, Mahmud; Marchio, Luciano; Nola, Selena; Oliosi, Beatrice; Pellacani, Annalisa; Perdona, Elisabetta; Sava, Anna; Semeraro, Teresa; Tarsi, Luca; Tomelleri, Silvia; Wong, Andrea; Visentini, Filippo; Zonzini, Laura; Heidbreder, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8549-8576</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 1,2,4-triazolyl 5-azaspiro[2.4]heptanes with high affinity and selectivity at the dopamine (DA) D3 receptor (D3R) is described.  Some of these compds. also have high selectivity over the hERG channel and were characterized with respect to their pharmacokinetic properties both in vitro and in vivo during lead identification and early lead optimization phases.  A few derivs. with overall favorable developability characteristics were selected for further late lead optimization studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCKMOaVTpugrVg90H21EOLACvtfcHk0liRa9OshcPNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltrjN&md5=9588db3bf4e320c6d082b4318a8143a4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00972%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCastelletti%26aufirst%3DL.%26aulast%3DCavallini%26aufirst%3DP.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DCremonesi%26aufirst%3DS.%26aulast%3DDal%2BCin%26aufirst%3DM.%26aulast%3DFeriani%26aufirst%3DA.%26aulast%3DGehanne%26aufirst%3DS.%26aulast%3DKajbaf%26aufirst%3DM.%26aulast%3DMarchio%26aufirst%3DL.%26aulast%3DNola%26aufirst%3DS.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DPellacani%26aufirst%3DA.%26aulast%3DPerdona%26aufirst%3DE.%26aulast%3DSava%26aufirst%3DA.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTomelleri%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DHeidbreder%26aufirst%3DC.%26atitle%3D1%252C2%252C4-Triazolyl%25205-Azaspiro%255B2.4%255Dheptanes%253A%2520Lead%2520Identification%2520and%2520Early%2520Lead%2520Optimization%2520of%2520a%2520New%2520Series%2520of%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8549%26epage%3D8576%26doi%3D10.1021%2Facs.jmedchem.6b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. M.</span></span> <span> </span><span class="NLM_article-title">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D<sub>3</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4968</span>, <span class="refDoi"> DOI: 10.1021/jm401798r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401798r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4962-4968&author=J.+Y.+Chenauthor=B.+Levantauthor=C.+Jiangauthor=T.+M.+Keckauthor=A.+H.+Newmanauthor=S.+M.+Wang&title=Tranylcypromine+Substituted+cis-Hydroxycyclobutylnaphthamides+as+Potent+and+Selective+Dopamine+D3+Receptor+Antagonists&doi=10.1021%2Fjm401798r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Jiang, Cheng; Keck, Thomas M.; Newman, Amy Hauck; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4962-4968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine.  Although tranylcypromine has a low affinity for the rat D3 receptor (Ki = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has Ki values of 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, resp., and displays resp. selectivities of >10000-fold and 223-fold over the rat and human D2 receptors.  Evaluation in a β-arrestin functional assay showed that (1R,2S)-11 is a potent and competitive antagonist at the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWudWdAfWgLVg90H21EOLACvtfcHk0lihW2weGMgOog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D&md5=e2ddf0711d00103be281cb043b19ec3a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm401798r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401798r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DS.%2BM.%26atitle%3DTranylcypromine%2520Substituted%2520cis-Hydroxycyclobutylnaphthamides%2520as%2520Potent%2520and%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4962%26epage%3D4968%26doi%3D10.1021%2Fjm401798r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D<sub>3</sub> Receptor (D3R) Selective Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+Significance+of+Chirality+in+Drug+Design+and+Synthesis+of+Bitopic+Ligands+as+D3+Receptor+%28D3R%29+Selective+Agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0lihW2weGMgOog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520Significance%2520of%2520Chirality%2520in%2520Drug%2520Design%2520and%2520Synthesis%2520of%2520Bitopic%2520Ligands%2520as%2520D3%2520Receptor%2520%2528D3R%2529%2520Selective%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+Medication+Targets+for+Psychostimulant+Addiction%3A+Unraveling+the+Dopamine+D3+Receptor+Hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0liLLA4di3sbrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520Medication%2520Targets%2520for%2520Psychostimulant%2520Addiction%253A%2520Unraveling%2520the%2520Dopamine%2520D3%2520Receptor%2520Hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D<sub>3</sub> Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+Receptor+Antagonist+%28GSK598809%29+Potentiates+the+Hypertensive+Effects+of+Cocaine+in+Conscious%2C+Freely-Moving+Dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0liLLA4di3sbrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520Receptor%2520Antagonist%2520%2528GSK598809%2529%2520Potentiates%2520the%2520Hypertensive%2520Effects%2520of%2520Cocaine%2520in%2520Conscious%252C%2520Freely-Moving%2520Dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpsoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harpsoeauthor=K.+Lansuauthor=S.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.-P.+Huangauthor=Y.+Wuauthor=L.+Shenauthor=W.+E.+Bjorn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=5-HT2C+Receptor+Structures+Reveal+the+Structural+Basis+of+GPCR+Polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Å and 2.7 Å, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0ljvvpZCdPIQKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarpsoe%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3D5-HT2C%2520Receptor%2520Structures%2520Reveal%2520the%2520Structural%2520Basis%2520of%2520GPCR%2520Polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+Human+Dopamine+D3+Receptor+in+Complex+with+a+D2%2FD3+Selective+Antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0ljvvpZCdPIQKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Dopamine%2520D3%2520Receptor%2520in%2520Complex%2520with%2520a%2520D2%252FD3%2520Selective%2520Antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1002%2Fcmdc.201300114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=23619931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1eksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=994-1001&author=S.+Samantaauthor=T.+L.+Limauthor=Y.+Lam&title=Synthesis+and+in+vitro+Evaluation+of+West+Nile+Virus+Protease+Inhibitors+Based+on+the+2-%7B6-%5B2-%285-Phenyl-4H-%7B1%2C2%2C4%5Dtriazol-3-ylsulfanyl%29acetylamino%5Dbenzothiazol-2-ylsulfanyl%7Dacetamide+Scaffold&doi=10.1002%2Fcmdc.201300114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 2-{6-[2-(5-Phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide Scaffold</span></div><div class="casAuthors">Samanta, Sanjay; Lim, Ting Liang; Lam, Yulin</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">994-1001</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Triazolylthioacetamido benzothiazolylthioacetamides and benzimidazolylthioacetamides I (R = Ph, 4-H2NC6H4, 4-O2NC6H4, 4-HOC6H4, cyclohexyl, n-Pr, 2-MeC6H4, 4-pyridinyl; R1 = H, Me, Et; R2 = H, Me; R3 = 4-FC6H4, 4-MeOC6H4, Ph, 4-MeC6H4, 4-ClC6H4, 4-MeC6H4, 4-EtC6H4, 4-n-PrC6H4, 3-FC6H4, 3-ClC6H4, 3-MeOC6H4, 3-EtC6H4; X = NH, S; Y = bond, CH2) such as I (R = R1 = R2 = H; R3 = 4-EtC6H4; X = S; Y = bond) (II) were prepd. as inhibitors of the West Nile virus (WNV) NS2B-NS3 protease for potential use as treatments for West Nile virus infection.  II was an uncompetitive inhibitor (IC50 = 3.4 ± 0.2 μM) of the WNV NS2B-NS3 protease.  Mol. docking of II into the WNV protease showed that it interfered with productive interactions of the NS2B cofactor with the NS3 protease and was an allosteric inhibitor of the WNV NS3 protease.  The stabilities and their toxicities to baby hamster kidney fibroblast cells of selected I were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcs3Xu65ygprVg90H21EOLACvtfcHk0ljvvpZCdPIQKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1eksrs%253D&md5=133605413f60e638ad024314f6ea9f8c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300114%26sid%3Dliteratum%253Aachs%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DT.%2BL.%26aulast%3DLam%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520Evaluation%2520of%2520West%2520Nile%2520Virus%2520Protease%2520Inhibitors%2520Based%2520on%2520the%25202-%257B6-%255B2-%25285-Phenyl-4H-%257B1%252C2%252C4%255Dtriazol-3-ylsulfanyl%2529acetylamino%255Dbenzothiazol-2-ylsulfanyl%257Dacetamide%2520Scaffold%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D994%26epage%3D1001%26doi%3D10.1002%2Fcmdc.201300114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malberg, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1902</span>, <span class="refDoi"> DOI: 10.1021/jm801354e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801354e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1885-1902&author=S.+J.+Choauthor=N.+H.+Jensenauthor=T.+Kuromeauthor=S.+Kadariauthor=M.+L.+Manzanoauthor=J.+E.+Malbergauthor=B.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Selective+5-Hydroxytryptamine+2C+Receptor+Agonists+Derived+from+the+Lead+Compound+Tranylcypromine%3A+Identification+of+Drugs+with+Antidepressant-Like+Action&doi=10.1021%2Fjm801354e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span></div><div class="casAuthors">Cho, Sung Jin; Jensen, Niels H.; Kurome, Toru; Kadari, Sudhakar; Manzano, Michael L.; Malberg, Jessica E.; Caldarone, Barbara; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1885-1902</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here the design, synthesis, and pharmacol. properties of a series of compds. related to tranylcypromine (9), which itself was discovered as a lead compd. in a high-throughput screening campaign.  Starting from 9, which shows modest activity as a 5-HT2C agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT2C agonists through iterative structural modifications.  Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring.  Among the tested compds., several were potent and efficacious 5-HT2C receptor agonists with selectivity over both 5-HT2A and 5-HT2B receptors in functional assays.  The most promising compd. is 37, with 120- and 14-fold selectivity over 5-HT2A and 5-HT2B, resp. (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, resp.).  In animal studies, compd. 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh5xre4fJybVg90H21EOLACvtfcHk0lj7LTU4kdA2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D&md5=d7711d01a8d462824a8fcf535e0a1be4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm801354e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801354e%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKurome%26aufirst%3DT.%26aulast%3DKadari%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DM.%2BL.%26aulast%3DMalberg%26aufirst%3DJ.%2BE.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%25205-Hydroxytryptamine%25202C%2520Receptor%2520Agonists%2520Derived%2520from%2520the%2520Lead%2520Compound%2520Tranylcypromine%253A%2520Identification%2520of%2520Drugs%2520with%2520Antidepressant-Like%2520Action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1885%26epage%3D1902%26doi%3D10.1021%2Fjm801354e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9841</span>– <span class="NLM_lpage">9878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00435</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00435" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9841-9878&author=L.+Tanauthor=W.+Yanauthor=J.+D.+McCorvyauthor=J.+Cheng&title=Biased+Ligands+of+G+Protein-Coupled+Receptors+%28GPCRs%29%3A+Structure-Functional+Selectivity+Relationships+%28SFSRs%29+and+Therapeutic+Potential&doi=10.1021%2Facs.jmedchem.8b00435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span></div><div class="casAuthors">Tan, Liang; Yan, Wenzhong; McCorvy, John D.; Cheng, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9841-9878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter.  Biased ligands selective for either pathway are expected to regulate biol. functions of GPCRs in a more precise way, therefore providing new drug mols. with superior efficacy and/or reduced side effects.  During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others.  In this Perspective, recent advances in this field are reviewed by discussing the structure-functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these mols.  Further understanding of the biol. functions assocd. with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFjkAvar29LVg90H21EOLACvtfcHk0lj7LTU4kdA2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N&md5=a7bd605b82666357f5a0a209002225e5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DBiased%2520Ligands%2520of%2520G%2520Protein-Coupled%2520Receptors%2520%2528GPCRs%2529%253A%2520Structure-Functional%2520Selectivity%2520Relationships%2520%2528SFSRs%2529%2520and%2520Therapeutic%2520Potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9841%26epage%3D9878%26doi%3D10.1021%2Facs.jmedchem.8b00435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10676</span>– <span class="NLM_lpage">10691</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.-H.+Biauthor=Z.-X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+High+Affinity+2-%5B%28Diphenylmethyl%29sulfinyl%5Dacetamide+%28Modafinil%29+Analogues+as+Atypical+Dopamine+Transporter+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0lj7LTU4kdA2ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520High%2520Affinity%25202-%255B%2528Diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528Modafinil%2529%2520Analogues%2520as%2520Atypical%2520Dopamine%2520Transporter%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+Determinants+of+Selectivity+and+Efficacy+at+the+Dopamine+D3+Receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0li1C7a4MXjJYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520Determinants%2520of%2520Selectivity%2520and%2520Efficacy%2520at%2520the%2520Dopamine%2520D3%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">PRESTO-Tango as an Open-Source Resource for Interrogation of the Druggable Human GPCRome</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1038/nsmb.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1038%2Fnsmb.3014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=25895059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=362-369&author=W.+K.+Kroezeauthor=M.+F.+Sassanoauthor=X.-P.+Huangauthor=K.+Lansuauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=N.+Sciakyauthor=B.+L.+Roth&title=PRESTO-Tango+as+an+Open-Source+Resource+for+Interrogation+of+the+Druggable+Human+GPCRome&doi=10.1038%2Fnsmb.3014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span></div><div class="casAuthors">Kroeze, Wesley K.; Sassano, Maria F.; Huang, Xi-Ping; Lansu, Katherine; McCorvy, John D.; Giguere, Patrick M.; Sciaky, Noah; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are essential mediators of cellular signaling and are important targets of drug action.  Of the approx. 350 nonolfactory human GPCRs, more than 100 are still considered to be 'orphans' because their endogenous ligands remain unknown.  Here, we describe a unique open-source resource that allows interrogation of the druggable human GPCRome via a G protein-independent β-arrestin-recruitment assay.  We validate this unique platform at more than 120 nonorphan human GPCR targets, demonstrate its utility for discovering new ligands for orphan human GPCRs and describe a method (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation (PRESTO-Tango)) for the simultaneous and parallel interrogation of the entire human nonolfactory GPCRome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbl7caV9gUrVg90H21EOLACvtfcHk0li1C7a4MXjJYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D&md5=2a78b74a5f1425fa9e8b79b730c16be6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3014%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPRESTO-Tango%2520as%2520an%2520Open-Source%2520Resource%2520for%2520Interrogation%2520of%2520the%2520Druggable%2520Human%2520GPCRome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzhigirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9644-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1007%2Fs10822-013-9644-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=23579614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=221-234&author=G.+M.+Sastryauthor=M.+Adzhigireyauthor=T.+Dayauthor=R.+Annabhimojuauthor=W.+Sherman&title=Protein+and+Ligand+Preparation%3A+Parameters%2C+Protocols%2C+and+Influence+on+Virtual+Screening+Enrichments&doi=10.1007%2Fs10822-013-9644-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span></div><div class="casAuthors">Sastry G Madhavi; Adzhigirey Matvey; Day Tyler; Annabhimoju Ramakrishna; Sherman Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of computer-aided molecular design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure-based virtual screening plays an important role in drug discovery and complements other screening approaches.  In general, protein crystal structures are prepared prior to docking in order to add hydrogen atoms, optimize hydrogen bonds, remove atomic clashes, and perform other operations that are not part of the x-ray crystal structure refinement process.  In addition, ligands must be prepared to create 3-dimensional geometries, assign proper bond orders, and generate accessible tautomer and ionization states prior to virtual screening.  While the prerequisite for proper system preparation is generally accepted in the field, an extensive study of the preparation steps and their effect on virtual screening enrichments has not been performed.  In this work, we systematically explore each of the steps involved in preparing a system for virtual screening.  We first explore a large number of parameters using the Glide validation set of 36 crystal structures and 1,000 decoys.  We then apply a subset of protocols to the DUD database.  We show that database enrichment is improved with proper preparation and that neglecting certain steps of the preparation process produces a systematic degradation in enrichments, which can be large for some targets.  We provide examples illustrating the structural changes introduced by the preparation that impact database enrichment.  While the work presented here was performed with the Protein Preparation Wizard and Glide, the insights and guidance are expected to be generalizable to structure-based virtual screening with other docking methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd2Qiai-OqeXqj_yg7twvpfW6udTcc2eZldRSZ2ppPtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D&md5=9eb1a820e121aca2742ed53f24481ace</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9644-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9644-8%26sid%3Dliteratum%253Aachs%26aulast%3DSastry%26aufirst%3DG.%2BM.%26aulast%3DAdzhigirey%26aufirst%3DM.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DProtein%2520and%2520Ligand%2520Preparation%253A%2520Parameters%252C%2520Protocols%252C%2520and%2520Influence%2520on%2520Virtual%2520Screening%2520Enrichments%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D221%26epage%3D234%26doi%3D10.1007%2Fs10822-013-9644-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genheden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryde, U.</span></span> <span> </span><span class="NLM_article-title">The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1517/17460441.2015.1032936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=10.1517%2F17460441.2015.1032936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=25835573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=449-461&author=S.+Genhedenauthor=U.+Ryde&title=The+MM%2FPBSA+and+MM%2FGBSA+Methods+to+Estimate+Ligand-Binding+Affinities&doi=10.1517%2F17460441.2015.1032936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities</span></div><div class="casAuthors">Genheden, Samuel; Ryde, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">449-461</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The mol. mechanics energies combined with the Poisson-Boltzmann or generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) methods are popular approaches to est. the free energy of the binding of small ligands to biol. macromols.  They are typically based on mol. dynamics simulations of the receptor-ligand complex and are therefore intermediate in both accuracy and computational effort between empirical scoring and strict alchem. perturbation methods.  They have been applied to a large no. of systems with varying success.  Areas covered: The authors review the use of MM/PBSA and MM/GBSA methods to calc. ligand-binding affinities, with an emphasis on calibration, testing and validation, as well as attempts to improve the methods, rather than on specific applications.  Expert opinion: MM/PBSA and MM/GBSA are attractive approaches owing to their modular nature and that they do not require calcns. on a training set.  They have been used successfully to reproduce and rationalize exptl. findings and to improve the results of virtual screening and docking.  However, they contain several crude and questionable approxns., for example, the lack of conformational entropy and information about the no. and free energy of water mols. in the binding site.  Moreover, there are many variants of the method and their performance varies strongly with the tested system.  Likewise, most attempts to ameliorate the methods with more accurate approaches, for example, quantum-mech. calcns., polarizable force fields or improved solvation have deteriorated the results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTBKte1pAZR7Vg90H21EOLACvtfcHk0lhK5SEBghb7EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGktr8%253D&md5=b123b88809f275564f95a2271ebd159f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1032936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1032936%26sid%3Dliteratum%253Aachs%26aulast%3DGenheden%26aufirst%3DS.%26aulast%3DRyde%26aufirst%3DU.%26atitle%3DThe%2520MM%252FPBSA%2520and%2520MM%252FGBSA%2520Methods%2520to%2520Estimate%2520Ligand-Binding%2520Affinities%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D449%26epage%3D461%26doi%3D10.1517%2F17460441.2015.1032936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL','PDB','3PBL'); return false;">PDB: 3PBL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG','PDB','6BQG'); return false;">PDB: 6BQG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQH','PDB','6BQH'); return false;">PDB: 6BQH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i148"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34344"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01835?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01835</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding p<i>K</i><sub>i</sub> ± SEM values; 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> activity of selected compounds; binding affinities of (1<i>R</i>,2<i>R</i>)-<b>22e</b> and (1<i>R</i>,2<i>R</i>)-<b>30q</b> at aminergic GPCRs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_002.csv">CSV</a>)</p></li><li><p class="inline">D3R+eticlopride (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_003.pdb">PDB</a>)</p></li><li><p class="inline">D3R+(1<i>R</i>,2<i>R</i>)-<b>22e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_004.pdb">PDB</a>)</p></li><li><p class="inline">D3R+(1<i>S</i>,2<i>S</i>)-<b>22e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_005.pdb">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (active) + ergotamine (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_006.pdb">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (active) + compound <b>2</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_007.pdb">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (inactive) + ritanserin (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_008.pdb">PDB</a>)</p></li><li><p class="inline">5-HT<sub>2C</sub> (inactive) + (1<i>S</i>,2<i>S</i>)-<b>22e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_009.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_001.pdf">jm9b01835_si_001.pdf (1.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_002.csv">jm9b01835_si_002.csv (8.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_003.pdb">jm9b01835_si_003.pdb (790.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_004.pdb">jm9b01835_si_004.pdb (793.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_005.pdb">jm9b01835_si_005.pdb (793.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_006.pdb">jm9b01835_si_006.pdb (498.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_007.pdb">jm9b01835_si_007.pdb (493.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_008.pdb">jm9b01835_si_008.pdb (538.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01835/suppl_file/jm9b01835_si_009.pdb">jm9b01835_si_009.pdb (541.55 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01835&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01835%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-9%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01835" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cae958f61228","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
